Dosing for treatment with Anti-CD20 / Anti-CD3 bispecific antibodies
Patent Information
- Application Number
- JP2023084249
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-05-14
- Filing Date
- 2023-05-23
- Publication Date
- 2024-11-07
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current bispecific antibodies for treating CD20-positive cell proliferative disorders, such as B-cell lymphomas, face challenges with high toxicity, including cytokine release syndrome and infusion-related reactions, limiting their effectiveness and safety.
A dosing regimen for bispecific antibodies that bind to CD20 and CD3, involving a step-up fractional dosing cycle with a higher third dose and subsequent lower base doses, reducing toxicity while maintaining efficacy, particularly through a method that includes a loading dose followed by lower maintenance doses.
The regimen effectively treats CD20-positive disorders with reduced toxicity, such as cytokine release syndrome, while achieving high response rates and prolonged duration of response, including complete and partial responses.
Smart Images

Figure 00000168_0000 
Figure 00000168_0001 
Figure 00000169_0000
Abstract
Description
Technical field
[0001] Sequence list This application contains a sequence listing submitted electronically in ASCII format, which is incorporated herein by reference in its entirety. The name of the ASCII copy created on October 28, 2021 is 50474-234WO3_Sequence_Listing_10_28_21_ST25 and the size is 35,298 bytes.
[0002] field of invention The present invention relates to the treatment of CD20-positive cell proliferative disorders. More specifically, the invention provides treatment of subjects with CD20-positive cell proliferative disorders by administration of bispecific antibodies that bind to anti-differentiation antigen group 20 (CD20) and anti-differentiation antigen group 3 (CD3). Regarding. [Background technology]
[0003] Background of the invention Cancer is characterized by uncontrolled proliferation of cell subpopulations. Cancer is the number one cause of death in the developed world and the second leading cause of death in the developing world, with over 14 million new cancer cases diagnosed and over 8 million cancer deaths each year. It is occurring. Cancer care therefore represents a significant and growing societal burden.
[0004] CD20-positive cell proliferative disorders, such as B-cell proliferative disorders, are a major cause of cancer-related death. For example, non-Hodgkin's lymphoma (NHL) is rapidly progressive and fatal if untreated. In the United States, B-cell lymphoma comprises approximately 80%-85% of all NHL cases. Diffuse large B-cell lymphoma (DLBCL) is the most common type of NHL, accounting for approximately 30%-40% of all NHL diagnoses, and follicular lymphoma (FL; 20%-25% of all NHL diagnoses). %) and mantle cell lymphoma (MCL; 6% to 10% of all NHL diagnoses). B-cell chronic lymphocytic leukemia (CLL) is the most common leukemia in adults, with approximately 15,000 new cases per year in the United States (American Cancer Society, 2015).
[0005] Bispecific antibodies target cell surface antigens through binding to cytotoxic cells (e.g., surface antigen class 3 (CD3)) with the intent that the bound cytotoxic cells destroy the bound cancer cells. It is possible to simultaneously bind on cancer cells (eg, B cells, etc. through binding to CD20). However, the use of antibody-based immunotherapies such as these has been associated with cytokine-driven toxicity (e.g., cytokine release syndrome (CRS)), infusion-related reactions (IRR), severe tumor lysis syndrome (TLS), and central nervous system (CNS) may be limited by undesirable effects, including CNS) toxicity.
[0006] Therefore, therapeutic bispecific antibodies (e.g., dual antibodies that bind CD20 and CD3) for the treatment of CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders) achieve a more favorable benefit-risk profile. There is an unmet need in the field to develop effective methods of administering specific antibodies. [Summary of the invention]
[0007] Summary of the invention The present invention provides bispecific antibodies that bind to anti-cluster of differentiation 20 (CD20) and anti-cluster of differentiation 3 (CD3), which reduce the risk of undesirable side effects such as cytokine-driven toxicity such as CRS. The present invention relates to a method of treating a subject with a CD20-positive cell proliferative disorder (eg, a B cell proliferative disorder) by administering (eg, intravenous administration) a sexual antibody.
[0008] The present invention provides a method for administering a relatively higher third dose (C1D3) and / or third administration cycle (C3D1) and / or a second administration in an amount greater than the dose of the additional administration cycle (“base dose”). A bispecific antibody (C2D1) that binds to CD20 and CD3 over multiple dosing cycles (e.g., the first dosing cycle is a step-up fractional dosing cycle) comprising a dose (“loading dose”) of cycle (C2D1). For example, a dosing regimen comprising administering a drug (eg, monetuzumab) effectively treats a subject with a CD20-positive cell proliferative disorder (e.g., B cell proliferative disorder) while reducing toxicity (e.g., cytokine release syndrome). Based in part on the discovery that Loading doses may increase efficacy during the critical day 0-42 period, where patients may have residual anti-CD20 monoclonal antibodies present from previous therapy, and for patients with high tumor burden. Step-up dosing can reduce the toxicity of cytokine release syndrome, and administering a base dose lower than the loading dose can potentially reduce chronic toxicity (e.g., neutropenia, infections, etc.) .
[0009] In one aspect, the invention provides a method for treating CD20-positive cell proliferative disorders (e.g., B-cell proliferative disorders (e.g., relapsed or refractory B-cell proliferative disorders), e.g., non-Hodgkin's lymphoma (NHL; e.g., diffuse large cell type B-cell lymphoma (DLBCL; e.g., Richter's transformed), follicular lymphoma (FL; e.g., grade 1FL, grade 2FL, grade 3FL (e.g., grade 3aFL or grade 3bFL) or transformed FL), mantle cell lymphoma ( MCL), or marginal zone lymphoma (MZL)), or chronic lymphocytic leukemia (CLL), such as relapsed or refractory NHL (e.g. relapsed or refractory DLBCL, relapsed or refractory FL, relapsed or refractory 1. A method of treating a subject with refractory MCL, or relapsed or refractory MZL) or relapsed or refractory CLL, comprising: administering CD20 and administering to the subject a bispecific antibody that binds CD3, wherein (a) the first administration cycle comprises a first dose (C1D1), a second dose (C1D2) and a third dose (C1D3); ), and C1D1 contains about 0.02 mg to about 2.0 mg (for example, about 0.02 to about 1.8 mg, about 0.02 to about 1.6 mg, about 0.02 to about 1.4 mg, about 0.02 to about 1.2 mg, about 0.05 to about 1.8 mg, about 0.1 to about 1.8 mg, about 0.4 to about 1.8 mg, about 0.6 to about 1.8 mg, about 0.8 to about 1.8 mg, about 0.5 to about 1.5 mg, about 0.8 to about 1.2 mg; e.g. , about 1 mg), and C1D2 is about 0.05 mg to about 4.0 mg (for example, about 0.05 to about 3.5 mg, about 0.05 to about 3.0 mg, about 0.05 to about 2.5 mg, about 0.05 to about 2.2 mg, about 0.1 to about About 3.5 mg, about 0.5 to about 3.5 mg, about 1.0 to about 3.5 mg, about 1.5 to about 3.5 mg, about 1.8 to about 3.5 mg, about 1.0 to about 3.0 mg, about 1.5 to about 2.5 mg; For example, about 2 mg ) and the C1D3 is greater than about 50 mg; (b) the second administration cycle comprises a single dose (C2D1) of the bispecific antibody.
[0010] In some embodiments, C1D3 is 50 mg to 200 mg (e.g., 50 mg to 175 mg, 50 mg to 150 mg, 50 mg to 125 mg, 50 mg to 100 mg, 50 mg to 75 mg, 50 mg to 70 mg, 52 mg to 100 mg, 52 mg to 75 mg, 50 mg to 180 mg, 55 mg to 150 mg, 55 mg to 100 mg, 55 mg to 70 mg, 55 mg to 65 mg, 58 mg to 62 mg; for example, about 60 mg). In some embodiments, the C1D3 is about 60 mg. In some embodiments, C1D1 is about 1 mg. In some embodiments, C1D2 is about 2 mg. In some embodiments, C2D1 is in about the same amount as C1D3.
[0011] In some embodiments, C1D1, C1D2, and C1D3 are administered on days 1, 8, and 15, or on days 1, 8, and 15, respectively, of the first administration cycle. administered to said subject. In some embodiments, C2D1 is administered to the subject on day 1 of the second administration cycle.
[0012] In some embodiments, the first administration cycle and the second administration cycle are 21 day administration cycles. In some embodiments, the second administration cycle is a 28 day administration cycle.
[0013] In some embodiments, the dosing regimen further comprises one or more additional dosing cycles after the second dosing cycle. In some embodiments, the dosing regimen includes 6 to 15 additional dosing cycles (e.g., 6 to 10 additional dosing cycles (e.g., 6 additional dosing cycles) after the second dosing cycle. administration cycle, 7 additional administration cycles, 8 additional administration cycles, 9 additional administration cycles, or 10 additional administration cycles), or 11 to 15 additional administration cycles (e.g. , 11 additional dosing cycles, 12 additional dosing cycles, 13 additional dosing cycles, 14 additional dosing cycles, or 15 additional dosing cycles). Some embodiments In some embodiments, the additional dosing cycle is a 21 day dosing cycle. In some embodiments, the additional dosing cycle is a 28 day dosing cycle.
[0014] In some embodiments, the one or more additional cycles of administration include an additional single dose of bispecific antibody. In some embodiments, an additional single dose of bispecific antibody is administered to the subject on day 1 of each additional administration cycle.
[0015] In some embodiments, an additional single dose (eg, a base dose) of bispecific antibody is greater than C1D1 and less than C1D3 and / or C2D1 (eg, a loading dose). In some embodiments, the additional single dose (e.g., base dose) of bispecific antibody is between 20% and 80% (e.g., between 20% and 70%) of C1D3 and / or C2D1 (e.g., loading dose). %, 20%~60%, 20%~55%, 30%~80%, 30%~70%, 40%~70%, 45%~70%, 40%~60%, 45%~55%, 48% to 52%; for example, about 50%). In some embodiments, the additional single dose of bispecific antibody is about 50% of the C1D3 and / or C2D1 (eg, loading dose).
[0016] In some embodiments, the additional single dose of bispecific antibody is about 30 mg.
[0017] In another aspect, the invention provides a method of treating a subject with a CD20-positive cell proliferative disorder, comprising: a dosing regimen comprising at least a first dosing cycle, a second dosing cycle, and a third dosing cycle; administering to the subject a bispecific antibody that binds CD20 and CD3, the first administration cycle comprising: (a) a first dose (C1D1), a second dose (C1D2) and a third dose; (C1D3); mg, about 0.05 to about 1.8 mg, about 0.1 to about 1.8 mg, about 0.4 to about 1.8 mg, about 0.6 to about 1.8 mg, about 0.8 to about 1.8 mg, about 0.5 to about 1.5 mg, about 0.8 to about 1.2 mg ; For example, about 1 mg), and C1D2 is about 0.05 mg to about 4.0 mg (for example, about 0.05 to about 3.5 mg, about 0.05 to about 3.0 mg, about 0.05 to about 2.5 mg, about 0.05 to about 2.2 mg, about 0.1 to about 3.5 mg, about 0.5 to about 3.5 mg, about 1.0 to about 3.5 mg, about 1.5 to about 3.5 mg, about 1.8 to about 3.5 mg, about 1.0 to about 3.0 mg, about 1.5 to about 2.5 mg; For example, (b) the second dosing cycle comprises a single dose (C2D1) of the bispecific antibody, and C2D1 is in an amount approximately equivalent to C1D3; (c) The third administration cycle is characterized by a method comprising a single dose (C3D1) of the bispecific antibody, C3D1 being more than C1D1 and less than C2D1.
[0018] In some embodiments, C1D3 and C2D1 (e.g., loading dose) are each 20mg to 200mg (e.g., 20mg to 175mg, 20mg to 150mg, 20mg to 100mg, 20mg to 75mg, 30mg to 175mg, 40mg to 175mg, 45mg ~175mg, 50mg~175mg, 30mg~150mg, 40mg~100mg, 45mg~75mg, 50mg~70mg, 55mg~65mg, 58mg~62mg;, about 20mg, about 30mg, about 45mg, or, for example, about 60mg). In some embodiments, C1D3 and C2D1 are each about 60 mg. In some embodiments, C3D1 is about 20% to about 80% of C2D1 (e.g., about 20% to about 70%, about 20% to about 60%, about 20% to about 55%, about 30% to Approximately 80%, approximately 30% to approximately 70%, approximately 40% to approximately 70%, approximately 45% to approximately 70%, approximately 40% to approximately 60%, approximately 45% to approximately 55%, or approximately 48% to approximately 52%; eg, about 40%, about 45%, about 50%, about 55%, or about 60%). In some embodiments, C3D1 is about 50% of C2D1. In some embodiments, C3D1 is about 12 mg to about 48 mg (e.g., about 12 mg to about 42 mg, about 12 mg to about 36 mg, about 12 mg to about 30 mg, about 18 mg to about 48 mg, about 18 mg to about 42 mg, about 24 mg ~about 42 mg, about 27 mg to about 42 mg, about 24 mg to about 36 mg, about 27 mg to about 33 mg, about 28 mg to about 32 mg; for example, about 24 mg, about 27 mg, about 30 mg, about 33 mg, or about 36 mg). In certain embodiments, the C3D1 is about 30 mg.
[0019] In some embodiments, the C3D1 is about 30 mg. In some embodiments, C1D1 is about 1 mg. In some embodiments, C1D2 is about 2 mg.
[0020] In some embodiments, C1D1, C1D2, and C1D3 are administered on days 1, 8, and 15, or on days 1, 8, and 15, respectively, of the first administration cycle. administered to said subject. In some embodiments, C2D1 is administered to the subject on day 1 of the second administration cycle and C3D1 is administered to the subject on day 1 of the third administration cycle. In some embodiments, the first dosing cycle, the second dosing cycle and the third dosing cycle are 21 day dosing cycles. In some embodiments, the second administration cycle and / or the third administration cycle is a 28 day administration cycle.
[0021] In some embodiments, the dosing regimen further comprises one or more additional dosing cycles after the third dosing cycle. In some embodiments, the dosing regimen includes 5 to 14 additional dosing cycles (e.g., 5 to 10 additional dosing cycles (e.g., 5 additional dosing cycles) after the third dosing cycle. dosing cycle, 6 additional dosing cycles, 7 additional dosing cycles, 8 additional dosing cycles, 9 additional dosing cycles, or 10 additional dosing cycles) or 11 to 14 times. (eg, 11 additional dosing cycles, 12 additional dosing cycles, 13 additional dosing cycles, 14 additional dosing cycles). In some embodiments, the additional dosing cycle is a 21 day dosing cycle. In some embodiments, the additional dosing cycle is a 28 day dosing cycle.
[0022] In some embodiments, one or more additional cycles of administration include an additional single dose (eg, a base dose) of the bispecific antibody. In some embodiments, an additional single dose of bispecific antibody is administered to the subject on day 1 of each additional administration cycle. In some embodiments, the additional single dose of bispecific antibody is about the same amount as C3D1.
[0023] In an additional aspect, the invention provides a method of treating a subject with a CD20-positive cell proliferative disorder, comprising administering a bispecific antibody that binds to CD20 and CD3 in a regimen comprising eight or more cycles of administration. (a) the first administration cycle comprises a first dose (C1D1), a second dose (C1D2) and a third dose (C1D3) of the bispecific antibody; , C1D1 is about 0.02 mg to about 2.0 mg (for example, about 0.02 to about 1.8 mg, about 0.02 to about 1.6 mg, about 0.02 to about 1.4 mg, about 0.02 to about 1.2 mg, about 0.05 to about 1.8 mg, about 0.1 ~about 1.8 mg, about 0.4 to about 1.8 mg, about 0.6 to about 1.8 mg, about 0.8 to about 1.8 mg, about 0.5 to about 1.5 mg, about 0.8 to about 1.2 mg; for example, about 1 mg), and C1D2 is About 0.05 mg to about 4.0 mg (for example, about 0.05 to about 3.5 mg, about 0.05 to about 3.0 mg, about 0.05 to about 2.5 mg, about 0.05 to about 2.2 mg, about 0.1 to about 3.5 mg, about 0.5 to about 3.5 mg, about 1.0 to about 3.5 mg, about 1.5 to about 3.5 mg, about 1.8 to about 3.5 mg, about 1.0 to about 3.0 mg, about 1.5 to about 2.5 mg; for example, about 2 mg), and C1D3 is about 20 mg broadly; (b) the second dosing cycle contains a single dose (C2D1) of the bispecific antibody, where C2D1 is approximately equivalent in amount to C1D3; (c) the third dosing cycle contains a single dose (C2D1) of the bispecific antibody; (d) the fourth administration cycle comprises a single dose (C4D1) of the bispecific antibody; (d) the fourth administration cycle comprises a single dose (C4D1) of the bispecific antibody; e) the fifth dosing cycle comprises a single dose (C5D1) of the bispecific antibody; (f) the sixth dosing cycle comprises a single dose (C6D1) of the bispecific antibody; g) the seventh dosing cycle comprises a single dose (C7D1) of the bispecific antibody; (h) the eighth dosing cycle comprises a single dose (C8D1) of the bispecific antibody; The method is characterized in that C3D1-C8D1 (eg, base doses) are approximately equivalent amounts.
[0024] In some embodiments, C1D3 and C2D1 (e.g., loading dose) are each 20mg to 200mg (e.g., 20mg to 175mg, 20mg to 150mg, 20mg to 100mg, 20mg to 75mg, 30mg to 175mg, 40mg to 175mg, 45mg ~175mg, 50mg~175mg, 30mg~150mg, 40mg~100mg, 45mg~75mg, 50mg~70mg, 55mg~65mg, 58mg~62mg; for example, about 60mg). In some embodiments, C1D3 and C2D1 are each about 60 mg.
[0025] In some embodiments, C3D1 is about 20% to about 80% of C2D1 (e.g., about 20% to about 70%, about 20% to about 60%, about 20% to about 55%, about 30% to Approximately 80%, approximately 30% to approximately 70%, approximately 40% to approximately 70%, approximately 45% to approximately 70%, approximately 40% to approximately 60%, approximately 45% to approximately 55%, or approximately 48% to approximately 52%; eg, about 40%, about 45%, about 50%, about 55%, or about 60%). In some embodiments, C3D1 is about 50% of C2D1. In some embodiments, C3D1 is about 12 mg to about 48 mg (e.g., about 12 mg to about 42 mg, about 12 mg to about 36 mg, about 12 mg to about 30 mg, about 18 mg to about 48 mg, about 18 mg to about 42 mg, about 24 mg ~about 42 mg, about 27 mg to about 42 mg, about 24 mg to about 36 mg, about 27 mg to about 33 mg, about 28 mg to about 32 mg; for example, about 24 mg, about 27 mg, about 30 mg, about 33 mg, or about 36 mg). In certain embodiments, the C3D1 is about 30 mg.
[0026] In some embodiments, the C3D1 is about 30 mg. In some embodiments, C1D1 is about 1 mg. In some embodiments, C1D2 is about 2 mg.
[0027] In some embodiments, C1D1, C1D2, and C1D3 are administered on days 1, 8, and 15, or on days 1, 8, and 15, respectively, of the first administration cycle. Administer to subject. In some embodiments, each of C2D1-C8D1 is administered to the subject on day 1 of the second through eighth administration cycles, respectively. In some embodiments, the dosing cycle is a 21 day dosing cycle. In some embodiments, the administration cycle after the first administration cycle is a 28 day administration cycle.
[0028] In some embodiments, the dosing regimen includes one or more additional dosing cycles after the eighth dosing cycle. In some embodiments, the additional dosing cycle is a 21 day dosing cycle. In some embodiments, the additional dosing cycle is a 28 day dosing cycle.
[0029] In some embodiments, the one or more additional cycles of administration include an additional single dose of bispecific antibody. In some embodiments, an additional single dose of bispecific antibody is administered to the subject on day 1 of each additional administration cycle. In some embodiments, the additional single dose of bispecific antibody is in an amount approximately equivalent to any one of C3D1-C8D1 (eg, the base dose).
[0030] In a further aspect, the invention provides a method of treating a subject with a CD20-positive cell proliferative disorder, the method comprising: binding to CD20 and CD3 in a regimen comprising eight or more 21-day or 28-day dosing cycles. (a) a first 21-day administration cycle comprising administering a bispecific antibody to said subject, wherein a first dose (C1D1), a second dose (C1D2) and a third dose (C1D3) ), C1D1 is approximately 1 mg, C1D2 is approximately 2 mg, and C1D3 is approximately 60 mg; (b) the second dosing cycle consists of a single dose (C2D1) double (c) the third dosing cycle comprises a single dose (C3D1) of bispecific antibody; (d) the fourth dosing cycle comprises a single dose (C3D1) of bispecific antibody; (e) the fifth dosing cycle comprises a single dose (C5D1) of the bispecific antibody; (f) the sixth dosing cycle comprises a single dose (C5D1) of the bispecific antibody; (g) the seventh dosing cycle comprises a single dose (C7D1) of the bispecific antibody; (h) the eighth dosing cycle comprises a single dose (C7D1) of the bispecific antibody; The method features a method comprising one dose (C8D1) of the bispecific antibody, where each of C3D1-C8D1 (eg, base dose) is about 30 mg. In some embodiments, the administration cycle after the first administration cycle is a 28 day administration cycle.
[0031] In some embodiments, the subject has received prior systemic therapy for a CD20-positive cell proliferative disorder. In some embodiments, the subject has received first-line and second-line systemic therapy for a CD20-positive cell proliferative disorder. In some embodiments, the subject exhibits progression of a CD20-positive cell proliferative disorder within 24 months of prior systemic therapy.
[0032] In some embodiments, the preceding systemic therapy comprises an anti-CD20 antibody. In some embodiments, the anti-CD20 antibody is rituximab. In some embodiments, the anti-CD20 antibody is obinutuzumab.
[0033] In some embodiments, the preceding systemic therapy includes a chemotherapeutic agent. In some embodiments, the chemotherapeutic agent is an alkylating agent. In some embodiments, the alkylating agent is bendamustine. In some embodiments, the chemotherapeutic agent is lenalidomide.
[0034] In some embodiments, the preceding systemic therapy comprises radioimmunotherapy. In some embodiments, the radioimmunotherapy is ibritumomab tiuxetan.
[0035] In some embodiments, the preceding systemic therapy comprises a phosphoinositide 3-kinase inhibitor. In some embodiments, the phosphoinositide 3-kinase inhibitor is selected from the group comprising idelalisib, alpelisib, copanlisib, and duvelisib.
[0036] In some embodiments, the preceding systemic therapy comprises CAR-T therapy.
[0037] In some embodiments, the subject is a human.
[0038] In some embodiments of any of the methods of the invention, the bispecific antibody is administered intravenously.
[0039] In yet another aspect, the invention provides a method of treating a population of subjects with a CD20-positive cell proliferative disorder, the method comprising: administering CD20 and CD3 in a regimen comprising at least a first administration cycle and a second administration cycle. (a) the first administration cycle comprises administering to said subject a bispecific antibody that binds to a first dose (C1D1), a second dose (C1D2) and a third dose (C1D3). ), and C1D1 contains about 0.02 mg to about 2.0 mg (for example, about 0.02 to about 1.8 mg, about 0.02 to about 1.6 mg, about 0.02 to about 1.4 mg, about 0.02 to about 1.2 mg, about 0.05 to about 1.8 mg, about 0.1 to about 1.8 mg, about 0.4 to about 1.8 mg, about 0.6 to about 1.8 mg, about 0.8 to about 1.8 mg, about 0.5 to about 1.5 mg, about 0.8 to about 1.2 mg; e.g. , about 1 mg), and C1D2 is about 0.05 mg to about 4.0 mg (for example, about 0.05 to about 3.5 mg, about 0.05 to about 3.0 mg, about 0.05 to about 2.5 mg, about 0.05 to about 2.2 mg, about 0.1 to about About 3.5 mg, about 0.5 to about 3.5 mg, about 1.0 to about 3.5 mg, about 1.5 to about 3.5 mg, about 1.8 to about 3.5 mg, about 1.0 to about 3.0 mg, about 1.5 to about 2.5 mg; For example, about 2 mg ) and the C1D3 is greater than about 50 mg; (b) the second administration cycle comprises a single dose (C2D1) of the bispecific antibody.
[0040] In some embodiments, C1D 3 is 50mg to 200mg (e.g., 50mg to 175mg, 50mg to 150mg, 50mg to 125mg, 50mg to 100mg, 50mg to 75mg, 50mg to 70mg, 52mg to 100mg, 52mg to 75mg, 50mg ~180mg, 55mg~150mg, 55mg~100mg, 55mg~70mg, 55mg~65mg, 58mg~62mg; for example, about 60mg).
[0041] In another aspect, the invention provides a method of treating a population of subjects with a CD20-positive cell proliferative disorder, comprising a dosing regimen comprising at least a first dosing cycle, a second dosing cycle, and a third dosing cycle. (a) a first administration cycle comprising administering to a subject a bispecific antibody that binds CD20 and CD3; of the bispecific antibody (C1D3), C1D1 is about 0.02 mg to about 2.0 mg (e.g., about 0.02 to about 1.8 mg, about 0.02 to about 1.6 mg, about 0.02 to about 1.4 mg, about 0.02 to about 2.0 mg) Approximately 1.2 mg, approximately 0.05 to approximately 1.8 mg, approximately 0.1 to approximately 1.8 mg, approximately 0.4 to approximately 1.8 mg, approximately 0.6 to approximately 1.8 mg, approximately 0.8 to approximately 1.8 mg, approximately 0.5 to approximately 1.5 mg, approximately 0.8 to approximately 1.2 mg; for example, about 1 mg), and C1D2 is about 0.05 mg to about 4.0 mg (for example, about 0.05 to about 3.5 mg, about 0.05 to about 3.0 mg, about 0.05 to about 2.5 mg, about 0.05 to about 2.2 mg). , about 0.1 to about 3.5 mg, about 0.5 to about 3.5 mg, about 1.0 to about 3.5 mg, about 1.5 to about 3.5 mg, about 1.8 to about 3.5 mg, about 1.0 to about 3.0 mg, about 1.5 to about 2.5 mg; (b) the second dosing cycle includes a single dose (C2D1) of the bispecific antibody, and C2D1 is in an approximately equivalent amount as C1D3; Yes; (c) the third administration cycle is characterized by a method comprising a single dose (C3D1) of the bispecific antibody, C3D1 being more than C1D1 and less than C2D1.
[0042] In another aspect, the invention provides a method of treating a population of subjects with a CD20-positive cell proliferative disorder, comprising: a bispecific protein that binds to CD20 and CD3 in a dosing regimen comprising eight or more cycles of administration; (a) the first administration cycle comprises administering to the subject a first dose (C1D1), a second dose (C1D2), and a third dose (C1D3) of the bispecific antibody; C1D1 is about 0.02 mg to about 2.0 mg (for example, about 0.02 to about 1.8 mg, about 0.02 to about 1.6 mg, about 0.02 to about 1.4 mg, about 0.02 to about 1.2 mg, about 0.05 to about 1.8 mg, about 0.1 to about 1.8 mg, about 0.4 to about 1.8 mg, about 0.6 to about 1.8 mg, about 0.8 to about 1.8 mg, about 0.5 to about 1.5 mg, about 0.8 to about 1.2 mg; for example, about 1 mg), C1D2 is about 0.05 mg to about 4.0 mg (for example, about 0.05 to about 3.5 mg, about 0.05 to about 3.0 mg, about 0.05 to about 2.5 mg, about 0.05 to about 2.2 mg, about 0.1 to about 3.5 mg, about 0.5 to about about 3.5 mg, about 1.0 to about 3.5 mg, about 1.5 to about 3.5 mg, about 1.8 to about 3.5 mg, about 1.0 to about 3.0 mg, about 1.5 to about 2.5 mg; for example, about 2 mg), and C1D3 is about greater than 20 mg; (b) the second dosing cycle includes a single dose (C2D1) of the bispecific antibody, where C2D1 is approximately equivalent to C1D3; (c) the third dosing cycle , comprising a single dose (C3D1) of the bispecific antibody, where C3D1 is more than C1D1 and less than C2D1; (d) the fourth administration cycle comprises a single dose (C4D1) of the bispecific antibody; (e) the fifth dosing cycle comprises a single dose (C5D1) of the bispecific antibody; (f) the sixth dosing cycle comprises a single dose (C6D1) of the bispecific antibody; ;(g) the seventh dosing cycle comprises a single dose (C7D1) of the bispecific antibody; (h) the eighth dosing cycle comprises a single dose (C8D1) of the bispecific antibody; and C3D1 to C8D1 (eg, base doses) are approximately equivalent amounts.
[0043] In some embodiments, C1D3 and C2D1 (e.g., loading dose) are each 20mg to 200mg (e.g., 20mg to 175mg, 20mg to 150mg, 20mg to 100mg, 20mg to 75mg, 30mg to 175mg, 40mg to 175mg, 45mg ~175mg, 50mg~175mg, 30mg~150mg, 40mg~100mg, 45mg~75mg, 50mg~70mg, 55mg~65mg, 58mg~62mg; for example, about 20mg, about 30mg, about 45mg, or about 60mg). In some embodiments, C1D3 and C2D1 are each about 60 mg.
[0044] In a further aspect, the invention provides a method of treating a population of subjects with a CD20-positive cell proliferative disorder, the method comprising: treating CD20 and CD3 in a regimen comprising eight or more 21-day or 28-day dosing cycles. administering to said subject a bispecific antibody that binds (a) a first 21-day administration cycle comprising: a first dose (C1D1), a second dose (C1D2), and a third dose; (C1D3), where C1D1 is about 1 mg, C1D2 is about 2 mg, and C1D3 is about 60 mg; (b) the second dosing cycle consists of a single dose of (C2D1); (c) the third dosing cycle comprises a single dose (C3D1) of the bispecific antibody; (d) the fourth dosing cycle comprises: (e) the fifth dosing cycle comprises a single dose (C5D1) of the bispecific antibody; (f) the sixth dosing cycle comprises: (g) the seventh dosing cycle comprises a single dose (C7D1) of the bispecific antibody; (h) the eighth dosing cycle comprises a single dose (C7D1) of the bispecific antibody; , containing a single dose (C8D1) of the bispecific antibody, with each of C3D1-C8D1 (eg, base dose) approximately 30 mg. In some embodiments, the administration cycle after the first administration cycle is a 28 day administration cycle.
[0045] In some embodiments, the complete response rate is at least about 15% (e.g., about 15% to about 30%, about 15% to about 40%, about 15% to about 50%, about 15% to about 60%). , about 15% to about 75%, about 15% to about 80%, about 15% to about 90%, about 15% to about 100%, about 20% to about 100%, about 20% to about 75%, about 20% to about 50%, about 25% to about 100%, about 25% to about 75%, about 25% to about 50%, about 30% to about 75%, about 30% to about 100%, or about 30 % to about 50%; for example, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, or about 45%). In some embodiments, the complete response rate is at least about 45% (e.g., about 45% to about 60%, about 45% to about 70%, about 45% to about 80%, about 45% to about 95%). , about 45% to about 100%, about 50% to about 100%, about 50% to about 95%, or about 50% to about 75%; for example, about 45%, about 50%, about 55%, or about 60%).
[0046] In some embodiments, the objective response rate is at least about 60% (e.g., about 60% to about 70%, about 60% to about 80%, about 60% to about 90%, or about 60% to about 100%). %; for example, about 60%, about 65%, about 70%, about 75%, about 80%, or about 85%). In some embodiments, the objective response rate at about 20 months after initiation of treatment is at least about 70% (e.g., about 70% to about 80%, about 70% to about 90%, about 70% to about 95%). , or about 70% to about 100%; for example, about 70%, about 75%, about 80%, about 85%, or about 90%).
[0047] In some embodiments, the objective response rate at about 24 months after initiation of treatment is at least about 75% (e.g., about 75% to about 80%, about 75% to about 90%, about 75% to about 95%). %, about 75% to about 100%, about 80% to about 100%, or about 90% to about 100%; for example, about 75%, about 80%, about 85%, or about 90%).
[0048] In some embodiments, the median duration of response (mDOR) is at least about 12 months (e.g., at least about 14 months, at least about 16 months, at least about 18 months; e.g., between about 12 months and about 14 months). from about 12 months to about 16 months, from about 12 months to about 18 months, or from about 12 months to about 20 months; e.g., about 12 months, about 14 months, about 16 months, or about 18 months) It is. In some embodiments, the mDOR is at least about 20 months (e.g., at least about 22 months, at least about 24 months, at least about 26 months, at least about 28 months, at least about 30 months, at least about 32 months, at least about 34 months). or at least about 36 months; for example, between about 20 months and about 24 months, between about 20 months and about 30 months, between about 20 months and about 36 months, between about 20 months and about 48 months, about 20 months to approximately 60 months, approximately 20 months to approximately 72 months, approximately 24 months to approximately 36 months, approximately 24 months to approximately 48 months, approximately 24 months to approximately 60 months, approximately Between 36 months and about 48 months, or between about 36 months and about 60 months; for example, about 20 months, about 24 months, about 28 months, about 32 months, about 36 months, about 40 months, about 48 months, (approximately 56 months, or approximately 60 months). In some embodiments, the population of subjects has a proportion of subjects in the population with a DOR of at least 12 months, and the proportion of subjects in the population with a DOR of at least 12 months is at least about 60% (e.g., about 60% to about 70%, about 60% to about 80%, about 60% to about 90%, or about 60% to about 100%; for example, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, or about 95%).
[0049] In some embodiments, the population of subjects exhibits cytokine release syndrome after administration of the bispecific antibody, and the proportion of cytokine release syndrome in the population of subjects is about 25% (e.g., about 23% or less, about 20%). % or less, about 18% or less, about 16% or less, about 15% or less, about 14% or less, about 13% or less, about 12% or less, about 11% or less, about 10% or less; For example, about 1% to about 25%, about 5% to about 25%, about 10% to about 25%, about 15% to about 25%, about 20% to about 25%, about 5% to about 15%, about 5% to about 10% , about 1% to about 15%, or about 1% to about 10%; for example, about 24%, about 22%, about 20%, about 18%, about 16%, about 14%, about 12%, about 10 %, about 8%, about 6%, about 5%, about 4%, about 3%, about 2%, about 1%, or about 0%). In some embodiments, the rate of cytokine release syndrome in the subject population is about 10% or less.
[0050] In some embodiments, cytokine release having grade 2 or higher (as defined by American Society for Transplantation and Cell Therapy, 2018; ASTCT; e.g., a grade between 2 and 5, e.g., a grade of 2, 3, 4, or 5). The proportion of the syndrome is about 10% or less (e.g. about 9% or less, about 8% or less, about 7% or less, about 6% or less, about 5% or less, about 4% or less, about 3% or less, about 2%) less than about 1%; for example, about 0.1% to about 10%, about 0.5% to about 10%, about 1% to about 10%, about 1% to about 7%, about 1% to about 5%, about 1% to about 3%, or about 5% to about 10%; for example, about 10%, about 8%, about 6%, about 5%, about 4%, about 3%, about 2%, about 1%, or approximately 0%). In some embodiments, the proportion of cytokine release syndrome having Grade 2 or higher (as defined by ASTCT) is about 5% (e.g., about 4% or less, about 3% or less, about 2% or less, about 1% or less; For example, about 0% to about 5%, about 1% to about 5%, about 2% to about 5%, about 3% to about 5%, about 4% to about 5%, about 1% to about 3%, from about 2% to about 5%, or from about 0% to about 2%; for example, about 5%, about 4%, about 3%, about 2%, about 1%, or about 0%). In some embodiments, the proportion of cytokine release syndrome having grade 3 or higher (as defined by ASTCT, eg, grades 3-5, eg, grades 3, 4, or 5) is about 0.
[0051] In some embodiments, the CD20 positive cell proliferative disorder is a B cell proliferative disorder. In some embodiments, the CD20-positive cell proliferative disorder is a relapsed or refractory B-cell proliferative disorder. In some embodiments, the CD20-positive cell proliferative disorder is non-Hodgkin's lymphoma (NHL) or chronic lymphocytic leukemia (CLL). In some embodiments, the NHL is diffuse large B-cell lymphoma (DLBCL). In some embodiments, the DLBCL is Richter's transformation. In some embodiments, the NHL is follicular lymphoma (FL). In some embodiments, the FL is a grade 1, 2, 3a or 3b FL. In some embodiments, the FL is a transformed FL. In some embodiments, the NHL is mantle cell lymphoma (MCL) or marginal zone lymphoma (MZL).
[0052] In some embodiments, the bispecific antibody has six hypervariable regions (HVRs): (a) HVR-H1 comprising the amino acid sequence of GYTFTSYNMH (SEQ ID NO: 1); (b) AIYPGNGDTSYNQKFKG (SEQ ID NO: 1); HVR-H2 containing the amino acid sequence of 2); (c) HVR-H3 containing the amino acid sequence of VVYYSNSYWYFDV (SEQ ID NO: 3); (d) HVR-L1 containing the amino acid sequence of RASSSVSYMH (SEQ ID NO: 4); (e) and (f) HVR-L3 comprising the amino acid sequence of QQWSFNPPT (SEQ ID NO: 6).
[0053] In some embodiments, the bispecific antibody has (a) a heavy chain variable (VH) domain comprising an amino acid sequence that has at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 7; (b) a light chain variable (VL) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 8; or (c) a VH domain as in (a) and a VH domain as in (b). The first binding domain includes an anti-CD20 arm that includes a VL domain.
[0054] In some embodiments, the first binding domain comprises a VH domain comprising the amino acid sequence of SEQ ID NO: 7 and a VL domain comprising the amino acid sequence of SEQ ID NO: 8.
[0055] In some embodiments, the bispecific antibody comprises the following six HVRs: (a) HVR-H1, which includes the amino acid sequence of NYYIH (SEQ ID NO: 9); (b) the amino acid sequence of WIYPGDGNTKYNEKFKG (SEQ ID NO: 10); (c) HVR-H3 containing the amino acid sequence of DSYSNYYFDY (SEQ ID NO: 11); (d) HVR-L1 containing the amino acid sequence of KSSQSLLNSRTRKNYLA (SEQ ID NO: 12); (e) WASTRES (SEQ ID NO: 13) ); (f) HVR-L3 comprising the amino acid sequence of TQSFILRT (SEQ ID NO: 14);
[0056] In some embodiments, the bispecific antibody comprises: (a) a VH domain comprising an amino acid sequence that has at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 15; (b) the amino acid sequence of SEQ ID NO: 16. or (c) a second binding domain comprising a VH domain as in (a) and a VL domain as in (b). Contains an anti-CD3 arm.
[0057] In some embodiments, the second binding domain comprises a VH domain comprising the amino acid sequence of SEQ ID NO: 15 and a VL domain comprising the amino acid sequence of SEQ ID NO: 16.
[0058] In some embodiments, the bispecific antibody comprises (a) a heavy chain comprising (i) an amino acid sequence that has at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 51; an anti-CD20 arm comprising a light chain comprising an amino acid sequence having at least 95% sequence identity with the amino acid sequence; and (b) (i) an amino acid sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 53. and (ii) a light chain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 54. In some antibodies, (a) the anti-CD20 arm comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 51 and a light chain comprising the amino acid sequence of SEQ ID NO: 52, and (b) the anti-CD3 arm comprises the amino acid sequence of SEQ ID NO: 53. and a light chain comprising the amino acid sequence of SEQ ID NO: 54.
[0059] In some embodiments, the bispecific antibody is a humanized antibody. In some embodiments, the bispecific antibody is a chimeric antibody.
[0060] In some embodiments, the bispecific antibody is an antibody fragment that binds CD20 and CD3. In some embodiments, the antibody fragments include Fab fragments, Fab'-SH fragments, Fv fragments, scFv fragments, and (Fab') 2 selected from the group consisting of fragments.
[0061] In some embodiments, the bispecific antibody is a full-length antibody.
[0062] In some embodiments, the bispecific antibody is an IgG antibody. In some embodiments, the IgG antibody is an IgG1 antibody.
[0063] In some embodiments, the IgG antibody comprises a mutation at amino acid residue N297 (EU numbering) that results in the absence of glycosylation. In some embodiments, the mutation at amino acid residue N297 is a substitution mutation. In some embodiments, mutation of amino acid residue N297 reduces effector function of the Fc region. In some embodiments, the mutation is the N297G or N297A mutation.
[0064] In some embodiments, the bispecific antibody comprises a mutation in the Fc region that reduces effector function. In some embodiments, the mutation is a substitution mutation. In some embodiments, the substitution mutations are at amino acid residues L234, L235, D265, and / or P329 (EU numbering). In some embodiments, the substitution mutation is selected from the group consisting of L234A, L235A, D265A, and P329G.
[0065] In some embodiments, the bispecific antibody comprises one or more heavy chain constant domains, the one or more heavy chain constant domains comprising a first CH1 (CH1 1 ) domain, the first CH2 (CH2 1 ) domain, the first CH3 (CH3 1 ) domain, second CH1 (CH1 2 ) domain, second CH2 (CH2 2 ) domain, and a second CH3 (CH3 2 ) domain. In some embodiments, at least one of the one or more heavy chain constant domains is paired with another heavy chain constant domain.
[0066] In some embodiments, CH3 1 domain and CH3 2 Each domain constitutes a protrusion or a void, and CH3 1 The protrusions or voids in the domain are CH3 2 Positionable in voids or protrusions in the domain. In some embodiments, CH3 1 domain and CH3 2 The domains contact at the interface between the protrusion and the void.
[0067] In some embodiments, the anti-CD20 arm of the bispecific antibody further comprises the T366W and N297G substitution mutations (EU numbering). In some embodiments, the anti-CD3 arm of the bispecific antibody further comprises the following substitution mutations (EU numbering): T366S, L368A, Y407V, and N297G. In some embodiments, (a) the anti-CD20 arm further comprises the T366W and N297G substitution mutations, and (b) the anti-CD3 arm further comprises the T366S, L368A, Y407V and N297G substitution mutations (EU numbering). .
[0068] In some embodiments, the dosing regimen further comprises administering to the subject a PD-1 axis binding antagonist. In some embodiments, the PD-1 axis binding antagonist is about 1100 mg to about 1300 mg (e.g., about 1150 mg to about 1250 mg, about 1175 mg to about 1225 mg, about 1190 mg to about 1210 mg; e.g., 1200 mg ± 5 mg, e.g., 1200 mg to about 1210 mg; ±2.5 mg, eg 1200±1.0 mg, eg 1200±0.5 mg; eg about 1200 mg). In certain embodiments, the PD-1 axis binding antagonist is administered at a dose of about 1200 mg. In some embodiments, the PD-1 axis binding antagonist is administered on day 1 (±1 day) of each administration cycle after the first administration cycle that includes administration of the bispecific antibody. In some embodiments, the PD-1 axis binding antagonist is atezolizumab. In some embodiments, the subject is a human. [Brief explanation of drawings]
[0069] The contents of this application file contain at least one drawing executed in color. Copies of this patent or patent application with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
[0070]
Figure 1
Figure 2
[0071] Detailed description of the invention The present invention provides for administering to a subject (e.g., intravenous administration) a bispecific antibody that binds CD20 and CD3 (e.g., mosnetuzumab) in a dosing regimen that includes at least a first dosing cycle and a second dosing cycle. CD20-positive cell proliferative disorders (e.g., B-cell proliferative disorders (e.g., relapsed or refractory B-cell proliferative disorders), e.g., non-Hodgkin's lymphoma (NHL; e.g., diffuse large B-cell lymphoma) follicular lymphoma (DLBCL; e.g., Richter's transformation), follicular lymphoma (FL; e.g., grade 1FL, grade 2FL, grade 3FL (e.g., grade 3aFL or grade 3bFL) or transformed FL), mantle cell lymphoma (MCL), or marginal zone lymphoma (MZL)), or chronic lymphocytic leukemia (CLL), such as relapsed or refractory NHL (e.g., relapsed or refractory DLBCL, relapsed or refractory FL, relapsed or refractory MCL, or relapsed or refractory (MZL)) or relapsed or refractory CLL). In some examples, the first administration cycle includes a first dose (C1D1), a second dose (C1D2), and a third dose (C1D3) of the bispecific antibody, where C1D1 is about 0.02 mg ~about 2.0 mg, C1D2 is about 0.05 mg to about 4.0 mg, and C1D3 is more than about 50 mg. In some examples, the second administration cycle includes a single dose (C2D1) of the bispecific antibody. In some instances, C1D3 and C2D1 are collectively referred to as a "loading dose."
[0072] In some examples, the present invention provides a bispecific antibody that binds CD20 and CD3 (e.g., mosnetuzumab) in a dosing regimen that includes at least a first dosing cycle, a second dosing cycle, and a third dosing cycle. wherein the first administration cycle includes a first dose (C1D1), a second dose (C1D2), and a third dose (C1D3) of the bispecific antibody; is about 0.02 mg to about 2.0 mg, C1D2 is about 0.05 mg to about 4.0 mg, C1D3 is greater than about 20 mg, and the second dosing cycle includes a single dose (C2D1) of the bispecific antibody. , C2D1 is approximately equivalent in amount to C1D3, and the third dosing cycle includes a single dose (C3D1) of bispecific antibody, with C3D1 being more than C1D1 and less than C2D1.
[0073] As mentioned above, the present invention provides a method for administering a relatively higher third dose (C1D3) and / or third dosing cycle (C3D1) and / or additional dosing cycle (“base dose”) dose. A double dose that binds to CD20 and CD3 over multiple dosing cycles (e.g., the first dosing cycle is a step-up fractional dosing cycle) including a second dosing cycle (C2D1) dose (a "loading dose") of A dosing regimen that includes administering a heavy specific antibody (e.g., mosnetuzumab) can treat subjects with CD20-positive cell proliferative disorders (e.g., B-cell proliferative disorders) while reducing toxicity (e.g., cytokine release syndrome). Based in part on the discovery that it can be effectively treated. Loading doses may increase efficacy during the critical day 0-42 period, where patients may have residual anti-CD20 monoclonal antibodies present from previous therapy, and for patients with high tumor burden. Step-up dosing can reduce the toxicity of cytokine release syndrome, and administering a base dose lower than the loading dose can potentially reduce chronic toxicity (e.g., neutropenia, infections, etc.) .
[0074] I. General techniques The techniques and procedures described or referenced herein are generally well understood and are described, for example, in Sambrook et al., Molecular Cloning: A Laboratory Manual 3d edition (2001) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. ;Current Protocols in Molecular Biology(F.M.Ausubel,et al.,eds.,(2003));the series Methods in Enzymology(Academic Press,Inc.):PCR 2:A Practical Approach(M.J.MacPherson,B.D.Hames and G.R.Taylor eds.(1995)),Harlow and Lane,eds.(1988)Antibodies,A Laboratory Manual,and Animal Cell Culture(R.I.Freshney,ed.(1987));Oligonucleotide Synthesis(M.J.Gait,ed.,1984);Methods in Molecular Biology,Humana Press;Cell Biology:A Laboratory Notebook(J.E.Cellis, ed.,1998)Academic Press;Animal Cell Culture(R.I.Freshney),ed.,1987);Introduction to Cell and Tissue Culture(J.P.Mather and P.E. Roberts, 1998) Plenum Press; Cell and Tissue Culture: Laboratory Procedures (A. Doyle, J. B. Griffiths, and D. G. Newell, eds., 1993-8) J. Wiley and Sons; Handbook of Experimental Immunology (D. M. Weir and C. C. Blackwell, Gene Transfer Vectors for Mammalian Cells (J.M. Miller and M.P. Calos, eds., 1987); PCR: The Polymerase Chain Reaction, (Mullis et al., eds., 1994); Current Protocols in Immunology (J.E. Coligan et al. al.,eds.,1991);Short Protocols in Molecular Biology(Wiley and Sons,1999);Immunobiology(C.A.Janeway and P.Travers,1997);Antibodies(P.Finch,1997);Antibodies:A Practical Approach(D .Catty.,ed.,IRL Press,1988-1989);Monoclonal Antibodies:A Practical Approach(P.Shepherd and C.Dean,eds.,Oxford University Press,2000);Using Antibodies:A Laboratory Manual(E.Harlow and D. Lane (Cold Spring Harbor Laboratory Press, 1999); The Antibodies (M. Zanetti and J. D. Capra, eds., Harwood Academic Publishers, 1995); and Cancer: Principles and Practice of Oncology (V. T. DeVita et al., eds. ., J.B. Lippincott Company, 1993) using conventional methodology, such as the widely used methodology described in J.B. Lippincott Company, 1993).
[0075] II. Definition It is understood that aspects and embodiments of the invention described herein include "comprising," "consisting of," and "consisting essentially of" aspects and embodiments.
[0076] As used herein, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.
[0077] As used herein, the term "about" refers to the normal margin of error for the respective value as readily understood by those skilled in the art. References herein to a value or parameter following "about" include (and describe) embodiments that are directed to that value or parameter itself.
[0078] The terms "cancer" and "cancerous" refer to or describe the physiological condition in mammals that is typically characterized by uncontrolled cell growth. Examples of cancers include mature B-cell cancers, excluding Hodgkin's lymphoma, but including non-Hodgkin's lymphomas (NHL) such as diffuse large B-cell lymphoma (DLBCL), which can be relapsed or refractory DLBCL. including, but not limited to, blood cancers. Cancer may include B-cell proliferative disorders (e.g., relapsed or refractory B-cell proliferative disorders), such as non-Hodgkin's lymphoma (NHL; e.g., diffuse large B-cell lymphoma (DLBCL; e.g., Richter's transformation); follicular lymphoma (FL; e.g., grade 1FL, grade 2FL, grade 3FL (e.g., grade 3aFL or grade 3bFL) or transformed FL), mantle cell lymphoma (MCL), or marginal zone lymphoma (MZL)), or chronic Lymphocytic leukemia (CLL), such as relapsed or refractory NHL (e.g., relapsed or refractory DLBCL, relapsed or refractory FL, relapsed or refractory MCL, or relapsed or refractory MZL), or relapsed Or it may be refractory CLL. In some instances, specific cancers include germinal center B-cell-like (GCB) diffuse large B-cell lymphoma (DLBCL), activated B-cell-like (ABC) DLBCL, and follicular lymphoma (FL). , mantle cell lymphoma (MCL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), marginal zone lymphoma (MZL), high-grade B cell lymphoma, primary mediastinal (thymus) large B cell Lymphoma (PMLBCL), small lymphocytic leukemia (SLL), lymphoplasmacytic lymphoma (LL), Waldenström hypergammaglobulinemia (WM), central nervous system lymphoma (CNSL), Burkitt lymphoma (BL) , B-cell prolymphocytic leukemia, splenic marginal zone lymphoma, hairy cell leukemia, splenic lymphoma / leukemia, unclassifiable, diffuse red pulp small B-cell lymphoma, hairy cell leukemia variant, heavy chain disease, alpha heavy chain disease, gamma heavy chain disease, mu heavy chain disease, plasma cell myeloma, solitary bone plasmacytoma, extraosseous plasmacytoma, extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), nodal marginal zone lymphoma, pediatric nodal marginal zone lymphoma, pediatric follicular lymphoma, primary cutaneous follicular center lymphoma, T-cell / histiocyte-rich large B-cell lymphoma, primary CNS DLBCL, primary cutaneous DLBCL, lower extremity type, EBV-positive DLBCL in the elderly, chronic inflammation-related DLBCL, lymphomatoid granulomatosis, intravascular large B-cell lymphoma, ALK-positive large B-cell lymphoma, plasmablastic lymphoma, HHV8 Large B-cell lymphoma due to associated multicentric Castleman disease, primary exudative lymphoma: unclassifiable B-cell lymphoma with features intermediate between DLBCL and Burkitt lymphoma; Includes unclassifiable B-cell lymphomas with features intermediate to those of classic Hodgkin lymphoma. Additionally, examples of cancer include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and lymphoid malignancies, including leukemia or B-cell lymphoma. More specific examples of cancers such as these include multiple myeloma (MM); low grade / follicular NHL; small lymphocytic (SL) NHL; intermediate grade / follicular NHL; intermediate grade diffuse NHL; grade immunoblastic NHL; high grade lymphocytic NHL; high grade small nondividing cell NHL; large mass lesion NHL; AIDS-related lymphoma; and acute lymphoblastic leukemia (ALL); chronic myeloblastic leukemia; and posttransplant lymphoma. including, but not limited to proliferative disorders (PTLD).
[0079] "Tumor" as used herein refers to all neoplastic cell growth and proliferation, as well as all precancerous and cancerous cells and tissues, whether malignant or benign.
[0080] The terms "cancer," "cancerous," "cell proliferative disorder," "proliferative disorder," and "tumor" when referred to herein are not mutually exclusive.
[0081] A "disorder" is any condition that would benefit from treatment, including, but not limited to, chronic and acute disorders or diseases, including conditions that predispose a mammal to the disorder in question.
[0082] The terms "cell proliferative disorder" and "proliferative disorder" refer to disorders that are associated with some degree of abnormal cell proliferation. In one embodiment, the cell proliferative disorder is cancer. In other embodiments, the cell proliferative disorder is a tumor.
[0083] The term "B cell proliferative disorder" or "B cell malignancy" refers to diseases associated with some degree of abnormal B cell proliferation, including, for example, lymphoma, leukemia, myeloma, and myelodysplastic syndromes. In one embodiment, the B-cell proliferative disorder is, for example, diffuse large B-cell lymphoma (DLBCL) (e.g., relapsed or refractory DLBCL or Richter's transformation), FL (e.g., relapsed and / or refractory DLBCL), lymphomas such as non-Hodgkin's lymphoma (NHL), including (transformed FL or transformed FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), high-grade B-cell lymphoma, or PMLBCL. In other embodiments, the B cell proliferative disorder is leukemia, such as chronic lymphocytic leukemia (CLL).
[0084] As used herein, "treatment" (and grammatical variations thereof such as "treat" or "treating") refers to the natural history of the subject being treated. refers to a clinical intervention in an attempt to change the disease, and can be carried out for prevention or during the course of clinical pathology. Desired effects of treatment include, but are not limited to, preventing the onset or recurrence of the disease, alleviating symptoms, attenuating any direct or indirect pathological consequences of the disease, preventing metastasis, disease These include reducing the rate of progression, ameliorating or alleviating the disease state, and improving recovery or prognosis. In some embodiments, antibodies of the invention are used to delay the onset of a disease or to slow the progression of a disease.
[0085] As used herein, "delaying the progression" of a disorder or disease refers to a disease or disorder (e.g., a CD20-positive cell proliferative disorder, e.g., a B cell proliferative disorder, e.g., NHL, means to defer, prevent, slow down, retard, stabilize, and / or retard the development of DLBCL). This delay may be of varying duration depending on the medical history and / or the individual being treated. As will be apparent to those skilled in the art, sufficient or significant delay may effectively encompass prevention in that the individual does not develop the disease. For example, late-stage cancer, such as the development of metastases, can be delayed.
[0086] "Reduce" or "inhibit" means the ability to cause an overall reduction of, for example, 20% or more, 50% or more, or 75%, 85%, 90%, 95%, or more. do. In certain embodiments, the reduction or inhibition is achieved using an anti-CD20 / anti-CD3 bispecific antibody using a fractionated dose escalation regimen of the invention compared to intravenous administration using the bispecific antibody. Cytokine-driven toxicities (e.g., cytokine release syndrome (CRS)), infusion-related reactions (IRR), macrophage activation syndrome (MAS), neurotoxicity, severe tumor lysis syndrome (TLS), and neutropenia after treatment with reduction or inhibition of undesirable events such as thrombocytopenia, elevated liver enzymes, and / or central nervous system (CNS) toxicity. In other embodiments, reducing or inhibiting can refer to antibody effector functions mediated by the antibody Fc region, and such effector functions specifically include complement-dependent cytotoxicity (CDC), antibody-dependent including cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP).
[0087] As used herein, "administering" refers to administering a compound (e.g., a bispecific antibody) or a composition (e.g., a pharmaceutical composition, e.g., a pharmaceutical composition comprising a bispecific antibody). means a method of administering a dosage to a subject. The compounds and / or compositions utilized in the methods described herein can be administered intravenously (eg, by intravenous infusion).
[0088] A "fixed" or "constant" dose of a therapeutic agent (eg, a bispecific antibody) herein refers to a dose that is administered to a patient regardless of the patient's weight or body surface area (BSA). Therefore, this fixed or constant dose is a mg / kg dose or mg / m 2 It is not provided as a dose, but rather as an absolute amount (eg, mg) of the therapeutic agent.
[0089] A "subject" or "individual" is a mammal. Mammals include primates (e.g., humans and non-human primates, such as monkeys), domestic animals (e.g., cows, sheep, cats, dogs, and horses), rabbits, and rodents (e.g., mice and rats). Including, but not limited to: In certain embodiments, the subject or individual is a human.
[0090] An "individual response" or "response" includes, but is not limited to (1) disease progression (e.g., CD20-positive cell proliferative disorders, e.g., B-cell proliferative disorders (e.g., relapsed or refractory B-cell proliferative disorders); cell proliferative disorders), e.g., non-Hodgkin's lymphoma (NHL; e.g., diffuse large B-cell lymphoma (DLBCL; e.g., Richter's transformation), follicular lymphoma (FL; e.g., grade 1 FL, grade 2 FL, grade 3 FL). (e.g., grade 3aFL or grade 3bFL) or transformed FL), mantle cell lymphoma (MCL), or marginal zone lymphoma (MZL)), or chronic lymphocytic leukemia (CLL), e.g., relapsed or refractory NHL ( Benefits to the subject, including, for example, some inhibition of relapsed or refractory DLBCL, relapsed or refractory FL, relapsed or refractory MCL, or relapsed or refractory MZL), or relapsed or refractory CLL) (2) reduction in tumor size; (3) inhibition (i.e., reduction, slowing, or complete cessation) of cancer cell invasion into adjacent peripheral organs and / or tissues; (4) inhibition of metastasis; (i.e., decrease, deceleration, or complete cessation); (5) some reduction in one or more symptoms associated with CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders); (6) overall survival and progression-free survival. prolongation or prolongation of survival including; and / or (7) reduction in mortality at a given time point after treatment.
[0091] As used herein, "complete response" or "CR" refers to disappearance of all target lesions (ie, all evidence of disease).
[0092] As used herein, a "partial response" or "PR" means a reduction of at least 30% in the sum of the longest diameters (SLD) of the target lesions, with reference to the baseline SLD, or Refers to at least a 50% reduction in lesion diameter product (SPD).
[0093] As used herein, "objective response rate" (ORR) means the sum of the complete response (CR) rate and the partial response (PR) rate.
[0094] As used herein, "duration of objective response" or "duration of response" (DOR) refers to the time from the first occurrence of a demonstrated objective response to disease progression, or 30 minutes after the last dose of treatment. Death from any cause within days, whichever occurs first.
[0095] "Sustained response" refers to a sustained effect on suppressing tumor growth after cessation of treatment. For example, the tumor size may remain the same or become smaller compared to the size at the beginning of the administration phase. In some embodiments, the sustained response has a duration at least as long as the treatment period, at least 1.5 times, 2.0 times, 2.5 times or 3.0 times the treatment period.
[0096] A subject's "effective response" or a subject's "responsiveness" and similar words to treatment with a drug refers to the clinical or therapeutic treatment given to a subject at risk of or suffering from a disease or disorder such as cancer. Refers to usefulness. In one embodiment, such benefit includes prolonging survival (including overall survival and progression-free survival), providing an objective response (including complete or partial response), or improving cancer control. Examples include improving one or more of the signs or symptoms.
[0097] Subjects who do not “respond effectively” to treatment are those who have prolonged survival (including overall survival and progression-free survival) and objective responses (including complete or partial responses). refers to a subject who has neither cancer nor improvement in signs or symptoms of cancer.
[0098] As used herein, the term "survival" refers to the patient being alive and includes overall survival and progression-free survival.
[0099] As used herein, "overall survival" (OS) refers to the proportion of subjects in a group who are alive after a specified period of time, eg, one year or five years from the time of diagnosis or treatment.
[0100] As used herein, "progression-free survival" (PFS) refers to the period during and after treatment of the disease being treated (e.g., a CD20-positive cell proliferative disorder (e.g., a B-cell proliferative disorder, e.g. , relapsed or refractory B-cell proliferative disorders), e.g., non-Hodgkin's lymphoma (NHL; e.g., diffuse large B-cell lymphoma (DLBCL; e.g., Richter's transformation), follicular lymphoma (FL; e.g., grade 1FL, grade 2FL, grade 3FL (e.g. grade 3aFL or grade 3bFL) or transformed FL), mantle cell lymphoma (MCL), or marginal zone lymphoma (MZL)), or chronic lymphocytic leukemia (CLL), e.g. Relapsed or refractory NHL (e.g., relapsed or refractory DLBCL, relapsed or refractory FL, relapsed or refractory MCL, or relapsed or refractory MZL), or relapsed or refractory CLL) does not worsen. Refers to the length of time. Progression-free survival can include the amount of time a patient experiences complete or partial remission, as well as the amount of time a patient experiences stable disease.
[0101] As used herein, "stable disease" or "SD" refers to either sufficient target lesion shrinkage to qualify as PR or sufficient increase in target lesion to qualify as PD, relative to the minimum SLD since treatment initiation. It refers to nothing.
[0102] As used herein, "progressive disease" or "PD" means an increase in the SLD of the target lesion by at least 20%, with reference to the minimum SLD, or after initiation of treatment or of one or more new lesions. Refers to an increase of at least 50% in the SPD of the target lesion, with reference to the lowest SPD recorded since its presence.
[0103] As used herein, "delaying the progression" of a disorder or disease refers to a disease or disorder (e.g., a CD20-positive cell proliferative disorder (e.g., a B-cell proliferative disorder (e.g., NHL (e.g., DLBCL)). (e.g., relapsed and / or refractory DLBCL or Richter's transformation), FL (e.g., relapsed and / or refractory FL or transformed FL), MCL, MZL, high-grade B-cell lymphoma or PMLBCL), or means to postpone, prevent, delay, stabilize, and / or postpone the onset of CLL)). This delay may be of varying duration depending on the medical history and / or the subject being treated. As will be clear to those skilled in the art, sufficient or significant delay may effectively encompass prevention in that the subject does not develop the disease. For example, in late-stage cancer, the development of central nervous system (CNS) metastases may be delayed.
[0104] As used herein, the term "reducing or inhibiting cancer recurrence" means reducing or inhibiting recurrence of a tumor or cancer, or progression of a tumor or cancer.
[0105] "Reduce or inhibit" means an overall reduction of 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, or more. means the ability to bring about Reduction or inhibition of symptoms of the disorder being treated (e.g., CD20-positive cell proliferative disorders, (e.g., B-cell proliferative disorders, such as NHL (e.g., DLBCL) (e.g., relapsed and / or refractory DLBCL or Richter's transformation), FL (e.g., relapsed and / or refractory FL or transformed FL), MCL, MZL, high-grade B-cell lymphoma or PMLBCL), or CLL), presence or size of metastases, or primary The size of the tumor may be measured.
[0106] By "prolonged survival" is meant for untreated patients (e.g., for patients not treated with medicine) or for patients who do not express the biomarker at a specified level, and / or An increase in overall survival or progression-free survival in treated patients relative to patients treated with approved anti-neoplastic agents. Objective response refers to a measurable response, including complete response (CR) or partial response (PR).
[0107] The term "antibody" is used herein in its broadest sense and is not limited to monoclonal, polyclonal, multispecific antibodies (e.g., It encompasses a variety of antibody structures, including bispecific antibodies), and antibody fragments.
[0108] "Antibody fragment" refers to a molecule other than an intact antibody that includes a portion of an intact antibody that binds to the antigen that the intact antibody binds. Examples of antibody fragments include Fv, Fab, Fab', Fab'-SH, F(ab') 2 diabodies; linear antibodies; single chain antibody molecules (eg, scFv); and multispecific antibodies formed from antibody fragments.
[0109] The terms "full-length antibody," "intact antibody," and "whole antibody" are used herein to have a structure substantially similar to the native antibody structure or to have an Fc region as defined herein. used synonymously to refer to an antibody that has a heavy chain containing
[0110] "Binding domain" means a compound or portion of a molecule that specifically binds to a target epitope, antigen, ligand, or receptor. The binding domain can be an antibody (e.g., monoclonal, polyclonal, recombinant, humanized, and chimeric antibody), antibody fragment or portion thereof (e.g., Fab fragment, Fab' 2, scFv antibodies, SMIPs, domain antibodies, diabodies, minibodies, scFv-Fc, affibodies, nanobodies, and VH and / or VL domains of antibodies), receptors, ligands, aptamers, and identified binding partners. including, but not limited to, other molecules with
[0111] The term "Fc region" is used herein to define the C-terminal region of an immunoglobulin heavy chain that contains at least a portion of the constant region. This term includes native sequence Fc regions and variant Fc regions. In one embodiment, the human IgG heavy chain Fc region extends from Cys226 or from Pro230 to the carboxyl terminus of the heavy chain. However, the C-terminal lysine (Lys447) of the Fc region may or may not be present. Unless otherwise specified herein, the numbering of amino acid residues in the Fc or constant regions refers to Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD; It follows the EU numbering system (also known as the EU index), as described in 1991.
[0112] The "class" of an antibody refers to the type of constant domain or region possessed by its heavy chain. There are five major classes of antibodies, namely IgA, IgD, IgE, IgG, and IgM, and some of these have further subclasses (isotypes), e.g. IgG 1 , IgG 2 , IgG 3 , IgG 4 , IgA 1 , and IgA 2 It can be divided into The heavy chain constant domains corresponding to different classes of immunoglobulins are called α, δ, ε, γ, and μ, respectively.
[0113] As used herein, the term IgG "isotype" or "subclass" refers to any of the subclasses of immunoglobulins defined by the chemical and antigenic properties of their constant regions.
[0114] "Framework" or "FR" refers to variable domain residues other than hypervariable region (HVR) residues. The variable domain FR generally consists of four FR domains: FR1 domain, FR2 domain, FR3 domain and FR4 domain. Therefore, HVR and FR sequences generally appear in the VH (or VL) in the following sequence: FR1-H1(L1)-FR2-H2(L2)-FR3-H3(L3)-FR4.
[0115] A "human consensus framework" is a framework that represents the most commonly occurring amino acid residues in a selection of human immunoglobulin VL or VH framework sequences. Generally, the selection of human immunoglobulin VL or VH sequences is from a subgroup of variable domain sequences. Generally, subgroups of sequences are those in Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition, NIH Publication 91-3242, Bethesda MD (1991), vols. 1-3. In one embodiment, for VL, the subgroup is subgroup kappa I in Kabat et al. (see above). In one embodiment, for VH, the subgroup is subgroup III in Kabat et al. (see above).
[0116] For purposes herein, an "acceptor human framework" refers to a light chain variable domain (VL) framework or a heavy chain variable domain derived from a human immunoglobulin framework or human consensus framework, as defined below. A framework containing the amino acid sequence of a domain (VH) framework. An acceptor human framework "derived from" a human immunoglobulin framework or human consensus framework may contain the same amino acid sequence or may contain amino acid sequence changes. In some embodiments, the number of amino acid changes is 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, or 2 or less. In some embodiments, the VL acceptor human framework is identical in sequence to a VL human immunoglobulin framework sequence or a human consensus framework sequence.
[0117] A "humanized" antibody refers to a chimeric antibody that contains amino acid residues from non-human HVR and amino acid residues from human FR. In certain embodiments, a humanized antibody comprises substantially all of at least one, typically two, variable domains, such that all or substantially all of the HVRs (e.g., CDRs) correspond to a non-human antibody. However, all or substantially all of the FRs correspond to human antibodies. A humanized antibody may optionally include at least a portion of an antibody constant region derived from a human antibody. A "humanized form" of an antibody, eg, a non-human antibody, refers to an antibody that has undergone humanization.
[0118] "Human antibody" refers to the amino acid sequence of an antibody produced by a human or human cells, or derived from a non-human source utilizing a human antibody repertoire, or an amino acid sequence that corresponds to a sequence encoding another human antibody. This is an antibody that has This definition of human antibody specifically excludes humanized antibodies that contain non-human antigen binding residues. Human antibodies can be produced using a variety of techniques known in the art, including phage display libraries. Hoogenboom and Winter, J.Mol.Biol.,227:381(1991);Marks et al.,J.Mol.Biol.,222:581(1991).Cole et al., Monoclonal Antibodies and Cancer Therapy,Alan R Liss, p. 77 (1985); Boerner et al., J. Immunol., 147(1):86-95 (1991) can also be used to prepare human monoclonal antibodies. See also van Dijk and van de Winkel, Curr. Opin. Pharmacol., 5:368-74 (2001). Human antibodies have been modified to produce such antibodies in response to antigen challenge, but the endogenous locus has been rendered incompetent by administering the antigen to a transgenic animal, e.g., an immunized xenomouse. (see, eg, US Pat. Nos. 6,075,181 and 6,150,584 for XENOMOUSE™ technology). For human antibodies produced by human B cell hybridoma technology, see, for example, Li et al., Proc. Natl. Acad. Sci. USA, 103:3557-3562 (2006).
[0119] The term "variable region" or "variable domain" refers to the domain of the heavy or light chain of an antibody that is responsible for binding the antibody to antigen. The heavy and light chain variable domains (VH, VL, respectively) of natural antibodies are generally similar, with each domain containing four conserved framework regions (FR) and three hypervariable regions (HVR). It has the structure of For example, Kindt et al., Kuby Immunology,6 th ed., W.H. Freeman and Co., p. 91 (2007). A single VH or VL domain may be sufficient to confer antigen binding specificity. Additionally, antibodies that bind to a particular antigen may be isolated by using the VH or VL domains of antibodies that bind to the antigen and screening a library of complementary VL or VH domains, respectively. See, eg, Portolano et al., J. Immunol. 150:880-887 (1993); Clarkson et al., Nature 352:624-628 (1991).
[0120] The term "hypervariable region" or "HVR" as used herein refers to a region that is hypervariable in sequence ("complementarity determining region" or "CDR") and / or structurally defined Refers to each region of an antibody variable domain that forms loops (“hypervariable loops”) and / or contains residues that contact antigen (“antigen contacts”). Generally, antibodies contain six HVRs, three in the VH (H1, H2, H3) and three in the VL (L1, L2, L3). Exemplary HVRs of the present invention include: (a) Superconductivity occurring at amino acid residues 26-32 (L1), 50-52 (L2), 91-96 (L3), 26-32 (H1), 53-55 (H2) and 96-101 (H3) Variable loop (Chothia and Lesk, J.Mol.Biol.196:901-917(1987)); (b) CDRs occurring at amino acid residues 24-34 (L1), 50-56 (L2), 89-97 (L3), 31-35b (H1), 50-65 (H2) and 95-102 (H3) (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (1991)); (c) occurs at amino acid residues 27c-36(L1), 46-55(L2), 89-96(L3), 30-35b(H1), 47-58(H2), and 93-101(H3) antigen contact (MacCallum et al. J. Mol. Biol. 262:732-745 (1996)); and (d) Combination of (a), (b) and / or (c), HVR amino acid residues 46-56(L2), 47-56(L2), 48-56(L2), 49-56(L2) , 26-35(H1), 26-35b(H1), 49-65(H2), 93-102(H3) and 94-102(H3).
[0121] Unless otherwise indicated, HVR residues and other residues within the variable domain (eg, FR residues) are numbered herein according to Kabat et al., supra.
[0122] An "immunoconjugate" is an antibody that is conjugated to one or more heterologous molecule(s), including, but not limited to, cytotoxic agents.
[0123] The term "isolated antibody," as used to describe various antibodies disclosed herein, refers to antibodies that have been identified, separated and / or recovered from the cells or cell culture in which they were expressed. means an antibody that has been tested. Contaminant components of its natural environment are materials that typically interfere with diagnostic or therapeutic uses of the polypeptide and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. In some embodiments, the antibodies are determined, for example, by electrophoresis (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatography (e.g., ion exchange or reversed phase HPLC). purified to >95% or >99% purity. For a review of methods for assessing antibody purity, see, eg, Flatman et al., J. Chromatogr. B 848:79-87 (2007). In a preferred embodiment, the antibody comprises (1) an N-terminal or internal amino acid sequence sufficient to obtain at least 15 residues using a spinning cup sequenator; or (2) Purified to homogeneity by SDS-PAGE under non-reducing or reducing conditions using Coomassie blue or preferably silver staining. Isolated antibody includes the antibody in situ within recombinant cells since at least one component of the polypeptide's natural environment will not be present. However, usually isolated polypeptides are prepared by at least one purification step.
[0124] The term "monoclonal antibody" as used herein refers to an antibody that is obtained from a substantially homogeneous population of antibodies. That is, with the exception of possible variant antibodies, which are generally present in small amounts, including, for example, naturally occurring mutations or mutations that occur during the manufacture of monoclonal antibody preparations, the individual antibodies that make up the collection are identical and / or bind the same epitope. In contrast to polyclonal antibody preparations, which usually include different antibodies directed against different determinants (epitopes), each monoclonal antibody in a monoclonal antibody preparation is directed against a single determinant on the antigen. Thus, the modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, monoclonal antibodies for use in accordance with the present invention may be produced using methods such as hybridoma methods, recombinant DNA methods, phage display methods, and methods that utilize transgenic animals containing all or part of human immunoglobulin loci. Such and other exemplary methods for making monoclonal antibodies, which can be made by a variety of non-limiting techniques, are described herein.
[0125] "Affinity" refers to the total strength of non-covalent interactions between a single binding site of a molecule (eg, an antibody) and its binding partner (eg, an antigen). Unless otherwise indicated, "binding affinity" as used herein refers to an inherent binding affinity that reflects a 1:1 interaction between members of a binding pair (e.g., an antibody and an antigen). . The affinity of molecule X for its partner Y is generally determined by the dissociation constant (K D ). Affinity can be measured by methods common in the art, including those described herein. Specific illustrative descriptions and exemplary embodiments for measuring binding affinity are described below.
[0126] An “affinity matured” antibody is one that has one or more changes in one or more hypervariable regions (HVRs) compared to the unaltered parent antibody, and such changes make the antibody more sensitive to its antigen. Refers to antibodies with improved affinity.
[0127] The terms "anti-CD3 antibody" and "antibody that binds CD3" mean that the antibody is capable of binding CD3 with sufficient affinity such that it is useful as a diagnostic and / or therapeutic agent targeting CD3. Refers to antibodies. In one embodiment, the degree of binding of the anti-CD3 antibody to an unrelated non-CD3 protein is less than about 10% of the binding of the antibody to CD3, as determined, for example, by radioimmunoassay (RIA). In certain embodiments, the antibody that binds CD3 is ≦1 μM, ≦100 nM, ≦10 nM, ≦1 nM, ≦0.1 nM, ≦0.01 nM or ≦0.001 nM (e.g., 10 -8 Below, for example 10 -8 M~10 -13 M, for example 10 -9 M~10 -13 It has a dissociation constant (Kd) of M). In certain embodiments, the anti-CD3 antibody binds to an epitope of CD3 that is conserved among CD3 from different species.
[0128] As used herein, the term "surface antigen class 3" or "CD3" refers to mammals such as primates (e.g., humans) and rodents (e.g., mice and rats), unless otherwise indicated. refers to any naturally occurring CD3 from any vertebrate source, including, for example, CD3ε, CD3γ, CD3α, and CD3β chains. The term encompasses "full length" unprocessed CD3 (e.g., unprocessed or unmodified CD3ε or CD3γ), as well as any form of CD3 obtained from intracellular processing. The term also encompasses naturally occurring variants of CD3, including, for example, splice or allelic variants. CD3 includes, for example, the human CD3ε protein (NCBI Reference SEQ ID NO: NP_000724), which is 207 amino acids long, and the human CD3γ protein (NCBI Reference SEQ ID NO: NP_000064), which is 182 amino acids long.
[0129] The terms "anti-CD20 antibody" and "antibody that binds CD20" refer to an antibody that is capable of binding to CD20 with sufficient affinity such that the antibody is useful as a diagnostic and / or therapeutic agent in targeting CD20. refers to In one embodiment, the degree of binding of the anti-CD20 antibody to an unrelated non-CD20 protein is less than about 10% of the binding of the antibody to CD20, for example, as measured by radioimmunoassay (RIA). In certain embodiments, the antibody that binds CD20 is ≦1 μM, ≦100 nM, ≦10 nM, ≦1 nM, ≦0.1 nM, ≦0.01 nM or ≦0.001 nM (e.g., 10 -8 MM or less, e.g. 10 -8 M~10 -13 M, for example 10 -9 M~10 -13 It has a dissociation constant (Kd) of M). In certain embodiments, the anti-CD20 antibody binds to an epitope of CD20 that is conserved among CD20 from different species.
[0130] As used herein, the term "surface antigen class 20" or "CD20" includes mammals such as primates (e.g., humans) and rodents (e.g., mice and rats), unless otherwise indicated. , refers to any natural CD20 derived from any vertebrate source. The term encompasses "full length", unprocessed CD20, as well as any form of CD20 resulting from intracellular processing. The term also encompasses naturally occurring variants of CD20, including, for example, splice or allelic variants. CD20 includes, for example, the human CD20 protein (see, e.g., NCBI Reference SEQ ID NOs: NP_068769.2 and NP_690605.1), which is e.g. 297 amino acids long, e.g. a variant lacking part of the 5' UTR. It can be produced from an mRNA transcript (see, eg, NCBI Reference SEQ ID NO: NM_021950.3), or a longer variant mRNA transcript (see, eg, NCBI Reference SEQ ID NO: NM_152866.2).
[0131] The terms "anti-CD20 / anti-CD3 bispecific antibody," "bispecific anti-CD20 / anti-CD3 antibody," and "antibody that binds CD20 and CD3," or variants thereof, mean that the antibody binds to CD20 and / or CD3. Multispecific antibodies (e.g., bispecific antibodies) that are capable of binding CD20 and CD3 with sufficient affinity so that they are useful as diagnostic and / or therapeutic agents in targeting Point. In one embodiment, the extent of binding of a bispecific antibody that binds CD20 and CD3 to an unrelated non-CD3 protein and / or non-CD20 protein is determined, e.g., by radioimmunoassay (RIA), etc. In this case, the binding of the antibody to CD3 and / or CD20 is less than about 10%. In certain embodiments, the bispecific antibody that binds CD20 and CD3 has a concentration of 1 μM or less, 100 nM or less, 10 nM or less, 1 nM or less, 0.1 nM or less, 0.01 nM or 0.001 nM (e.g., 10 -8 M or less, for example 10-8 M~10 -13 M, for example 10 -9 M~10 -13 It has a dissociation constant (Kd) of M). In certain embodiments, the bispecific antibody that binds CD20 and CD3 binds to an epitope of CD3 that is conserved between CD3 from different species and / or to an epitope of CD20 that is conserved between CD20 from different species. binds to the epitope of Examples of anti-CD20 / anti-CD3 bispecific antibodies are discussed below under "Therapeutic Methods - Bispecific Antibodies that Bind CD20 and CD3." In one embodiment, the bispecific antibody that binds CD20 and CD3 is monetuzumab.
[0132] As used herein, the term "mosnetuzumab" refers to the International Nonproprietary Names (INN) List 117 (WHO Drug Information, Vol. 31, No. 2, 2017, p. 303) or CAS Registration Number 1905409- Refers to an anti-CD20 / anti-CD3 bispecific antibody with 39-3.
[0133] As used herein, the term "binds," "binds specifically to," or "specific for" refers to a measurable and Refers to reproducible interactions that determine the presence of a target in the presence of a heterogeneous population of molecules, including biomolecules. For example, an antibody that specifically binds to a target (which may be an epitope) binds to this target with higher affinity, avidity, more easily, and / or for a longer duration than it binds to other targets. It is an antibody that binds to. In one embodiment, the extent to which the antibody binds to an unrelated target is less than about 10% of the antibody's binding to the target, as measured by radioimmunoassay (RIA). In certain embodiments, antibodies that specifically bind to a target have a dissociation constant (K D ). In certain embodiments, the antibody specifically binds to an epitope on a protein that is conserved between proteins from different species. In another embodiment, specific binding can include, but does not require exclusive binding. The terms used herein are, for example, 10 -4 M or less or 10 -5 M or less or 10 -6 M or less or 10 -7 M or less or 10 -8 M or less or 10 -9 M or less or 10 -10 M or less or 10 -11 M or less or 10 -12 K for targets below M D , or 10 -4 M~10 -6 M or 10 -6 M~10 -10 M or 10 -7 M~10 -9 K in the range of M D can be represented by a molecule with As understood by those skilled in the art, affinity and K D The values are inversely correlated. High affinity for antigen results in low K D measured by value. In one embodiment, the term "specific binding" means that a molecule binds to a particular polypeptide or epitope on a particular polypeptide without substantially binding to any other polypeptide or polypeptide epitope. Refers to the combination when they are combined.
[0134] "Percent Amino Acid Sequence Identity" (%) with respect to a reference polypeptide sequence means that any conservative substitutions will improve the sequence identity after aligning the sequences and introducing gaps if necessary to obtain maximum percent sequence identity. It is defined as the percentage of amino acid residues in a candidate sequence that are identical to amino acid residues in a reference polypeptide, if not considered as part of the amino acid residues. Alignments to determine percent amino acid sequence identity can be performed using various methods within the skill of the art, such as BLAST, BLAST-2, ALIGN or MEGALIGN® (DNASTAR®) software. can be obtained using commonly available computer software. Those skilled in the art can determine appropriate parameters for alignment of sequences, including any algorithms necessary to achieve maximal alignment over the entire length of the sequences being compared. However, for purposes herein, % amino acid sequence identity values are generated using the sequence comparison computer program ALIGN-2. The ALIGN-2 sequence comparison computer program was created by Genentech, Inc. and the source code, together with user documentation, is filed with the United States Copyright Office, Washington, D.C., 20559, under United States Copyright Registration No. TXU510087. Registered. The ALIGN-2 program is publicly available from Genentech, Inc. (South San Francisco, California) or can be compiled from its source code. The ALIGN-2 program should be compiled for use with UNIX® operating systems, including Digital UNIX® V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and remain unchanged.
[0135] In situations where ALIGN-2 is used for amino acid sequence comparisons, the percent amino acid sequence identity of a given amino acid sequence A to, with, or to a given amino acid sequence B (or (described as a given amino acid sequence A) having or comprising a specified % amino acid sequence identity to, with, or to a given amino acid sequence B) is calculated as follows: Will be: 100 x fraction X / Y
[0136] At this time, X is the number of amino acid residues scored as identical in the alignment of A and B by the sequence alignment program ALIGN-2, and Y is the total number of amino acid residues in B. It will be appreciated that if the length of amino acid sequence A differs from the length of amino acid sequence B, then the % amino acid sequence identity of A to B will be different than the % amino acid sequence identity of B to A. Unless otherwise specified, as used herein, all % amino acid sequence identity values are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program.
[0137] The term "pharmaceutical preparation" refers to a preparation that is in such a form that the biological activity of the active ingredient contained in the preparation is effected and that does not contain additional components that are unacceptably toxic to the subject to whom the preparation is administered. Refers to preparations that do not contain
[0138] "Pharmaceutically acceptable carrier" refers to an ingredient in a pharmaceutical formulation, other than the active ingredient, that is non-toxic to the subject. Pharmaceutically acceptable carriers include, but are not limited to, buffers, excipients, stabilizers, or preservatives.
[0139] As used herein, the term "chemotherapeutic agent" refers to CD20-positive cell proliferative disorders (e.g., B-cell proliferative disorders (e.g., relapsed or refractory B-cell proliferative disorders), e.g. Hodgkin lymphoma (NHL; e.g., diffuse large B-cell lymphoma (DLBCL; e.g., Richter's transformation), follicular lymphoma (FL; e.g., grade 1FL, grade 2FL, grade 3FL (e.g., grade 3aFL, grade 3bFL) or transformed FL), mantle cell lymphoma (MCL), or marginal zone lymphoma (MZL)), or chronic lymphocytic leukemia (CLL), such as relapsed or refractory NHL (e.g., relapsed or refractory DLBCL, Refers to compounds useful in the treatment of cancers such as relapsed or refractory FL, relapsed or refractory MCL or marginal zone lymphoma (MZL), or relapsed or refractory CLL). Examples of chemotherapeutic agents include EGFR inhibitors (including small molecule inhibitors such as erlotinib (TARCEVA®, Genentech / OSI Pharm.); PD 183805 (CI 1033,2-propenamide, N- [4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-dihydrochloride, Pfizer Inc.); ZD1839, gefitinib (IRESSA( (registered trademark))4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline, AstraZeneca); BIBX-1382(N8-(3-chloro-4-fluoro-phenyl)-N2-(1-methylpiperidin-4-yl)-pyrimido[5,4-d]pyrimidine -2,8-diamine (Boehringer Ingelheim);PKI-166((R)-4-[4-[(1-phenylethyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl] -phenol);(R)-6-(4-hydroxyphenyl)-4-[(1-phenylethyl)amino]-7H-pyrrolo[2,3-d]pyrimidine);CL-387785(N-[4 -[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide);EKB-569(N-[4-[(3-chloro-4-fluorophenyl)amino]-3-cyano-7- Ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide) (Wyeth); AG1478 (Pfizer); AG1571 (SU 5271; Pfizer); and lapatinib (TYKERB®, GSK572016 or N-[3 -chloro-4-[(3fluorophenyl)methoxy]phenyl]-6[5[[[2methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-4-quinazolineamine)) HER2 tyrosine kinase inhibitors; tyrosine kinase inhibitors (e.g. EGFR inhibitors; small molecule HER2 tyrosine kinase inhibitors such as TAK165 (Takeda); CP-724,714, oral selective inhibition of ErbB2 receptor tyrosine kinase (Pfizer and OSI) Dual HER inhibitors such as EKB-569 (available from Wyeth) (which preferentially binds EGFR but inhibits both HER2 and EGFR overexpressing cells); PKI-166 (Novartis); Pan-HER inhibitors such as canertinib (CI-1033; Pharmacia); antisense agents that inhibit Raf-1 signaling Raf-1 inhibitors such as ISIS-5132 ((ISIS Pharmaceuticals); imatinib mesylate (GLEEVEC® ), Glaxo SmithKline); multi-targeted tyrosine kinase inhibitors such as sunitinib (SUTENT®, Pfizer); VEGF receptors such as vatalanib (PTK787 / ZK222584, Novartis / Schering AG) Tyrosine kinase inhibitor; MAPK extracellular regulated kinase I inhibitor CI-1040 (Pharmacia); Quinazolines such as PD153035, 4-(3-chloroanilino)quinazoline; Pyridopyrimidine; Pyrimidopyrimidine; CGP 59326, CGP 60261 and CGP 62706 pyrrolopyrimidines such as; pyrazolopyrimidine, 4-(phenylamino)-7H-pyrrolo[2,3-d]pyrimidine; curcumin (diferuloylmethane, 4,5-bis(4-fluoroanilino)phthalimide); Tyrophostin containing a nitrothiophene moiety; PD-0183805 (Warner-Lamber); antisense molecules (e.g., those that bind to nucleic acids encoding HER); Quinoxaline (U.S. Patent No. 5,804,396); Triphostin (U.S. Patent No. 5,804,396) Pan-HER inhibitors such as ZD6474 (Astra Zeneca); PTK-787 (Novartis / Schering AG); CI-1033 ((Pfizer); Affinitac (ISIS 3521; Isis / Lilly); PKI 166 (Novartis); GW2016 (Glaxo CI-1033 (Pfizer); EKB-569 (Wyeth); Semaxinib (Pfizer); ZD6474 (AstraZeneca); PTK-787 (Novartis / Schering AG); INC-1C11 (Imclone); Proteasome inhibitors such as bortezomib (VELCADE®, Millennium Pharm.); disulfiram; epigallocatechin gallate; salinosporamide A; carfilzomib; 17-AAG (geldanamycin); radicicol; lactate dehydrogenase A (LDH-A); fulvestrant (FASLODEX®, AstraZeneca); letrozole (Femara®, Novartis); finasunate (VATALANIB®, Novartis); oxaliplatin (ELOXATIN®, Sanofi); 5-FU (5-fluorouracil); leucovorin; lonafamib (SCH 66336) ; sorafenib (NEXAVAR®, Bayer Labs); alkylating agents such as AG1478, thiotepa and CYTOXAN® cyclophosphamide; alkyl sulfonates such as busulfan, improsulfan and piposulfan; benzodopa, carbocone, aziridines such as meturedopa and uredopa; ethyleneimine and methylamelamine, including altretamine, triethylene melamine, triethylene phosphoramide, triethylene thiophosphoramide and trimelomelamine; acetogenins (particularly buratacin and buratacinone); camptothecin (topotecan and irinotecan); bryostatin; kallistatin; CC-1065 (including its adzeresin, carzelesin and vizeresin synthetic analogs); cryptophycin (particularly cryptophycin 1 and cryptophycin 8); corticosteroids (including prednisone and prednisolone) ; cyproterone acetate; 5α-reductase, including finasteride and dutasteride); vorinostat, romidepsin, panobinostat, valproic acid, mosetinostat, dolastatin; aldesleukin, talc duocarmycin (including synthetic analogs, KW-2189 and CB1-TM1) ); eruterobin; pancratistatin; sarcodictin; spongistatin; chlorambucil, chromafazine, chlorophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novemvitin, fenesterine, prednimustine, trofosfamide, uracil Nitrogen mustards such as mustard; nitrosoureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimustine; antibiotics such as enediyne antibiotics (e.g. calichemycins, especially calicheamicin γ1 and calicheamicin ω1); dynemycin dynemycin, including A; bisphosphonates such as crossphonates; esperamycin; and the neocardinostatin chromophore and related chromogenic proteins enedidine antibiotic chromophore), aclacinomycin, actinomycin, autotramycin, azaserine, cacchinomycin; Nomycin, carabicin, caminomycin, cardinophilin, chromomycin, dactinomycin, detorubicin, 6-diazo-5-oxo-L-norleucine, morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and deoxydoxorubicin ), mitomycin such as epirubicin, esorubicin, idarubicin, marcellomycin, mitomycin C, mycophenolic acid, nogaramycin, olibomycin, peplomycin, porphyromycin, puromycin, keramycin, rhodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, Dinostatin, zorubicin; antimetabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogs such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamipurine, thioguanine ; Pyrimidine analogs such as ancitabine, azacytidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxyfluridine, enocitabine, floxuridine; Androgens such as carsterone, dromostanolone propionate, epithiostanol, mepithiostane, testolactone; aminoglutethimi anti-adrenals such as mitotane, trilostane; folic acid supplements such as folic acid; acegratone; aldophosphamide glycosides; aminolevulinic acid; enilrasil; amsacrine; bestrabcil; bisanthrene; edatraxate; defofamine; Demecolcin; diazicon; erfomitin; elliptinium acetate; epothilone; etoglucide; gallium nitrate; hydroxyurea; lentinan; lonidyne; maytansinoids such as maytansine and ansamitocin; mitoguazone; mitoxantrone; mopidamnol; nitraerin; pentostatin; phenamet; pirarubicin; rosoxantrone ;podophyllic acid;2-ethylhydrazide;procarbazine;PSK(R) polysaccharide complex (JHS natural product);razoxane;rizoxin;schizofuran;spirogermanium;tenuazonic acid;triazicon;2,2',2''-trichlorotriethylamine ; trichothecenes (particularly T-2 toxins, veracrine A, loridine A and angidine); urethanes; vindesine; dacarbazine; mannomustine; mitobronitol; mitractol; pipobroman; gasitocin; arabinoside (''Ara-C''); cyclophosphamide; Thiotepa; Chlorambucil; GEMZAR® (Gemcitabine); 6-thioguanine; Mercaptopurine; Methotrexate; Etoposide (VP-16); Ifosfamide; Mitoxantrone; Novantrone; Teniposide; Edatrexate; Daunomycin; Aminopterin; Capecitabine (XELODA( (registered trademark)); ibandronate; CPT-11; topoisomerase inhibitor RFS2000; difluoromethylornithine (DMFO); retinoids such as retinoic acid; pharmaceutically acceptable salts, acids, prodrugs, and Examples include derivatives. .
[0140] Chemotherapeutic agents also include (i) antihormonal agents that act to modulate or inhibit hormonal action on tumors, such as antiestrogens and selective estrogen receptor modulators (SERMs) (tamoxifen (NOLVADEX®); (ii) Aromatase inhibitors that inhibit the enzyme aromatase that regulates estrogen production in the adrenal glands, such as 4(5)-imidazole, aminoglutethimide, MEGASE® (megestrol acetate), AROMASIN® (exemestane; (iii) flutamide, nilutamide , bicalutamide, leuprolide, and goserelin; buserelin, triptererin, medroxyprogesterone acetate, diethylstilbestrol, Premarin, fluoxymesterone, all trans-rethionic acids, fenretinide, and troxacitabine (1,3-dioxolane nucleoside). (cytosine analogs); (iv) protein kinase inhibitors; (v) lipid kinase inhibitors; (vi) antisense oligonucleotides, especially those that inhibit the expression of genes in signal transduction pathways involved in abnormal cell proliferation, e.g. , PKC-alpha, Ralf and H-Ras; (vii) ribozymes such as VEGF expression inhibitors (e.g. ANGIOZYME®) and HER2 expression inhibitors; (viii) gene therapy vaccines, e.g. ALLOVECTIN® (ix) Vaccines such as vinca (e.g., vincristine and vinblastine), NAVELBINE® (vinorelbine), taxanes (e.g., paclitaxel, nab-paclitaxel, and docetaxel); ), topoisomerase II inhibitors (e.g., doxorubicin, epirubicin, daunorubicin, etoposide, and bleomycin), and DNA alkylating agents (e.g., tamoxigen, dacarbazine, mechlorethamine, cisplatin, methotrexate, 5-fluorouracil, and ara-C). Growth inhibitors; (x) including pharmaceutically acceptable salts, acids, prodrugs, and derivatives of any of the above.
[0141] The term "cytotoxic agent," as used herein, refers to any agent that is harmful to cells (e.g., causes cell death, inhibits proliferation, or otherwise interferes with cell function). Refers to drugs. Cytotoxic agents include radioactive isotopes (e.g. At 211 ,I 131 ,I 125 ,Y 90 , Re 186 , Re 188 , Sm 153 , Bi 212 ,P 32 ,Pb 212, and radioactive isotopes of Lu), chemotherapeutic agents, enzymes such as nucleolytic enzymes and fragments thereof, and small molecule toxins or enzymatically active substances derived from bacteria, fungi, plants or animals, including fragments and / or variants thereof. Examples include, but are not limited to, toxins such as toxins. Exemplary cytotoxic agents include anti-microtubule agents, platinum coordination complexes, alkylating agents, antibiotic agents, topoisomerase II inhibitors, antimetabolites, topoisomerase I inhibitors, hormones and hormone analogs, signal transduction pathway inhibitors. agents, non-receptor tyrosine kinase angiogenesis inhibitors, immunotherapeutics, pro-apoptotic agents, LDH-A inhibitors, fatty acid biosynthesis inhibitors, cell cycle signaling inhibitors, HDAC inhibitors, proteasome inhibitors, and cancer metabolism. inhibitors. In one example, the cytotoxic agent is a platinum-based chemotherapeutic agent (eg, carboplatin or cisplatin). In one example, the cytotoxic agent is an antagonist of EGFR, such as N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine (eg, erlotinib). In one example, the cytotoxic agent is a RAF inhibitor, such as a BRAF and / or CRAF inhibitor. In one example, the RAF inhibitor is vemurafenib. In one example, the cytotoxic agent is a PI3K inhibitor.
[0142] The term "PD-1 axis binding antagonist" refers to a PD-1 axis binding partner and any one of its binding partners that ablate T cell dysfunction resulting from signaling on the PD-1 signaling axis. refers to a molecule that inhibits interaction with one or more cells and, as a result, restores or enhances T cell function (eg, proliferation, cytokine production, target cell killing). As used herein, PD-1 axis binding antagonists include PD-1 binding antagonists, PD-L1 binding antagonists, and PD-L2 binding antagonists.
[0143] The term "PD-1 binding antagonist" refers to reducing, blocking, inhibiting, or impairing the signaling that occurs as a result of the interaction of PD-1 with one or more binding partners, such as PD-L1, PD-L2, etc. , or a molecule that interferes. In some embodiments, a PD-1 binding antagonist is a molecule that inhibits the binding of PD-1 to one or more of its binding partners. In certain embodiments, a PD-1 binding antagonist inhibits the binding of PD-1 to PD-L1 and / or PD-L2. For example, PD-1 binding antagonists include anti-PD-1 antibodies, antigen-binding fragments thereof, immunoadhexins, fusion proteins, oligopeptides, and Other molecules that reduce, block, inhibit, compromise, or interfere with the resulting signal transduction are included. In one embodiment, the PD-1 binding antagonist reduces negative costimulatory signals mediated by or through cell surface proteins expressed on T lymphocytes that mediated signaling through PD-1; Making dysfunctional T cells less dysfunctional (eg, enhancing effector responses to antigen recognition). In some embodiments, the PD-1 binding antagonist is an anti-PD-1 antibody. In certain embodiments, the PD-1 binding antagonist is MDX-1106 (nivolumab). In another specific embodiment, the PD-1 binding antagonist is pembrolizumab (formerly lambrolizumab (MK-3475)). In another specific embodiment, the PD-1 binding antagonist is AMP-224. In some embodiments, the PD-1 binding antagonist is MDX-1106 (nivolumab). In some embodiments, the PD-1 binding antagonist is MK-3475 (pembrolizumab). In some embodiments, the PD-1 binding antagonist is MED1-0680. In some examples, the PD-1 binding antagonist is PDR001 (spartalizumab). In some examples, the PD-1 binding antagonist is REGN 2810 (cemiplimab). In some examples, the PD-1 binding antagonist is BGB-108. In other examples, the PD-1 binding antagonist is prologlimab, canrelizumab, sintilimab, tislelizumab, or toripalimab.
[0144] Further examples of PD-1 axis binding antagonists include cemiplimab, prolgolimab, camrelizumab, sintilimab, tislelizumab, tripalimab, dostarimab, retifanlimab, spartalizumab, sasanlimab, penplimab, CS1003, HLX10, SCT-I10A, SHR-1316, CS1001 , embafolimab, TQB2450, ZKAB001, LP-002, zimbelelimab, balstilimab, genomicuzumab, BI754091, setrelimab, YBL-006, BAT1306, HX008, CX-072, IMC-001, KL-A167, budicalimab, CX-188, JTX -4014, 609A, Sym021, LZM009, F520, SG001, APL-502, cocibelimab, lodapolimab, GS-4224, INCB086550, FAZ053, TG-1501, BGB-A333, BCD-135, AK-106, LDP, GR1405, HLX20 , MSB2311, MAX-10181, RC98, BION-004, AM0001, CB201, ENUM 244C8, ENUM 388D4, AUNP-012, STI-1110, ADG104, AK-103, LBL-006, hAb21, AVA-004, PDL-GEX , INCB090244, KD036, KY1003, LYN192, MT-6035, VXM10, YBL-007, ABSK041, GB7003, JS-003, and HS-636.
[0145] The term "PD-L1 binding antagonist" refers to reducing, blocking, inhibiting, Refers to molecules that inhibit or hinder. In some embodiments, a PD-L1 binding antagonist is a molecule that inhibits the binding of PD-L1 to its binding partner. In certain embodiments, a PD-L1 binding antagonist inhibits binding of PD-L1 to PD-1 and / or B7-1. In some embodiments, PD-L1 binding antagonists include anti-PD-L1 antibodies, antigen-binding fragments thereof, immunoadhesins, fusion proteins, oligopeptides, and anti-PD-L1 binding antagonists thereof, such as PD-L1, PD-1, or B7-1. Includes other molecules that reduce, block, inhibit, abrogate, or interfere with signal transduction resulting from interaction with one or more of the binding partners. In one embodiment, the PD-L1 binding antagonist reduces negative costimulatory signals mediated by or through cell surface proteins expressed on T lymphocytes that mediated signaling through PD-L1. , alleviating the dysfunctional state of dysfunctional T cells (eg, enhancing effector responses to antigen recognition). In some embodiments, the PD-L1 binding antagonist is an anti-PD-L1 antibody. In certain embodiments, the anti-PD-L1 antibody is atezolizumab, also known as MPDL3280A. In another specific embodiment, the anti-PD-L1 antibody is MDX-1105. In yet another specific embodiment, the anti-PD-L1 antibody is MEDI4736.
[0146] As used herein, the term "atezolizumab" refers to the International Nonproprietary Names (INN) List 112 (WHO Drug Information, Vol. 28. No. 4, 2014, p. 488) or CAS Registration Number 1380723- 44-3 refers to an anti-PD-L1 antagonist antibody.
[0147] The term "PD-L2 binding antagonist" refers to an agent that reduces, blocks, or inhibits the signal transduction resulting from the interaction of PD-L2 with any one or more of its binding partners, e.g., PD-1. , refers to molecules that inhibit or interfere. In some embodiments, a PD-L2 binding antagonist is a molecule that inhibits the binding of PD-L2 to one or more of its binding partners. In certain embodiments, a PD-L2 binding antagonist inhibits the binding of PD-L2 to PD-1. In some embodiments, the PD-L2 antagonist is any one of an anti-PD-L2 antibody, an antigen-binding fragment thereof, an immunoadhesin, a fusion protein, an oligopeptide, and PD-L2 and its binding partner. These include, for example, other molecules that reduce, block, inhibit, suppress, or interfere with signal transduction resulting from interaction with PD-1. In one embodiment, the PD-L2 binding antagonist reduces negative co-stimulatory signals mediated by or through cell surface proteins expressed on T lymphocytes that mediated PD-L2-mediated signaling. , reduce the dysfunction of dysfunctional T cells (eg, enhance effector responses to antigen recognition). In some embodiments, the PD-L2 binding antagonist is an immunoadhesin.
[0148] The term "package insert" refers to the commercial packaging customary for therapeutic products containing information regarding indications, usage, dosage, administration, concomitant therapy, contraindications and / or warnings regarding the use of such therapeutic product. used to refer to the instructions included with the product.
[0149] III. Treatment method binds to CD20 and CD3 (e.g., mosnetuzumab) in a dosing regimen that includes at least a first dosing cycle and a second dosing cycle (e.g., a first dosing cycle, a second dosing cycle, and a third dosing cycle). CD20-positive cell proliferative disorders (e.g., B-cell proliferative disorders (e.g., relapsed or refractory B-cell proliferative disorders), For example, non-Hodgkin's lymphoma (NHL; e.g., diffuse large B-cell lymphoma (DLBCL; e.g., Richter's transformation), follicular lymphoma (FL; e.g., grade 1FL, grade 2FL, grade 3FL (e.g., grade 3aFL, grade 3bFL) or transformed FL), mantle cell lymphoma (MCL), or marginal zone lymphoma MZL), or chronic lymphocytic leukemia (CLL), such as relapsed or refractory NHL (e.g. relapsed or refractory DLBCL). Provided herein are methods of treating a subject with relapsed or refractory FL, relapsed or refractory MCL, or relapsed or refractory (MZL)), or relapsed or refractory CLL).
[0150] Also, in a dosage regimen that includes at least a first dosing cycle and a second dosing cycle (e.g., a first dosing cycle, a second dosing cycle, and a third dosing cycle), CD20 and CD3 (e.g., mosnetuzumab) CD20-positive cell proliferative disorders (e.g., B-cell proliferative disorders (e.g., relapsed or refractory B-cell proliferative disorders), e.g., non-Hodgkin's lymphoma (NHL; e.g., diffuse large B-cell lymphoma (DLBCL; e.g., Richter's transformation), follicular lymphoma (FL; e.g., grade 1 FL, grade 2 FL, grade 3 FL ( For example, grade 3aFL, grade 3bFL) or transformed FL), mantle cell lymphoma (MCL), or marginal zone lymphoma MZL), or chronic lymphocytic leukemia (CLL), such as relapsed or refractory NHL (e.g., relapsed The present invention provides a method for treating a population of subjects with relapsed or refractory DLBCL, relapsed or refractory FL, relapsed or refractory MCL, or relapsed or refractory (MZL)), or relapsed or refractory CLL). Provided in the statement.
[0151] In some examples, the first administration cycle includes a first dose (C1D1), a second dose (C1D2), and a third dose (C1D3) of the bispecific antibody, where C1D1 is about 0.02 mg ~about 2.0 mg, C1D2 is about 0.05 mg to about 4.0 mg, and C1D3 is more than about 50 mg. In some examples, the second administration cycle includes a single dose (C2D1) of the bispecific antibody. In some examples, the present invention provides a bispecific antibody that binds CD20 and CD3 (e.g., mosnetuzumab) in a dosing regimen that includes at least a first dosing cycle, a second dosing cycle, and a third dosing cycle. wherein the first administration cycle comprises a first dose (C1D1), a second dose (C1D2), and a third dose (C1D3) of the bispecific antibody; is about 0.02 mg to about 2.0 mg, C1D2 is about 0.05 mg to about 4.0 mg, C1D3 is greater than about 20 mg, and the second dosing cycle includes a single dose (C2D1) of the bispecific antibody. , C2D1 is approximately equivalent in amount to C1D3, and the third dosing cycle includes a single dose (C3D1) of bispecific antibody, with C3D1 being more than C1D1 and less than C2D1. In some instances of any of the methods of the invention, the dosing regimen results in a reduction in the rate of cytokine release syndrome.
[0152] First, we will consider dosing regimens, followed by anti-CD20 / anti-CD3 bispecific antibodies. The various formats and properties of antibodies and additional therapeutic agents that can be used in the disclosed methods are then discussed.
[0153] A. Dosing regimen In some examples, the invention provides methods of administering to a subject a bispecific antibody that binds CD20 and CD3 (e.g., atezolizumab) in a dosing regimen that includes at least a first dosing cycle and a second dosing cycle. , CD20-positive cell proliferative disorders (e.g., B-cell proliferative disorders (e.g., relapsed or refractory B-cell proliferative disorders), e.g., non-Hodgkin's lymphoma (NHL; e.g., diffuse large B-cell lymphoma (DLBCL) ; for example, Richter's transformation), follicular lymphoma (FL; for example, grade 1FL, grade 2FL, grade 3FL (e.g., grade 3aFL, grade 3bFL) or transformed FL), mantle cell lymphoma (MCL), or marginal zone lymphoma (MZL)), or chronic lymphocytic leukemia (CLL), such as relapsed or refractory NHL (e.g., relapsed or refractory DLBCL, relapsed or refractory FL, relapsed or refractory MCL, or relapsed or refractory or refractory MZL) or relapsed or refractory CLL), comprising: (a) a first administration cycle comprising: a first dose (C1D1), a second dose (C1D1); (C1D2) and a third dose (C1D3) of the bispecific antibody, where C1D1 is about 0.02 mg to about 2.0 mg (e.g., about 0.02 to about 1.8 mg, about 0.02 to about 1.6 mg, about 0.02 ~1.4mg, 0.02~1.2mg, 0.05~1.8mg, 0.1~1.8mg, 0.4~1.8mg, 0.6~1.8mg, 0.8~1.8mg, 0.5~ about 1.5 mg, about 0.8 to about 1.2 mg; for example, about 1 mg), and C1D2 is about 0.05 to about 4.0 mg (for example, about 0.05 to about 3.5 mg, about 0.05 to about 3.0 mg, about 0.05 to about 2.5 mg, about 0.05 to about 2.2 mg, about 0.1 to about 3.5 mg, about 0.5 to about 3.5 mg, about 1.0 to about 3.5 mg, about 1.5 to about 3.5 mg, about 1.8 to about 3.5 mg, about 1.0 to about 3.0 mg , about 1.5 to about 2.5 mg; e.g., about 2 mg) and C1D3 is greater than about 50 mg; (b) the second administration cycle comprises a single dose (C2D1) of the bispecific antibody; do.
[0154] In some examples, C1D3 is 50mg to 200mg (e.g., 50mg to 175mg, 50mg to 150mg, 50mg to 125mg, 50mg to 100mg, 50mg to 75mg, 50mg to 70mg, 52mg to 100mg, 52mg to 75mg, 50mg to 180mg , 55mg to 150mg, 55mg to 100mg, 55mg to 70mg, 55mg to 65mg, 58mg to 62mg; for example, about 60mg). In some embodiments, the C1D3 is about 60 mg. In some embodiments, C1D1 is about 1 mg and / or C1D2 is about 2 mg. In some embodiments, C2D1 is about the same amount as C1D3.
[0155] In some examples, C1D1, C1D2, and C1D3 are administered on days 1, 8, and 15, respectively, of a first dosing cycle (e.g., a 21-day dosing cycle), or about day 1, about 8 and on approximately day 15. In some embodiments, C2D1 is administered to the subject on day 1 of a second administration cycle (eg, a 21 or 28 day administration cycle).
[0156] In some examples, the dosing regimen further comprises one or more additional dosing cycles after the second dosing cycle. For example, in some embodiments, the dosing regimen includes a second dosing cycle followed by 6 to 15 additional dosing cycles (e.g., 6 to 10 additional dosing cycles (e.g., 6 additional dosing cycles, 7 additional dosing cycles, 8 additional dosing cycles, 9 additional dosing cycles, or 10 additional dosing cycles), or 11 to 15 additional dosing cycles. (eg, 11 additional dosing cycles, 12 additional dosing cycles, 13 additional dosing cycles, 14 additional dosing cycles, or 15 additional dosing cycles).
[0157] In some embodiments, one or more additional cycles of administration include an additional single dose of bispecific antibody (eg, atezolizumab). In some embodiments, an additional single dose of bispecific antibody is administered to the subject on day 1 of each additional administration cycle.
[0158] In some instances, the additional single dose of bispecific antibody is greater than C1D1 and less than C1D3 and / or said C2D1. In some embodiments, the additional single dose of bispecific antibody is 20% to 80% (e.g., 20% to 70%, 20% to 60%, 20% to 55% of C1D3 and / or C2D1). %, 30%~80%, 30%~70%, 40%~70%, 45%~70%, 40%~60%, 45%~55%, 48%~52%; for example, about 50%) It is. In certain examples, the additional single dose of bispecific antibody is about 50% of C1D3 and / or C2D1.
[0159] In some instances, the additional single dose of bispecific antibody is about 30 mg.
[0160] In some examples, the invention provides a bispecific antibody (e.g., atezolizumab) that binds CD20 and CD3 in a dosing regimen that includes at least a first dosing cycle, a second dosing cycle, and a third dosing cycle. by administering (e.g., by intravenous administration) to a subject, CD20-positive cell proliferative disorders (e.g., B-cell proliferative disorders (e.g., relapsed or refractory B-cell proliferative disorders), e.g., non- Hodgkin lymphoma (NHL; e.g., diffuse large B-cell lymphoma (DLBCL; e.g., Richter's transformation), follicular lymphoma (FL; e.g., grade 1FL, grade 2FL, grade 3FL (e.g., grade 3aFL, grade 3bFL) or transformed FL), mantle cell lymphoma (MCL), or marginal zone lymphoma (MZL)), or chronic lymphocytic leukemia (CLL), such as relapsed or refractory NHL (e.g., relapsed or refractory DLBCL, A method of treating a subject with relapsed or refractory FL, relapsed or refractory MCL, or relapsed or refractory MZL) or relapsed or refractory CLL, the method comprising: (a) a first administration cycle comprising: , a first dose (C1D1), a second dose (C1D2), and a third dose (C1D3) of the bispecific antibody, where C1D1 is about 0.02 mg to about 2.0 mg (e.g., about 0.02 to about 1.8 mg). mg, about 0.02 to about 1.6 mg, about 0.02 to about 1.4 mg, about 0.02 to about 1.2 mg, about 0.05 to about 1.8 mg, about 0.1 to about 1.8 mg, about 0.4 to about 1.8 mg, about 0.6 to about 1.8 mg , about 0.8 to about 1.8 mg, about 0.5 to about 1.5 mg, about 0.8 to about 1.2 mg; for example, about 1 mg), and C1D2 is about 0.05 mg to about 4.0 mg (for example, about 0.05 to about 3.5 mg, about 0.05 to about 3.0 mg, about 0.05 to about 2.5 mg, about 0.05 to about 2.2 mg, about 0.1 to about 3.5 mg, about 0.5 to about 3.5 mg, about 1.0 to about 3.5 mg, about 1.5 to about 3.5 mg, about 1.8 ~about 3.5 mg, about 1.0 to about 3.0 mg, about 1.5 to about 2.5 mg; e.g., about 2 mg) and C1D3 is greater than about 20 mg; (b) the second dosing cycle is a single dose (C2D1) (c) the third dosing cycle contains a single dose (C3D1) of bispecific antibody, with C2D1 in an approximately equivalent amount as C1D3; Features more, less methods than C2D1. In some examples, C1D3 and C2D1 are each 20mg to 200mg (e.g., 20mg to 175mg, 20mg to 150mg, 20mg to 100mg, 20mg to 75mg, 30mg to 175mg, 40mg to 175mg, 45mg to 175mg, 50mg to 175mg, 30mg to 150mg, 40mg to 100mg, 45mg to 75mg, 50mg to 70mg, 55mg to 65mg, 58mg to 62mg; for example, about 20mg, about 30mg, about 45mg, or about 60mg). In some embodiments, C1D3 and C2D1 are each about 60 mg. In some embodiments, C3D1 is 20%-80% of C2D1 (e.g., 20%-70%, 20%-60%, 20%-55%, 30%-80%, 30%-70%, 40% to 70%, 45% to 70%, 40% to 60%, 45% to 55%, or 48% to 52%; for example, about 40%, about 45%, about 50%, about 55%, or approximately 60%). In some embodiments, C3D1 is about 50% of C2D1. In some embodiments, C3D1 is about 12 mg to about 48 mg (e.g., about 12 mg to about 42 mg, about 12 mg to about 36 mg, about 12 mg to about 30 mg, about 18 mg to about 48 mg, about 18 mg to about 42 mg, about 24 mg ~about 42 mg, about 27 mg to about 42 mg, about 24 mg to about 36 mg, about 27 mg to about 33 mg, about 28 mg to about 32 mg; for example, about 24 mg, about 27 mg, about 30 mg, about 33 mg, or about 36 mg). In certain embodiments, the C3D1 is about 30 mg.
[0161] In some examples, C3D1 is about 30 mg. In some embodiments, C1D1 is about 1 mg. In some embodiments, C1D2 is about 2 mg. For example, in a particular example, C1D1 is about 1 mg, C1D2 is about 2 mg, and C1D3 is about 30 mg.
[0162] In some examples, C1D1, C1D2, and C1D3 are administered on days 1, 8, and 15, respectively, of a first dosing cycle (e.g., a 21-day dosing cycle), or about day 1, about 8 and on approximately day 15. In some embodiments, C2D1 is administered to the subject on day 1 of the second administration cycle and C3D1 is administered to the subject on day 1 of the third administration cycle (e.g., during the second administration cycle and 3 dosing cycles are 21-day or 28-day dosing cycles).
[0163] In some embodiments, the dosing regimens of the invention further include one or more additional dosing cycles after the third dosing cycle. For example, in some instances, the dosing regimen may include a third dosing cycle followed by 5 to 14 additional dosing cycles (e.g., 5 to 10 additional dosing cycles (e.g., 5 additional dosing cycles). dosing cycles, 6 additional dosing cycles, 7 additional dosing cycles, 8 additional dosing cycles, 9 additional dosing cycles, or 10 additional dosing cycles) or 11 to 14 (eg, 11 additional dosing cycles, 12 additional dosing cycles, 13 additional dosing cycles, 14 additional dosing cycles).
[0164] In some embodiments, the one or more additional cycles of administration include an additional single dose of bispecific antibody. In some embodiments, an additional single dose of bispecific antibody is administered to the subject on day 1 of each additional administration cycle. In some embodiments, the additional single dose of bispecific antibody is about the same amount as C3D1.
[0165] The present invention provides a method for detecting CD20-positive patients by administering (e.g., intravenous administration) to a subject a bispecific antibody (e.g., mosnetuzumab) that binds CD20 and CD3 in a dosing regimen that includes eight or more dosing cycles. Cell proliferative disorders (e.g., B-cell proliferative disorders (e.g., relapsed or refractory B-cell proliferative disorders), e.g., non-Hodgkin's lymphoma (NHL; e.g., diffuse large B-cell lymphoma (DLBCL; e.g., Richter's transformation), follicular lymphoma (FL; e.g., grade 1FL, grade 2FL, grade 3FL (e.g., grade 3aFL, grade 3bFL), or transformed FL), mantle cell lymphoma (MCL), or marginal zone lymphoma ( MZL)), or chronic lymphocytic leukemia (CLL), such as relapsed or refractory NHL (e.g., relapsed or refractory DLBCL, relapsed or refractory FL, relapsed or refractory MCL, or relapsed or refractory A method of treating a subject with relapsed or refractory MZL), or relapsed or refractory CLL, comprising: (a) a first administration cycle comprising a first dose (C1D1), a second dose (C1D2) and a second dose (C1D2); 3 doses (C1D3) of the bispecific antibody, C1D1 is about 0.02 mg to about 2.0 mg (e.g., about 0.02 to about 1.8 mg, about 0.02 to about 1.6 mg, about 0.02 to about 1.4 mg, about 0.02 ~1.2mg, approx. 0.05~1.8mg, approx. 0.1~1.8mg, approx. 0.4~1.8mg, approx. 0.6~1.8mg, approx. 0.8~1.8mg, approx. 0.5~1.5mg, approx. 0.8~ about 1.2 mg; for example, about 1 mg), and C1D2 is about 0.05 mg to about 4.0 mg (for example, about 0.05 to about 3.5 mg, about 0.05 to about 3.0 mg, about 0.05 to about 2.5 mg, about 0.05 to about 2.2 mg, about 0.1 to about 3.5 mg, about 0.5 to about 3.5 mg, about 1.0 to about 3.5 mg, about 1.5 to about 3.5 mg, about 1.8 to about 3.5 mg, about 1.0 to about 3.0 mg, about 1.5 to about 2.5 mg (e.g., about 2 mg) and C1D3 is greater than about 20 mg; (b) the second dosing cycle includes a single dose (C2D1) of the bispecific antibody, and C2D1 is in an approximately equivalent amount as C1D3; (c) the third dosing cycle includes a single dose (C3D1) of the bispecific antibody, with C3D1 being more than C1D1 and less than C2D1; (d) the fourth dosing cycle being a single dose (C3D1) of the bispecific antibody; (e) the fifth dosing cycle comprises a single dose (C5D1) of the bispecific antibody; (f) the sixth dosing cycle comprises a single dose (C5D1) of the bispecific antibody; (g) the seventh dosing cycle comprises a single dose (C7D1) of the bispecific antibody; (h) the eighth dosing cycle comprises a single dose (C7D1) of the bispecific antibody; The method is characterized by comprising one dose (C8D1) of the bispecific antibody, wherein C3D1-C8D1 are approximately equivalent amounts.
[0166] In some examples, C1D3 and C2D1 are each 20mg to 200mg (e.g., 20mg to 175mg, 20mg to 150mg, 20mg to 100mg, 20mg to 75mg, 30mg to 175mg, 40mg to 175mg, 45mg to 175mg, 50mg to 175mg, 30mg to 150mg, 40mg to 100mg, 45mg to 75mg, 50mg to 70mg, 55mg to 65mg, 58mg to 62mg; for example, about 20mg, about 30mg, about 45mg, or about 60mg). In some embodiments, C1D3 and C2D1 are each about 60 mg. In some embodiments, C3D1 is 20%-80% of C2D1 (e.g., 20%-70%, 20%-60%, 20%-55%, 30%-80%, 30%-70%, 40% to 70%, 45% to 70%, 40% to 60%, 45% to 55%, or 48% to 52%; for example, about 40%, about 45%, about 50%, about 55%, or approximately 60%). In some embodiments, C3D1 is about 50% of C2D1. In some embodiments, C3D1 is about 12 mg to about 48 mg (e.g., about 12 mg to about 42 mg, about 12 mg to about 36 mg, about 12 mg to about 30 mg, about 18 mg to about 48 mg, about 18 mg to about 42 mg, about 24 mg ~about 42 mg, about 27 mg to about 42 mg, about 24 mg to about 36 mg, about 27 mg to about 33 mg, about 28 mg to about 32 mg; for example, about 24 mg, about 27 mg, about 30 mg, about 33 mg, or about 36 mg). In certain embodiments, the C3D1 is about 30 mg. In some embodiments, C1D1 is about 1 mg. In some embodiments, C1D2 is about 2 mg.
[0167] In some examples, C1D1, C1D2, and C1D3 are targeted on days 1, 8, and 15, or about days 1, 8, and 15, respectively, of the first dosing cycle. to be administered. In some embodiments, each of C2D1-C8D1 is administered to the subject on day 1 of the second through eighth administration cycles, respectively. In some embodiments, the dosing cycle is a 21 day or 28 day dosing cycle. In some embodiments, the dosing regimen includes one or more additional dosing cycles after the eighth dosing cycle. In some embodiments, the additional dosing cycle is a 21 day dosing cycle. In some embodiments, the additional dosing cycle is a 28 day dosing cycle.
[0168] In some examples, the one or more additional administration cycles include an additional single dose of bispecific antibody. In some embodiments, an additional single dose of bispecific antibody is administered to the subject on day 1 of each additional administration cycle. In some embodiments, the additional single dose of bispecific antibody is approximately equivalent to any one of C3D1-C8D1.
[0169] In some embodiments, the dosing regimen further comprises administering to the subject a PD-1 axis binding antagonist. In some embodiments, the PD-1 axis binding antagonist is about 1100 mg to about 1300 mg (e.g., about 1150 mg to about 1250 mg, about 1175 mg to about 1225 mg, about 1190 mg to about 1210 mg; e.g., 1200 mg ± 5 mg, e.g., 1200 mg to about 1210 mg; ±2.5 mg, eg 1200±1.0 mg, eg 1200±0.5 mg; eg about 1200 mg). In certain embodiments, the PD-1 axis binding antagonist is administered at a dose of about 1200 mg. In some embodiments, the PD-1 axis binding antagonist is administered on day 1 (±1 day) of each administration cycle after the first administration cycle that includes administration of the bispecific antibody. In some embodiments, the PD-1 axis binding antagonist is atezolizumab. In some embodiments, the subject is a human.
[0170] The present invention provides for administering to a subject a bispecific antibody (e.g., mosnetuzumab) that binds CD20 and CD3 in a dosing regimen comprising eight or more 21-day or 28-day dosing cycles (e.g., intravenous administration). CD20-positive cell proliferative disorders (e.g., B-cell proliferative disorders (e.g., relapsed or refractory B-cell proliferative disorders), e.g., non-Hodgkin's lymphoma (NHL; e.g., diffuse large B-cell proliferative disorders) lymphoma (DLBCL; e.g., Richter's transformation), follicular lymphoma (FL; e.g., grade 1 FL, grade 2 FL, grade 3 FL (e.g., grade 3aFL, grade 3bFL), or transformed FL), mantle cell lymphoma (MCL), or marginal zone lymphoma (MZL)), or chronic lymphocytic leukemia (CLL), such as relapsed or refractory NHL (e.g., relapsed or refractory DLBCL, relapsed or refractory FL, relapsed or refractory MCL) , or relapsed or refractory MZL), or relapsed or refractory CLL), comprising: (a) a first 21-day administration cycle comprising: a first dose (C1D1); (b) a second dose (C1D2) and a third dose (C1D3) of the bispecific antibody, wherein C1D1 is about 1 mg, C1D2 is about 2 mg, and C1D3 is about 60 mg; (c) The third dosing cycle includes a single dose (C2D1) of the bispecific antibody, and C2D1 is approximately 60 mg; (c) the third dosing cycle includes a single dose (C3D1) of the bispecific antibody; (d) the fourth dosing cycle comprises a single dose (C4D1) of the bispecific antibody; (e) the fifth dosing cycle comprises a single dose (C5D1) of the bispecific antibody; (f) the sixth dosing cycle comprises a single dose (C6D1) of the bispecific antibody; (g) the seventh dosing cycle comprises a single dose (C7D1) of the bispecific antibody; ; (h) the eighth administration cycle comprises a single dose (C8D1) of the bispecific antibody, each of C3D1-C8D1 being about 30 mg. In some embodiments, the administration cycle after the first administration cycle is a 28 day administration cycle.
[0171] In some examples of any of the foregoing methods, the subject receives prior systemic therapy for a CD20-positive cell proliferative disorder (e.g., a B-cell proliferative disorder (e.g., a relapsed or refractory B-cell proliferative disorder); For example, non-Hodgkin's lymphoma (NHL; e.g., diffuse large B-cell lymphoma (DLBCL; e.g., Richter's transformation), follicular lymphoma (FL; e.g., grade 1FL, grade 2FL, grade 3FL (e.g., grade 3aFL, have received prior systemic therapy for grade 3bFL) or transformed FL), mantle cell lymphoma (MCL), or marginal zone lymphoma (MZL)), or chronic lymphocytic leukemia (CLL)). In some instances, the subject has received a first-line systemic therapy and a second-line systemic therapy for a CD20-positive cell proliferative disorder (e.g., the dosing regimen provided herein is a third-line systemic therapy). may be the treatment of choice). In some embodiments, the subject exhibits progression of a CD20-positive cell proliferative disorder within 24 months of any prior systemic therapy.
[0172] In some instances, the prior systemic therapy includes an anti-CD20 antibody (eg, rituximab or obinutuzumab). In some instances, the preceding systemic therapy includes a chemotherapeutic agent, such as an alkylating agent (eg, bendamustine). In some embodiments, the prior systemic therapy comprises lenalidomide. In some instances, the preceding systemic therapy includes radioimmunotherapy (eg, ibritumomab tiuxetan). In some instances, the preceding systemic therapy includes a phosphoinositide 3-kinase inhibitor (eg, idelalisib, alpelisib, copanlisib, or duvelisib). In some instances, the prior systemic therapy includes CAR-T therapy.
[0173] The invention also provides for administering to one or more subjects a bispecific antibody that binds CD20 and CD3 (e.g., mosnetuzumab) in a dosage regimen that includes at least a first administration cycle and a second administration cycle (e.g., CD20-positive cell proliferative disorders (e.g., B-cell proliferative disorders (e.g., relapsed or refractory B-cell proliferative disorders), e.g., non-Hodgkin's lymphoma (NHL; e.g., diffuse large cell type B-cell lymphoma (DLBCL; e.g., Richter's transformed), follicular lymphoma (FL; e.g., grade 1FL, grade 2FL, grade 3FL (e.g., grade 3aFL, grade 3bFL) or transformed FL), mantle cell lymphoma ( MCL), or marginal zone lymphoma (MZL)), or chronic lymphocytic leukemia (CLL), such as relapsed or refractory NHL (e.g. relapsed or refractory DLBCL, relapsed or refractory FL, relapsed or refractory 1. A method of treating a population of subjects with refractory MCL, or relapsed or refractory MZL), or relapsed or refractory CLL, comprising: (a) a first administration cycle comprising a first dose (C1D1 ), a second dose (C1D2) and a third dose (C1D3) of the bispecific antibody, wherein C1D1 is about 0.02 mg to about 2.0 mg (e.g., about 0.02 to about 1.8 mg, about 0.02 to about 1.6 mg, about 0.02 to about 1.4 mg, about 0.02 to about 1.2 mg, about 0.05 to about 1.8 mg, about 0.1 to about 1.8 mg, about 0.4 to about 1.8 mg, about 0.6 to about 1.8 mg, about 0.8 to about 1.8 mg , about 0.5 to about 1.5 mg, about 0.8 to about 1.2 mg; for example, about 1 mg), and C1D2 is about 0.05 to about 4.0 mg (for example, about 0.05 to about 3.5 mg, about 0.05 to about 3.0 mg, about 0.05 to about 2.5 mg, about 0.05 to about 2.2 mg, about 0.1 to about 3.5 mg, about 0.5 to about 3.5 mg, about 1.0 to about 3.5 mg, about 1.5 to about 3.5 mg, about 1.8 to about 3.5 mg, about 1.0 ~3.0 mg, about 1.5 to about 2.5 mg; e.g., about 2 mg) and C1D3 is greater than about 50 mg; (b) the second dosing cycle comprises a single dose (C2D1) of the bispecific antibody; provide a method.
[0174] In other particular examples, the invention provides bispecific antibodies that bind CD20 and CD3 (e.g., atezolizumab CD20-positive cell proliferative disorders (e.g., B-cell proliferative disorders (e.g., relapsed or refractory B-cell proliferative disorders), e.g., non-Hodgkin's lymphoma (NHL; e.g. , diffuse large B-cell lymphoma (DLBCL; e.g., Richter's transformation), follicular lymphoma (FL; e.g., grade 1FL, grade 2FL, grade 3FL (e.g., grade 3aFL, grade 3bFL) or transformed FL), mantle cell lymphoma (MCL), or marginal zone lymphoma (MZL)), or chronic lymphocytic leukemia (CLL), such as relapsed or refractory NHL (e.g., relapsed or refractory DLBCL, relapsed or refractory FL). , relapsed or refractory MCL, or relapsed or refractory MZL) or relapsed or refractory CLL), comprising: (a) a first administration cycle comprising: dose (C1D1), a second dose (C1D2) and a third dose (C1D3) of the bispecific antibody, where C1D1 is about 0.02 mg to about 2.0 mg (e.g., about 0.02 to about 1.8 mg, about 0.02 ~1.6mg, 0.02~1.4mg, 0.02~1.2mg, 0.05~1.8mg, 0.1~1.8mg, 0.4~1.8mg, 0.6~1.8mg, 0.8~ about 1.8 mg, about 0.5 to about 1.5 mg, about 0.8 to about 1.2 mg; for example, about 1 mg), and C1D2 is about 0.05 mg to about 4.0 mg (for example, about 0.05 to about 3.5 mg, about 0.05 to about 3.0 mg, about 0.05 to about 2.5 mg, about 0.05 to about 2.2 mg, about 0.1 to about 3.5 mg, about 0.5 to about 3.5 mg, about 1.0 to about 3.5 mg, about 1.5 to about 3.5 mg, about 1.8 to about 3.5 mg , about 1.0 to about 3.0 mg, about 1.5 to about 2.5 mg; e.g., about 2 mg) and C1D3 is greater than about 20 mg; (c) the third dosing cycle contains a single dose (C3D1) of bispecific antibody, C3D1 is more than C1D1 and C2D1 is more than C2D1; Less, including methods.
[0175] Also, by administering to one or more subjects a bispecific antibody that binds CD20 and CD3 in a regimen of 8 or more dosing cycles, CD20-positive cell proliferative disorders (e.g., B-cell proliferative disorders, e.g. relapsed or refractory B-cell proliferative disorders), e.g., non-Hodgkin lymphoma (NHL; e.g., diffuse large B-cell lymphoma (DLBCL; e.g., Richter's transformation), follicular lymphoma (FL; e.g., grade 1 FL). , grade 2FL, grade 3FL (e.g., grade 3aFL, grade 3bFL) or transformed FL), mantle cell lymphoma (MCL), or marginal zone lymphoma (MZL)), or chronic lymphocytic leukemia (CLL), e.g., relapse Populations of subjects with severe or refractory NHL (e.g., relapsed or refractory DLBCL, relapsed or refractory FL, relapsed or refractory MCL, or relapsed or refractory MZL) or relapsed or refractory CLL) (a) the first administration cycle comprises a first dose (C1D1), a second dose (C1D2) and a third dose (C1D3) of the bispecific antibody; C1D1 is approximately 0.02 mg to approximately 2.0 mg (for example, approximately 0.02 to approximately 1.8 mg, approximately 0.02 to approximately 1.6 mg, approximately 0.02 to approximately 1.4 mg, approximately 0.02 to approximately 1.2 mg, approximately 0.05 to approximately 1.8 mg, approximately 0.1 to about 1.8 mg, about 0.4 to about 1.8 mg, about 0.6 to about 1.8 mg, about 0.8 to about 1.8 mg, about 0.5 to about 1.5 mg, about 0.8 to about 1.2 mg; for example, about 1 mg), and C1D2 is about 0.05 mg to about 4.0 mg (for example, about 0.05 to about 3.5 mg, about 0.05 to about 3.0 mg, about 0.05 to about 2.5 mg, about 0.05 to about 2.2 mg, about 0.1 to about 3.5 mg, about 0.5 to about 3.5 mg , about 1.0 to about 3.5 mg, about 1.5 to about 3.5 mg, about 1.8 to about 3.5 mg, about 1.0 to about 3.0 mg, about 1.5 to about 2.5 mg; for example, about 2 mg), and C1D3 is greater than about 20 mg. (b) the second dosing cycle includes a single dose (C2D1) of the bispecific antibody, C2D1 is approximately equivalent to C1D3; (c) the third dosing cycle includes a single dose (C2D1) of the bispecific antibody; (d) the fourth administration cycle comprises a single dose (C4D1) of the bispecific antibody; (e ) the fifth dosing cycle comprises a single dose (C5D1) of the bispecific antibody; (f) the sixth dosing cycle comprises a single dose (C6D1) of the bispecific antibody; (g ) the seventh dosing cycle comprises a single dose (C7D1) of the bispecific antibody; (h) the eighth dosing cycle comprises a single dose (C8D1) of the bispecific antibody; C3D1 Also provided herein are methods in which ~C8D1 is in approximately equivalent amounts.
[0176] The present invention provides for administering to one or more subjects a bispecific antibody that binds CD20 and CD3 (e.g., mosnetuzumab) in a dosing regimen that includes eight or more 21-day or 28-day dosing cycles (e.g., intravenously). CD20-positive cell proliferative disorders (e.g., B-cell proliferative disorders (e.g., relapsed or refractory B-cell proliferative disorders), e.g., non-Hodgkin's lymphoma (NHL; e.g., diffuse large cell Type B-cell lymphoma (DLBCL; e.g., Richter's transformed), follicular lymphoma (FL; e.g., grade 1FL, grade 2FL, grade 3FL (e.g., grade 3aFL, grade 3bFL) or transformed FL), mantle cell lymphoma (MCL). ), or marginal zone lymphoma (MZL)), or chronic lymphocytic leukemia (CLL), such as relapsed or refractory NHL (e.g., relapsed or refractory DLBCL, relapsed or refractory FL, relapsed or refractory or relapsed or refractory MZL) or relapsed or refractory CLL), comprising: (a) a first 21-day dosing cycle comprising: a first dose ( (b ) the second dosing cycle contains a single dose (C2D1) of the bispecific antibody, where C2D1 is approximately 60 mg; (c) the third dosing cycle contains a single dose (C3D1) of the bispecific antibody; (d) the fourth dosing cycle comprises a single dose (C4D1) of the bispecific antibody; (e) the fifth dosing cycle comprises a single dose (C5D1) of the bispecific antibody; (f) the sixth dosing cycle comprises a single dose (C6D1) of the bispecific antibody; (g) the seventh dosing cycle comprises a single dose (C7D1) of the bispecific antibody; (h) the eighth administration cycle comprises a single dose (C8D1) of the bispecific antibody, and each of C3D1-C8D1 is about 30 mg. In some embodiments, the administration cycle after the first administration cycle is a 28 day administration cycle.
[0177] In some embodiments, the proportion of cytokine release syndrome having Grade 2 or higher (as defined by American Society for Transplantation and Cell Therapy, 2018; ASTCT) is about 10% or less (e.g., about 9% or less, about 8% or less, about 7% or less, about 6% or less, about 5% or less, about 4% or less, about 3% or less, about 2% or less, about 1% or less; for example, about 0.1% to about 10%, about 0.5% to about 10 %, about 1% to about 10%, about 1% to about 7%, about 1% to about 5%, about 1% to about 3%, or about 5% to about 10%; for example, about 9%, about 8%, about 7%, about 6%, about 5%, about 4%, about 3%, about 2%, about 1%, or about 0%). In some embodiments, the proportion of cytokine release syndrome having grade 2 or higher (as defined by ASTCT) is about 5% (e.g., about 4% or less, about 3% or less, about 2% or less, about 1% or less; For example, about 0% to about 5%, about 1% to about 5%, about 2% to about 5%, about 3% to about 5%, about 4% to about 5%, about 1% to about 3%, from about 2% to about 5%, or from about 0% to about 2%; for example, about 5%, about 4%, about 3%, about 2%, about 1%, or about 0%). In some embodiments, the rate of cytokine release syndrome having grade 3 or higher (as defined by ASTCT) is about 0%.
[0178] Any of the methods described herein may include monitoring a subject for cytokine release syndrome (CRS) (eg, a CRS event after initiation of any of the methods described above). Current clinical responses are focused on treating individual signs and symptoms, providing supportive care, and using high doses of corticosteroids to attempt to attenuate the inflammatory response. There is. However, this approach is not always successful, especially in cases of late intervention. The CRS grading criteria used by the methods described herein define mild, moderate, severe or life-threatening CRS and harmonize reporting across clinical trials to facilitate rapid recognition and treatment of CRS. has been published by the American Society for Transplantation and Cell Therapy (ASTCT) (Lee et al., Biology of Blood and Marrow Transplantation.25(4):625-638, 2019). The ASTCT criteria are objective, easy to apply, and are intended to more accurately classify the severity of CRS. This revised CRS grading system is shown in Table 1 below.
table 1
[0179] Fever is defined as a temperature of 38°C or higher that is not due to other causes. Then, in subjects with CRS, upon receiving antipyretic or anticytokine therapy such as tocilizumab or steroids, fever is no longer required to grade subsequent CRS severity. In this case, CRS grading is determined by hypotension and / or hypoxia.
[0180] CRS grade is determined by more severe events, hypotension or hypoxia not due to other causes. For example, a subject with a temperature of 39.5°C, hypotension requiring one vasopressor, and hypoxia requiring a low-flow nasal cannula would be classified as grade 3 CRS.
[0181] A low flow nasal cannula is defined as oxygen delivered at ≦6L / min. Low flow also includes blow-by oxygen delivery, which is sometimes used in pediatrics. High flow nasal cannula is defined as oxygen delivered at >6L / min.
[0182] CRS is associated with elevation of a wide range of cytokines, including markedly elevated levels of IFNγ, IL-6 and TNF-α. Emerging evidence specifically implicates CRS and IL-6 as a central mediator. IL-6 is a proinflammatory multifunctional cytokine produced by a variety of cell types, and this cytokine has been shown to be involved in a wide variety of physiological processes involving T cell activation. Regardless of the inducer, CRS is associated with high IL-6 levels (Nagorsen et al., Cytokine.25(1):31-5,2004;Lee et al.,Blood.124(2):188-95,2014) ;Doesegger et al., Clin.Transl.Immunology.4(7):e39,2015) and IL-6 correlate with the severity of CRS, and subjects who experience grade 4 or 5 CRS events are more likely to experience CRS. have much higher IL-6 levels compared to subjects who do not experience or who experience milder CRS (grades 0-3) (Chen et al., J. Immunol. Methods. 434:1-8, 2016).
[0183] Therefore, the use of agents that inhibit IL-6-mediated signaling to block the inflammatory effects of IL-6 to manage the CRS observed in subjects during a two-step fractionated dose escalation regimen is adversely affect T cell function or reduce the efficacy or clinical benefit of anti-CD20 / anti-CD3 bispecific antibody therapy in the treatment of CD20-positive cell proliferative disorders (e.g., B-cell proliferative disorders); It is an unexpected alternative to steroid treatment.
[0184] Tocilizumab (ACTEMRA® / RoACTEMRA®) is a recombinant, humanized, anti-human monoclonal antibody directed against the soluble membrane-bound IL-6R that inhibits IL-6-mediated signaling. (see, eg, WO1992 / 019579, which is incorporated herein by reference in its entirety).
[0185] If the subject has a cytokine release syndrome (CRS) event after administration of the bispecific antibody, the method administers to the subject an interleukin-6 receptor (IL-6R) antagonist (e.g., an anti-IL-6R antibody). , eg, tocilizumab (ACTEMRA® / RoACTEMRA®)) to manage the event. In some examples, tocilizumab is administered to the subject intravenously as a single dose of about 8 mg / kg. Other anti-IL-6R antibodies that can be used in place of or in combination with tocilizumab include sarilumab, bovalizumab (ALX-0061), SA-237, and variants thereof.
[0186] If the subject has a CRS event that does not resolve or worsen within 24 hours after administering an IL-6R antagonist to treat the symptoms of the CRS event, the method provides for administering to the subject an IL-6R antagonist (e.g. The method may further comprise administering one or more additional doses of an anti-IL-6R antibody (eg, tocilizumab) to manage the CRS event. If the CRS event is not managed through administration of an IL-6R antagonist, the subject may be administered a corticosteroid such as methylprednisolone or dexamethasone.
[0187] Management of CRS events can be tailored based on the stage of CRS and the presence of comorbidities. For example, if a subject has a grade 2 cytokine release syndrome (CRS) event in the absence of comorbidities or in the presence of minimal comorbidities after administration of the bispecific antibody, this method It can further provide for treating symptoms of a grade 2 CRS event pending treatment with the bispecific antibody. If the Grade 2 CRS event resolves to a Grade ≦1 CRS event for at least 3 consecutive days, the method may further comprise restarting treatment with the bispecific antibody without changing the dose. can. On the other hand, if the grade 2 CRS event does not resolve within 24 hours of treating the symptoms of the grade 2 CRS event or worsen to a grade ≧3 event, the method provides the subject with interleukin-6 receptor ( administering an effective amount of an IL-6R) antagonist (e.g., an anti-IL-6R antibody, e.g., tocilizumab (ACTEMRA® / RoACTEMRA®)) to suppress Grade 2 or Grade ≥3 CRS events. It may further include managing. In some examples, tocilizumab is administered to the subject intravenously as a single dose of about 8 mg / kg. Other anti-IL-6R antibodies that can be used in place of or in combination with tocilizumab include sarilumab, bovalizumab (ALX-0061), SA-237, and variants thereof.
[0188] If the subject has a grade 2, 3, or 4 CRS event in the presence of extensive comorbidities after administration of the bispecific antibody, this method can eliminate the CRS event while discontinuing treatment with the bispecific antibody. such as administering to the subject an initial dose of an IL-6R antagonist (e.g., an anti-IL-6R antibody, e.g., tocilizumab (ACTEMRA® / RoACTEMRA®)) to manage the CRS event. may further include methods understood in the art. Other anti-IL-6R antibodies that can be used in place of or in combination with tocilizumab include sarilumab, bovalizumab (ALX-0061), SA-237, and variants thereof. In some examples, the method further comprises administering to the subject an effective amount of a corticosteroid, such as methylprednisolone or dexamethasone.
[0189] In some examples, the methods of the present invention provide at least about 15% (e.g., 15%-30%, 15%-40%, 15%-50%, 15%-60%, 15%-75%, 15% %~80%, 15%~90%, 15%~100%, 20%~100%, 20%~75%, 20%~50%, 25%~100%, 25%~75%, 25%~ 50%, 30% to 75%, 30% to 100% or 30% to 50%; for example, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, or about 45 %) resulting in a complete response rate. In some embodiments, the complete response rate is at least about 45% (e.g., 45%-60%, 45%-70%, 45%-80%, 45%-95%, 45%-100%, 50%). % to 100%, 50% to 95%, or 50% to 75%; for example, about 45%, about 50%, about 55%, or about 60%). In some embodiments, the objective response rate is at least about 60% (e.g., 60%-70%, 60%-80%, 60%-90%, or 60%-100%; e.g., about 60%, about 65%, about 70%, about 75%, about 80%, or about 85%). In some embodiments, the objective response rate at about 20 months after initiation of treatment is at least about 70% (e.g., 70%-80%, 70%-90%, 70%-95%, or 70%-100%). %; for example, about 70%, about 75%, about 80%, about 85%, or about 90%). In some embodiments, the objective response rate at about 24 months after initiation of treatment is at least about 75% (e.g., 75%-80%, 75%-90%, 75%-95%, 75%-100% , 80% to 100%, or 90% to 100%; for example, about 75%, about 80%, about 85%, or about 90%). In some embodiments, the median duration of response (mDOR) is at least about 12 months (e.g., at least about 14 months, at least about 16 months, or at least about 18 months; e.g., between 12 and 14 months, 12 months). ~16 months, between 12 months and 18 months, or between 12 months and 20 months; eg, about 12 months, about 14 months, about 16 months, or about 18 months). In some embodiments, the mDOR is at least about 20 months (e.g., at least about 22 months, at least about 24 months, at least about 26 months, at least about 28 months, at least about 30 months, at least about 32 months, at least about 34 months). , or at least about 36 months; for example, between 20 months and 24 months, between 20 months and 30 months, between 20 months and 36 months, between 20 months and 48 months, between 20 months and 60 months, 20 For example, between 24 months and 72 months, between 24 months and 36 months, between 24 months and 48 months, between 24 months and 60 months, between 36 months and 48 months, or between 36 months and 60 months; about 20 months, about 24 months, about 28 months, about 32 months, about 36 months, about 40 months, about 48 months, about 56 months, or about 60 months). In some embodiments, the population of subjects has a proportion of subjects in the population with a DOR of at least 12 months, and the proportion of subjects in the population with a DOR of at least 12 months is at least about 60% (e.g., 60%). %~70%, 60%~80%, 60%~90%, or 60%~100%; for example, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, approximately 90%, or approximately 95%).
[0190] In some embodiments, the population of subjects exhibits cytokine release syndrome after administration of the bispecific antibody, and the proportion of cytokine release syndrome in the population of subjects is about 25% (e.g., about 23% or less, about 20%). % or less, about 18% or less, about 16% or less, about 15% or less, about 14% or less, about 13% or less, about 12% or less, about 11% or less, or about 10% or less; for example, about 1%~ Approximately 25%, approximately 5% to approximately 25%, approximately 10% to approximately 25%, approximately 15% to approximately 25%, approximately 20% to approximately 25%, approximately 5% to approximately 15%, approximately 5% to approximately 10 %, about 1% to about 15%, or about 1% to about 10%; for example, about 5%, about 10%, about 15%, about 20%, or about 25%). In some embodiments, the rate of cytokine release syndrome in the subject population is about 10% or less (e.g., about 9% or less, about 8% or less, about 7% or less, about 6% or less, about 5% or less, About 4% or less, about 3% or less, about 2% or less, or about 1% or less; for example, between about 0.1% and about 10%, between about 0.5% and about 10%, about 1% and about 10% between about 1% and about 7%, between about 1% and about 5%, between about 1% and about 3%, or between about 5% and about 10%; for example, about 1%, (about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, or about 8%).
[0191] In some instances, the dosing regimens of the invention are administered for more than 4 months (e.g., at least 4.5 months, at least 5 months, at least 5.5 months, at least 6 months, at least 6.5 months, at least 7 months, at least 7.5 months, at least 8 months, at least 8.5 months, at least 9.0 months, at least 9.5 months, at least 10 months, at least 11 months, at least 12 months, at least 13 months, at least 14 months, at least 15 months, at least 16 months, at least 17 months, at least 18 months , at least 20 months, at least 24 months, at least 30 months, at least 36 months, at least 42 months, at least 48 months, at least 54 months or more; e.g., between about 4 months and about 48 months, between about 4 months and about 36 months for about 4 months to about 24 months, for about 4 months to about 12 months, for about 4 months to about 10 months; for about 4 months to about 8 months, for about 8 months to about 24 months For example, about 4.5 months, about 5 months, about 5.5 months, about 6 months, about 6.5 months, about 7 months , about 7.5 months, about 8 months, about 8.5 months, about 9.0 months, about 9.5 months, about 10 months, about 11 months, about 12 months, about 13 months, about 14 months, about 15 months, about 16 months, about Median progression-free survival (PFS) of the target population ).
[0192] In some instances, the dosing regimens of the invention are administered for more than 4 months (e.g., at least 4.5 months, at least 5 months, at least 5.5 months, at least 6 months, at least 6.5 months, at least 7 months, at least 7.5 months, at least 8 months, at least 8.5 months, at least 9.0 months, at least 9.5 months, at least 10 months, at least 11 months, at least 12 months, at least 13 months, at least 14 months, at least 15 months, at least 16 months, at least 17 months, at least 18 months , at least 20 months, at least 24 months, at least 30 months, at least 36 months, at least 42 months, at least 48 months, at least 54 months or more; e.g., between about 4 months and about 48 months, between about 4 months and about 36 months months, from about 4 months to about 24 months, from about 4 months to about 12 months, from about 4 months to about 10 months; from about 4 months to about 8 months, from about 8 months to about 24 months for about 12 months to about 24 months, or from about 8 months to about 16 months; for example, about 4.5 months, about 5 months, about 5.5 months, about 6 months, about 6.5 months, about 7 months, about 7.5 months, about 8 months, about 8.5 months, about 9.0 months, about 9.5 months, about 10 months, about 11 months, about 12 months, about 13 months, about 14 months, about 15 months, about 16 months, about 17 months , about 18 months, about 20 months, about 24 months, about 30 months, about 36 months, about 42 months, about 48 months, about 54 months or more) have FL (e.g., relapsed and / or refractory FL) yields the median PFS for the population of interest.
[0193] In some instances, the dosing regimens of the invention are administered for about 2 months or more (e.g., at least 2 months, at least 2.5 months, at least 3 months, at least 3.5 months, at least 4 months, at least 4.5 months, at least 5 months, at least 5.5 months). .months, at least 6 months, at least 6.5 months, at least 7 months, at least 7.5 months, at least 8 months, at least 8.5 months, at least 9.0 months, at least 9.5 months, at least 10 months, at least 11 months, at least 12 months, at least 13 months , at least 14 months, at least 15 months, at least 16 months, at least 17 months, at least 18 months, at least 20 months, at least 24 months, at least 30 months, at least 36 months, at least 42 months, at least 48 months, at least 54 months, or For example, between about 2 months and about 48 months, between about 2 months and about 36 months, between about 2 months and about 24 months, between about 2 months and about 12 months, and between about 2 months and about 10 months. Between about 2 months to about 8 months, about 2 months to about 6 months, about 2 months to about 4 months, about 4 months to about 12 months, about 8 months to about 12 For example, about 2.5 months, about 3 months, about 3.5 months, about 4 months, about 4.5 months, about 5 months, about 5.5 months, about 6 months, about 6.5 months, about 7 months, about 7.5 months, about 8 months, about 8.5 months, about 9.0 months, about 9.5 months, about 10 months, about 11 months, about 12 months, about 13 months, about 14 months, about 15 months , about 16 months, about 17 months, about 18 months, about 20 months, about 24 months, about 30 months, about 36 months, about 42 months, about 48 months, about 54 months or more) DLBCL (e.g., relapse) yields median PFS for a population of subjects with severe and / or refractory DLBCL).
[0194] In some instances, the dosing regimens of the invention are administered for more than 6.3 months (e.g., at least 6.5 months, at least 6.7 months, at least 7 months, at least 7.3 months, at least 7.5 months, at least 8 months, at least 8.5 months, at least 9.0 months). months, at least 9.5 months, at least 10 months, at least 11 months, at least 12 months, at least 13 months, at least 14 months, at least 15 months, at least 16 months, at least 17 months, at least 18 months, at least 20 months, at least 24 months, at least 30 months, at least 36 months, at least 42 months, at least 48 months, at least 54 months, or more; for example, between about 6 months and about 48 months, between about 6 months and about 36 months, between about 6 months and about For 24 months, for about 6 months to about 12 months, for about 6 months to about 10 months; for about 6 months to about 8 months, for about 8 months to about 24 months, for about 12 months to about For 24 months, or between about 8 months and about 16 months; for example, about 6.3 months, about 6.5 months, about 7 months, about 7.5 months, about 8 months, about 8.5 months, about 9.0 months, about 9.5 months, About 10 months, about 11 months, about 12 months, about 13 months, about 14 months, about 15 months, about 16 months, about 17 months, about 18 months, about 20 months, about 24 months, about 30 months, about 36 months, about 42 months, about 48 months, about 54 months, or more) provide median PFS for a population of subjects with DLBCL (eg, relapsed and / or refractory DLBCL). In some instances, the dosing regimens of the invention result in a median PFS for a population of subjects with DLBCL (eg, relapsed and / or refractory DLBCL) of at least 6.7 months. In some instances, the dosing regimens of the invention result in a median PFS for a population of subjects with DLBCL (eg, relapsed and / or refractory DLBCL) of at least 7.3 months. In some instances, the dosing regimens of the invention result in a median PFS for a population of subjects with DLBCL (eg, relapsed and / or refractory DLBCL) of at least 8.0 months.
[0195] In some instances, the dosing regimens of the invention are administered for more than 9.5 months (e.g., at least 10 months, at least 11 months, at least 12 months, at least 13 months, at least 14 months, at least 15 months, at least 16 months, at least 17 months). months, at least 18 months, at least 20 months, at least 24 months, at least 30 months, at least 36 months, at least 42 months, at least 48 months, at least 54 months, or more; for example, from about 9 months to about 48 months; About 9 months About 36 months, About 9 months to about 24 months, About 9 months to about 12 months, About 10 months to about 18 months; About 12 months to about 24 months, About Between 18 months and about 36 months, between about 12 months and about 36 months, or between about 24 months and about 48 months; for example, about 10 months, about 11 months, about 12 months, about 13 months, about 14 months month, approximately 15 months, approximately 16 months, approximately 17 months, approximately 18 months, approximately 20 months, approximately 24 months, approximately 30 months, approximately 36 months, approximately 42 months, approximately 48 months, approximately 54 months, or more) Provides median overall survival (OS) for the population of interest.
[0196] In some instances, the dosing regimens of the invention are administered for more than 9.5 months (e.g., at least 10 months, at least 11 months, at least 12 months, at least 13 months, at least 14 months, at least 15 months, at least 16 months, at least 17 months). months, at least 18 months, at least 20 months, at least 24 months, at least 30 months, at least 36 months, at least 42 months, at least 48 months, at least 54 months, or more; for example, from about 9 months to about 48 months; About 9 months About 36 months, About 9 months to about 24 months, About 9 months to about 12 months, About 10 months to about 18 months; About 12 months to about 24 months, About Between 18 months and about 36 months, between about 12 months and about 36 months, or between about 24 months and about 48 months; for example, about 10 months, about 11 months, about 12 months, about 13 months, about 14 months month, approximately 15 months, approximately 16 months, approximately 17 months, approximately 18 months, approximately 20 months, approximately 24 months, approximately 30 months, approximately 36 months, approximately 42 months, approximately 48 months, approximately 54 months, or more) Provide median OS for a population of subjects with FL (eg, relapsed and / or refractory FL).
[0197] In some instances, the dosing regimens of the invention are administered for more than 9.5 months (e.g., at least 10 months, at least 11 months, at least 12 months, at least 13 months, at least 14 months, at least 15 months, at least 16 months, at least 17 months). months, at least 18 months, at least 20 months, at least 24 months, at least 30 months, at least 36 months, at least 42 months, at least 48 months, at least 54 months, or more; for example, from about 9 months to about 48 months; About 9 months About 36 months, About 9 months to about 24 months, About 9 months to about 12 months, About 10 months to about 18 months; About 12 months to about 24 months, About Between 18 months and about 36 months, between about 12 months and about 36 months, or between about 24 months and about 48 months; for example, about 10 months, about 11 months, about 12 months, about 13 months, about 14 months month, approximately 15 months, approximately 16 months, approximately 17 months, approximately 18 months, approximately 20 months, approximately 24 months, approximately 30 months, approximately 36 months, approximately 42 months, approximately 48 months, approximately 54 months, or more) Provide median OS for a population of subjects with DLBCL (eg, relapsed and / or refractory DLBCL).
[0198] In some instances, the dosing regimens of the invention are administered for more than 12.5 months (e.g., at least 13 months, at least 14 months, at least 14.6 months, at least 15 months, at least 15.8 months, at least 16 months, at least 17 months, at least 17.3 months). months, at least 18 months, at least 20 months, at least 24 months, at least 30 months, at least 36 months, at least 42 months, at least 48 months, at least 54 months, or more; for example, between about 13 months and about 48 months; Between about 13 months and about 36 months, between about 13 months and about 24 months, between about 16 months and about 60 months, between about 24 months and about 36 months; between about 12 months and about 24 months, About 18 months to about 36 months, about 24 months to about 36 months, about 24 months to about 48 months; For example, about 13 months, about 14 months, about 15 months, about 16 months, about 17 months months, about 18 months, about 20 months, about 24 months, about 30 months, about 36 months, about 42 months, about 48 months, about 54 months, or more) DLBCL (e.g., relapsed and / or refractory DLBCL) ) yields a median OS for a population of subjects with In some instances, the dosing regimens of the invention result in a median OS for a population of subjects with DLBCL (eg, relapsed and / or refractory DLBCL) of greater than 14.6 months. In some instances, the dosing regimens of the invention result in a median OS for a population of subjects with DLBCL (eg, relapsed and / or refractory DLBCL) of greater than 15.8 months. In some instances, the dosing regimens of the invention result in a median OS for a population of subjects with DLBCL (eg, relapsed and / or refractory DLBCL) of greater than 17.3 months.
[0199] In some examples, the dosing regimens of the invention provide at least about 42% (e.g., at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or more, such as 42% to 45%, 45% to 50%, 50% to 55%, 55%~60%, 60%~65%, 65%~70%, 70%~75%, or more, such as about 42%, about 45%, about 50%, about 55%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or more).
[0200] In some instances, the dosing regimens of the invention result in CR at a rate of at least about 50% in a population of subjects with FL (eg, relapsed and / or refractory FL). In some examples, the dosing regimens of the invention provide at least about 55% (e.g., at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or more, such as 55% to 60%, 60% to 65%, 65% to 70%, 70% to 75%, or more, such as about 42%, about 45%, about 50%, about 55%, about 65%, about 70%, about 75%, about 80%, about 85% , about 90%, about 95%, or more).
[0201] In some examples, the dosing regimens of the invention provide at least about 20% (e.g., at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%). In some examples, the dosing regimens of the invention provide at least about 42% (e.g., at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or more, e.g. 42%~45%, 45%~50%, 50%~55%, 55%~60%, 60%~65%, 65%~70%, 70%~75%, or more, for example, about 42 %, about 45%, about 50%, about 55%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or more) results in response (CR).
[0202] In some examples, the dosing regimens of the invention provide at least about 50% (e.g., at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or more, such as 50% to 55% , 55%-60%, 60%-65%, 65%-70%, 70%-75%, or more, such as about 42%, about 45%, about 50%, about 55%, about 65% , about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or more). In some instances, the dosing regimens of the invention result in CR at a rate of at least about 55% in a population of subjects with DLBCL (eg, relapsed and / or refractory DLBCL). In some instances, the dosing regimens of the invention result in CR at a rate of at least about 60% in a population of subjects with DLBCL (eg, relapsed and / or refractory DLBCL). In some instances, the dosing regimens of the invention result in CR at a rate of at least about 65% in a population of subjects with DLBCL (eg, relapsed and / or refractory DLBCL). In some instances, the dosing regimens of the invention result in CR at a rate of at least about 20% in a population of subjects with DLBCL (eg, relapsed and / or refractory DLBCL).
[0203] B. Bispecific antibody that binds to CD20 and CD3 The invention relates to CD20-positive cell proliferative disorders, such as B cell proliferative disorders (e.g., B cell proliferative disorders (e.g., relapsed or refractory B cell proliferative disorders), e.g. non-Hodgkin's lymphoma (NHL; e.g. Diffuse large B-cell lymphoma (DLBCL; e.g., Richter's transformation), follicular lymphoma (FL; e.g., grade 1FL, grade 2FL, grade 3FL (e.g., grade 3aFL, grade 3bFL), or transformed FL); mantle cell lymphoma (MCL), or marginal zone lymphoma (MZL)), or chronic lymphocytic leukemia (CLL), such as relapsed or refractory NHL (e.g., relapsed or refractory DLBCL, relapsed or refractory FL). CD20 and CD3 (i.e., anti-CD20 / anti-CD3) useful for treating relapsed or refractory MCL, or relapsed or refractory MZL or relapsed or refractory CLL). provides a bispecific antibody that binds to an antibody).
[0204] In some examples, the invention provides (a) HVR-H1 comprising the amino acid sequence of GYTFTSYNMH (SEQ ID NO: 1); (b) HVR-H2 comprising the amino acid sequence of AIYPGNGDTSYNQKFKG (SEQ ID NO: 2); (c) VVYYSNSYWYFDV HVR-H3 (SEQ ID NO: 3) comprising the amino acid sequence of; (d) HVR-L1 comprising the amino acid sequence of RASSSVSYMH (SEQ ID NO: 4); (e) HVR-L2 (SEQ ID NO: 5) comprising the amino acid sequence of APSNLAS; and (f) a first comprising at least one, two, three, four, five or six hypervariable regions (HVRs) selected from HVR-L3 (SEQ ID NO: 6) comprising the amino acid sequence of QQWSFNPPT. Provided are bispecific antibodies comprising an anti-CD20 arm having a binding domain of: In some examples, the anti-CD20 / anti-CD3 antibody comprises at least one of the heavy chain framework regions FR-H1, FR-H2, FR-H3, and FR-H4, each comprising a sequence of SEQ ID NOs: 17-20. (e.g., one, two, three, or four) and / or light chain framework regions FR-L1, FR-L2, FR-L3, and FR, each comprising a sequence of SEQ ID NOs: 21-24. - at least one (eg, one, two, three, or four) of L4. In some examples, the bispecific antibody has (a) at least 90% sequence identity to SEQ ID NO: 7 (e.g., at least 91%, 92%, 93%, 94%, 95%, 96% , 97%, 98% or 99% sequence identity) or a heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO: 7; (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity), or the amino acid sequence of SEQ ID NO: 8. a light chain variable (VL) domain; or (c) an anti-CD20 arm comprising a first binding domain comprising a VH domain as in (a) and a VL domain as in (b). Thus, in some examples, the first binding domain comprises a VH domain comprising the amino acid sequence of SEQ ID NO: 7 and a VL domain comprising the amino acid sequence of SEQ ID NO: 8.
[0205] In some examples, the invention provides (a) HVR-H1 comprising the amino acid sequence of NYYIH (SEQ ID NO: 9); (b) HVR-H2 comprising the amino acid sequence of WIYPGDGNTKYNEKFKG (SEQ ID NO: 10); (c) DSYSNYYFDY HVR-H3 containing the amino acid sequence of (SEQ ID NO: 11); (d) HVR-L1 containing the amino acid sequence of KSSQSLLNSRTRKNYLA (SEQ ID NO: 12); (e) HVR-L2 containing the amino acid sequence of WASTRES (SEQ ID NO: 13); (f) a second binding domain comprising at least one, two, three, four, five or six HVRs selected from HVR-L3 comprising the amino acid sequence of TQSFILRT (SEQ ID NO: 14); Bispecific antibodies comprising a CD3 arm are provided. In some examples, the anti-CD20 / anti-CD3 antibody comprises at least one of the heavy chain framework regions FR-H1, FR-H2, FR-H3, and FR-H4, each comprising the sequences SEQ ID NOs: 25-28. (e.g., one, two, three, or four) and / or light chain framework regions FR-L1, FR-L2, FR-L3, and FR, each comprising a sequence of SEQ ID NOs: 29-32. - at least one (eg, one, two, three, or four) of L4. In some examples, the bispecific antibody has (a) at least 90% sequence identity to SEQ ID NO: 15 (e.g., at least 91%, 92%, 93%, 94%, 95%, 96% , 97%, 98% or 99% sequence identity), or a VH domain comprising the amino acid sequence of SEQ ID NO: 15; (b) at least 90% sequence identity to SEQ ID NO: 16 (e.g. an amino acid sequence having at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity); (c) comprises an anti-CD3 arm comprising a VH domain as in (a) and a second binding domain comprising a VL domain as in (b). Thus, in some examples, the second binding domain comprises a VH domain comprising the amino acid sequence of SEQ ID NO: 15 and a VL domain comprising the amino acid sequence of SEQ ID NO: 16.
[0206] In some examples, the invention provides: (1) HVR-H1 comprising the amino acid sequence of GYTFTSYNMH (SEQ ID NO: 1); (b) HVR-H2 comprising the amino acid sequence of AIYPGNGDTSYNQKFKG (SEQ ID NO: 2); (c) VVYYSNSYWYFDV HVR-H3 (SEQ ID NO: 3) comprising the amino acid sequence of; (d) HVR-L1 comprising the amino acid sequence of RASSSVSYMH (SEQ ID NO: 4); (e) HVR-L2 (SEQ ID NO: 5) comprising the amino acid sequence of APSNLAS; and (f) having a first binding domain comprising at least one, two, three, four, five or six HVRs selected from HVR-L3 (SEQ ID NO: 6) comprising the amino acid sequence of QQWSFNPPT. anti-CD20 arm and (2) (a) HVR-H1 containing the amino acid sequence of NYYIH (SEQ ID NO: 9); (b) HVR-H2 containing the amino acid sequence of WIYPGDGNTKYNEKFKG (SEQ ID NO: 10); (c) the amino acid of DSYSNYYFDY HVR-H3 comprising the sequence (SEQ ID NO: 11); (d) HVR-L1 comprising the amino acid sequence of KSSQSLLNSRTRKNYLA (SEQ ID NO: 12); (e) HVR-L2 comprising the amino acid sequence of WASTRES (SEQ ID NO: 13); and ( f) an anti-CD3 having a second binding domain comprising at least one, two, three, four, five or six HVRs selected from HVR-L3 comprising the amino acid sequence of TQSFILRT (SEQ ID NO: 14); A bispecific antibody comprising an arm is provided. In some examples, the anti-CD20 / anti-CD3 bispecific antibody comprises (1) heavy chain framework regions FR-H1, FR-H2, FR-H3 and FR- H4 (e.g., 1, 2, 3, or 4) and / or the light chain framework regions FR-L1, FR-L2, FR-L3 and FR- at least one of L4 (e.g., 1, 2, 3, or 4); and (2) heavy chain framework regions FR-H1, FR-H2, FR-H3, and FR, each comprising a sequence of SEQ ID NOs: 25 to 28. -H4 (e.g., 1, 2, 3, or 4), and / or light chain framework regions FR-L1, FR-L2, FR-L3, and FR, each comprising a sequence of SEQ ID NOs: 29 to 32. -L4 (eg, 1, 2, 3, or 4). In some examples, the anti-CD20 / anti-CD3 bispecific antibody has (1)(a) at least 90% sequence identity to SEQ ID NO: 7 (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity) or a VH domain comprising the amino acid sequence of SEQ ID NO: 7; (b) at least 90% to SEQ ID NO: 8; (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity); (c) an anti-CD20 arm comprising a first binding domain comprising a VH as in (a) and a VL as in (b); and (2) (a) a VL domain as in SEQ ID NO: 15. an amino acid sequence having at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity) to a VH domain comprising the amino acid sequence of SEQ ID NO: 15; (b) at least 90% sequence identity to SEQ ID NO: 16 (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97 or (c) a VH as in (a) and a VL as in (b); or (c) a VH as in (a) and a VL as in (b). and an anti-CD3 arm comprising a second binding domain comprising an anti-CD3 arm. In some examples, the anti-CD20 / anti-CD3 bispecific antibody has a first binding domain comprising (1) a VH domain comprising the amino acid sequence of SEQ ID NO: 7 and a VL domain comprising the amino acid sequence of SEQ ID NO: 8; , (2) a second binding domain comprising a VH domain comprising the amino acid sequence of SEQ ID NO: 15 and a VL domain comprising the amino acid sequence of SEQ ID NO: 16.
[0207] In some cases, the antibody is monetuzumab, which has International Nonproprietary Names (INN) List 117 (WHO Drug Information, Vol. 31, No. 2, 2017, p. 303) or CAS Registration Number 1905409-39-3. . In some embodiments, the anti-CD20 / anti-CD3 bispecific antibody (1) (a) has at least 90% sequence identity to SEQ ID NO: 51 (e.g., at least 91%, 92%, 93% , 94%, 95%, 96%, 97%, 98% or 99% sequence identity), or a heavy chain comprising the amino acid sequence of SEQ ID NO: 51; % sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity), or of SEQ ID NO: 52. (c) an anti-CD20 arm comprising a first binding domain comprising a heavy chain as in (a) and a light chain as in (b); and (2) the sequence in (a). Amino acids having at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity) to number 53 or a heavy chain comprising the amino acid sequence of SEQ ID NO: 53; (b) at least 90% sequence identity to SEQ ID NO: 54 (e.g., at least 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98% or 99% sequence identity) or a light chain comprising the amino acid sequence of SEQ ID NO:54; or (c) a heavy chain as in (a) and and an anti-CD3 arm comprising a second binding domain comprising a light chain. In some embodiments, the anti-CD20 / anti-CD3 bispecific antibody has a first linkage comprising (1) a heavy chain comprising the amino acid sequence of SEQ ID NO: 51 and a light chain comprising the amino acid sequence of SEQ ID NO: 52. an anti-CD20 arm comprising a domain; and (2) an anti-CD3 arm comprising a second binding domain comprising a heavy chain comprising an amino acid sequence of SEQ ID NO: 53 and a light chain comprising an amino acid sequence of SEQ ID NO: 54.
[0208] The amino acid sequence of mosnetuzumab is provided in Table 2 below. [Table 2]
[0209] Anti-CD20 / anti-CD3 bispecific antibodies can be produced using recombinant methods and compositions, for example, as described in US Pat. No. 4,816,567.
[0210] In some examples, an anti-CD20 / anti-CD3 bispecific antibody according to any of the embodiments above includes any of the features, alone or in combination, as described in Section C below. It may also be incorporated.
[0211] C. Antibody format and properties The methods described herein may further include any of the antibodies described above, where the antibody comprises any of the characteristics described below, alone or in combination.
[0212] 1. Antibody affinity In certain examples, the anti-CD20 / anti-CD3 bispecific antibody is ≦1 μM, ≦100 nM, ≦10 nM, ≦1 nM, ≦0.1 nM, ≦0.01 nM or ≦0.001 nM (e.g., 10 -8 M or less, for example 10 -8 M~10 -13 M, for example 10 -9 M~10 -13 M) dissociation constant (K D ).
[0213] In one example, K D is measured by radiolabeled antigen binding assay (RIA). In one example, RIA is performed using a Fab version of the antibody of interest and its antigen. For example, the solution binding affinity of a Fab for an antigen is determined in the presence of a titration system of unlabeled antigen at a minimum concentration of ( 125 I) Equilibrate the Fab with labeled antigen and then measure the bound antigen by capturing it on a plate coated with anti-Fab antibodies (e.g. Chen et al., J. Mol. Biol. 293:865-881 (1999 ). To establish assay conditions, MICROTITER® multiwell plates (Thermo Scientific) were incubated overnight with 5 μg / mL of capture anti-Fab antibody (Cappel Labs) in 50 mM sodium carbonate (pH 9.6). Coat and then block with 2% (w / v) bovine serum albumin in PBS for 2-5 h at room temperature (approximately 23 °C). 100 pM or 26 pM [ 125 [I]-antigen is mixed with serial dilutions of the Fab of interest (e.g., consistent with the evaluation of anti-VEGF antibody Fab-12 in Presta et al., Cancer Res. 57:4593-4599 (1997)). The Fab of interest is then incubated overnight, but incubation can be continued for a longer period (eg, about 65 hours) to ensure equilibrium is reached. Thereafter, transfer the mixture to a capture plate for incubation (e.g., 1 h) at room temperature. The solution is then removed and the plate washed 8 times with 0.1% polysorbate 20 (TWEEN-20®) in PBS. When the plate is dry, 150 μL / well of scintillant (MICROSCINT-20™; Packard) is added and the plate is counted for 10 minutes in a TOPCOUNT™ gamma counter (Packard). The concentration of each Fab that yields 20% or less of maximal binding is selected for use in competitive binding assays.
[0214] According to another example, K D is measured using the BIACORE® surface plasmon resonance assay. For example, assays using the BIACORE®-2000 or BIACORE®-3000 (BIAcore®, Inc., Piscataway, NJ) contain approximately 10 response units (RU) of immobilized antigen on a CM5 chip. The test is carried out at 25°C. In one example, a carboxymethylated dextran biosensor chip (CM5, BIACORE, Inc.) was prepared with N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC) and N- Activated using hydroxysuccinimide (NHS). The antigen was diluted to 5 μg / ml (approximately 0.2 μM) with 10 mM sodium acetate, pH 4.8, and then injected at a flow rate of 5 μL / min to generate approximately 10 response units (RU) of coupled protein. achieve. After antigen injection, 1M ethanolamine is injected to block unreacted groups. For kinetic measurements, 2-fold serial dilutions of the Fab (0.78 nM to 500 nM) were diluted in 0.05% polysorbate 20 (TWEEN-20®) surfactant at a flow rate of approximately 25 μL / min at 25 °C. (PBST) in PBS. Association velocity (k on ) and dissociation rate (k off ) is calculated by simultaneously fitting the associated and dissociated sensorgrams using a simple one-to-one Langmuir binding model (BIACORE® evaluation software version 3.2). Equilibrium dissociation constant (K D ) is k off / k on Calculated as a ratio. See, eg, Chen et al., J. Mol. Biol. 293:865-881 (1999). The on-rate was determined by surface plasmon resonance assay above 10 6 M -1 s -1 , this on rate is measured in a spectrometer such as a stop-flow mounted spectrophotometer with a stirred cuvette (Aviv Instruments) or an 8000 Series SLM-AMINCO™ spectrophotometer (ThermoSpectronic). Increase or decrease in fluorescence emission intensity (excitation = 295 nm, emission = 340 nm, 16 nm bandpass) of 20 nM anti-antigen antibody (Fab type) in PBS (pH 7.2) at 25 °C in the presence of a concentration of antigen. can be determined by using fluorescence quenching techniques, which measure .
[0215] 2. Antibody fragment In certain examples, the anti-CD20 / anti-CD3 bispecific antibodies provided herein are antibody fragments. Antibody fragments include Fab, Fab', Fab'-SH, F(ab') 2 , Fv, and scFv fragments, and other fragments described below. For a review of specific antibody fragments, see Hudson et al., Nat. Med. 9:129-134 (2003). For references to scFv fragments, see e.g. Pluckthun, in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., (Springer-Verlag, New York), pp. 269-315 (1994); , WO 93 / 16185; and also US Pat. Nos. 5,571,894 and 5,587,458. Fab and F(ab’) that constitute salvage receptor binding epitope residues and have increased in vivo half-life 2 See US Pat. No. 5,869,046 for a discussion of fragments.
[0216] A "diabody" is an antibody fragment that has two antigen-binding sites and may be bivalent or bispecific. For example, European Patent No. 404,097, International Publication No. 1993 / 01161, Hudson et al.Nat.Med.9:129-134(2003); and Hollinger et al.Proc.Natl.Acad.Sci.USA 90:6444 -6448 (1993). Triabodies and tetrabodies are also described in Hudson et al. Nat. Med. 9:129-134 (2003).
[0217] Single domain antibodies are antibody fragments that contain all or part of the heavy chain variable domain or all or part of the light chain variable domain of an antibody. In certain examples, the single domain antibody is a human single domain antibody (Domantis, Inc., Waltham, Mass.; see, eg, US Pat. No. 6,248,516 B1).
[0218] Antibody fragments can be produced by a variety of techniques, including, but not limited to, proteolysis and production of intact antibodies by recombinant host cells (e.g., E. coli or phages), as described herein. .
[0219] 3. Chimeric antibodies and humanized antibodies In certain examples, the anti-CD20 / anti-CD3 bispecific antibodies provided herein are chimeric antibodies. Certain chimeric antibodies are described, for example, in US Pat. No. 4,816,567 and in Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984). In one example, a chimeric antibody comprises a non-human variable region (eg, a variable region derived from a non-human primate such as a mouse, rat, hamster, rabbit, or monkey) and a human constant region. In a further example, a chimeric antibody is a "class-switched" antibody in which the class or subclass has been changed from that of the parent antibody. Chimeric antibodies include antigen-binding fragments thereof.
[0220] In certain examples, chimeric antibodies are humanized antibodies. Typically, non-human antibodies are humanized to reduce immunogenicity to humans while retaining the specificity and affinity of the parent non-human antibody. Generally, humanized antibodies include one or more variable domains in which the HVRs, eg, CDRs (or portions thereof) are derived from a non-human antibody and FRs (or portions thereof) are derived from human antibody sequences. Humanized antibodies also optionally include at least a portion of a human constant region. In some instances, some FR residues in a humanized antibody are derived from a non-human antibody (e.g., the antibody from which the HVR residues are derived), e.g., to restore or improve antibody specificity or affinity. is replaced with the corresponding residue of
[0221] Humanized antibodies and methods for their production are reviewed in Almagro and Fransson, Front. Biosci. 13:1619-1633 (2008) and further described in: Riechmann et al., Nature 332:323- 329(1988);Queen et al.,Proc.Natl Acad.Sci.USA 86:10029-10033(1989);U.S. Pat. al., Methods 36:25-34 (2005)) (describing specificity-determining region (SDR) grafting); Padlan, Mol. Immunol. 28:489-498 (1991) (describing resurfacing); Dall' Acqua et al., Methods 36:43-60 (2005) (describing "FR shuffling"; and Osbourn et al., Methods 36:61-68 (2005) and Klimka et al., Br. J. Cancer, 83 :252-260 (2000) (Describing the ``Guided Selection Approach'' for FR Shuffle).
[0222] Human framework regions that may be used for humanization include, but are not limited to: framework regions selected using a "best fit" method (e.g., Sims et al., J. Immunol. 151:2296 (1993)); framework regions derived from human antibody consensus sequences for specific subgroups of light or heavy chain variable regions (e.g., Carter et al., Proc. Natl. Acad .Sci.USA, 89:4285 (1992); and Presta et al., J. Immunol., 151:2623 (1993)); human mature (somatic mutation) framework regions or human germline frameworks. regions (see, e.g., Almagro and Fransson, Front. Biosci.13:1619-1633 (2008)); and framework regions derived from screening of FR libraries (e.g., Baca et al., J.Biol.Chem.272); :10678-10684 (1997) and Rosok et al., J. Biol. Chem. 271:22611-22618 (1996)).
[0223] 4.Human antibodies In certain examples, the anti-CD20 / anti-CD3 bispecific antibody is a human antibody. Human antibodies can be made using a variety of techniques known in the art. Human antibodies are generally described in van Dijk and van de Winkel, Curr. Opin. Pharmacol. 5:368-74 (2001) and Lonberg, Curr. Opin. Immunol. 20:450-459 (2008). .
[0224] Human antibodies may be prepared by administering an immunogen to transgenic animals that have been modified to produce intact human antibodies or intact antibodies with human variable regions in response to antigenic challenge. Such animals typically contain all or part of the human immunoglobulin loci that replace endogenous immunoglobulin loci or are extrachromosomal or randomly integrated into the animal's chromosomes. Contains. In such transgenic mice, endogenous immunoglobulin loci are generally inactivated. For a review of methods for obtaining human antibodies from transgenic animals, see Lonberg, Nat. Biotech. 23:1117-1125 (2005). Also, for example, US Pat. See also Patent No. 7,041,870; and US Patent Application Publication No. 2007 / 0061900, which describes VelociMouse® technology. Human variable regions from intact antibodies produced by such animals may be further modified, for example, by combining with different human constant regions.
[0225] Human antibodies can also be produced by hybridoma-based methods. Human myeloma and mouse-human xenomyeloma cell lines for producing human monoclonal antibodies have been described. (For example, Kozbor J. Immunol., 133:3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, pp. 51-63 (Marcel Dekker, Inc., New York, 1987); and Boerner et al. ., J. Immunol., 147:86 (1991)) Human antibodies produced through human B-cell hybridoma technology are also produced by Li et al., Proc. Natl. Acad. Sci. USA, 103:3557 -3562 (2006). Additional methods include, for example, U.S. Pat. No. 7,189,826 (describing the production of monoclonal human IgM antibodies from hybridoma cell lines), and Ni, (describing human hybridomas). Human hybridoma technology (trioma technology) is also described in Histology and Histopathology, 20(3):927-937 (2005) and Vollmers and Brandlein, Methods and Findings in Experimental and Clinical Pharmacology, 27(3):185-91 (2005). It is also stated.
[0226] Human antibodies can also be made by isolating Fv clone variable domain sequences selected from phage display libraries of human origin. Such variable domain sequences can then be combined with the desired human constant domains. Techniques for selecting human antibodies from antibody libraries are described below.
[0227] 5. Library-derived antibodies Anti-CD20 / anti-CD3 bispecific antibodies of the invention can be isolated by screening combinatorial libraries for antibodies with the desired activity(s). For example, various methods are known in the art for creating phage display libraries and screening such libraries for antibodies with desired binding properties. Such methods are reviewed, for example, by Hoogenboom et al. in Methods in Molecular Biology 178:1-37 (O'Brien et al., ed., Human Press, Totowa, NJ, 2001) and by McCafferty et al. .,Nature 348:552-554;Clackson et al.,Nature 352:624-628(1991);Marks et al.,J.Mol.Biol.222:581-597(1992);Marks and Bradbury,in Methods in Molecular Biology 248:161-175(Lo,ed.,Human Press,Totowa,NJ,2003);Sidhu et al.,J.Mol.Biol.338(2):299-310(2004);Lee et al .,J.Mol.Biol.340(5):1073-1093(2004);Fellouse,Proc.Natl.Acad.Sci.USA 101(34):12467-12472(2004);and Lee et al.,J Immunol. Methods 284(1-2):119-132 (2004).
[0228] In certain phage display methods, repertoires of VH and VL genes are cloned separately by polymerase chain reaction (PCR), randomly recombined in a phage library, and then recombined randomly in a phage library, as described by Winter et al., Ann. Rev. Immunol. Screening for antigen-binding phages can be performed as described in J. Phys., 12:433-455 (1994). Phage typically display antibody fragments as either single chain Fv (scFv) fragments or Fab fragments. Libraries from immunogens provide high affinity antibodies against the immunogen without the need to construct hybridomas. Alternatively, the naïve repertoire is a collection of antibodies against a wide range of non-self and also self-antigens without immunization, as described by Griffiths et al., EMBO J, 12:725-734 (1993). can be cloned (eg, from a human) to provide a single source of Finally, a naive library was created by cloning unrearranged V gene segments from stem cells and using PCR primers containing random sequences to encode highly variable CDR3 regions, as described by Hoogenboom and Winter, J. It can also be made synthetically by achieving rearrangement in vitro, as described in Mol. Biol., 227:381-388 (1992). Patent publications describing human antibody phage libraries include, for example: U.S. Pat. No. 2007 / 0160598, No. 2007 / 0237764, No. 2007 / 0292936, and No. 2009 / 0002360.
[0229] Anti-CD20 / anti-CD3 bispecific antibodies or antibody fragments isolated from human antibody libraries are considered herein to be human antibodies or human antibody fragments.
[0230] 6. Antibody variants In certain instances, amino acid sequence variants of the anti-CD20 / anti-CD3 bispecific antibodies of the invention are contemplated. As described in detail herein, anti-CD20 / anti-CD3 bispecific antibodies can be optimized based on desired structural and functional properties. For example, it may be desirable to improve the binding affinity and / or other biological properties of antibodies. Amino acid sequence variants of antibodies may be prepared by introducing appropriate modifications into the nucleotide sequence encoding the antibody or by peptide synthesis. Such modifications include, for example, deletions from, and / or insertions into, residues within the amino acid sequence of the antibody, and / or substitutions of residues within the amino acid sequence of the antibody. can be mentioned. Any combination of deletions, insertions, and substitutions can be made to arrive at the final construct, provided that the final construct retains the desired characteristics, such as antigen binding.
[0231] a. Substitution, insertion and deletion variants In certain examples, anti-CD20 / anti-CD3 bispecific antibody variants with one or more amino acid substitutions are provided. Sites of interest for mutagenesis by substitution include HVR and FR. Conservative substitutions are shown in Table 3 under the heading "Preferred Substitutions." More substantial changes are provided in Table 3 under the heading "Exemplary Substitutions" and as further described below with reference to amino acid side chain classes. Amino acid substitutions can be introduced into antibodies of interest and the products screened for a desired activity, such as retained / improved antigen binding, decreased immunogenicity, or improved ADCC or CDC. [Table 3]
[0232] Amino acids can be classified according to their general side chain properties. (1) Hydrophobicity: norleucine, Met, Ala, Val, Leu, Ile; (2) Neutral hydrophilic: Cys, Ser, Thr, Asn, Gln; (3) Acidic: Asp, Glu; (4) Basic: His, Lys, Arg; (5) Residues that affect chain orientation: Gly, Pro; (6) Aromatic: Trp, Tyr, Phe.
[0233] Non-conservative substitutions involve exchanging a member of one of these classes with another.
[0234] Certain substitutional variants involve substituting one or more hypervariable region residues of a parent antibody (eg, a humanized or human antibody). Generally, the resulting variant(s) selected for further study are modified in a particular biological property (e.g., increased affinity, decreased immunogenicity) compared to the parent antibody. (e.g., an improvement) and / or substantially retain certain biological properties of the parent antibody. Exemplary substitutional variants are affinity matured antibodies, which can be conveniently generated using, eg, phage display-based affinity maturation techniques as described herein. Briefly, one or more HVR residues are mutated, and variant antibodies are displayed on phage and screened for specific biological activity (eg, binding affinity).
[0235] Modifications (eg, substitutions) may be made, eg, in the HVR, to improve antibody affinity. Such changes may occur at HVR "hotspots," i.e., residues encoded by codons that undergo high frequency of mutation during the somatic cell maturation process (e.g., Chowdhury, Methods Mol. Biol. 207:179-196( (2008)) and / or within residues that contact the antigen, and the resulting variants VH or VL are tested for binding affinity. Affinity maturation by construction of a secondary library and reselection therefrom is described, for example, in Hoogenboom et al., in Methods in Molecular Biology 178:1-37 (O'Brien et al., ed., Human Press, Totowa, NJ, (2001).). In some examples of affinity maturation, diversity is created in the variable genes selected for maturation by any of a variety of methods (e.g., error-prone PCR, strand shuffling, or oligonucleotide-directed mutagenesis). be introduced. A secondary library is then created. This library is then screened to identify any antibody variants with the desired affinity. Another method for introducing diversity involves HVR-directed approaches, in which several HVR residues are randomized (eg, 4-6 residues at a time). HVR residues involved in antigen binding can be specifically identified using, for example, alanine scanning mutagenesis or modeling. In particular, CDR-H3 and CDR-L3 are often targeted.
[0236] In certain instances, substitutions, insertions, or deletions may occur within one or more HVRs so long as such changes do not substantially reduce the ability of the antibody to bind antigen. For example, conservative changes (eg, conservative substitutions provided herein) that do not substantially reduce binding affinity may be made in the HVR. Such changes may be outside of antigen contacting residues within the HVR, for example. In certain examples of variant VH and VL sequences described above, each HVR is either unaltered or has one, two, or no more than three amino acid substitutions.
[0237] A useful method for identifying residues or regions of antibodies that can be targeted for mutagenesis is called "alanine scanning mutagenesis," as described in Cunningham and Wells (1989) Science, 244:1081-1085. . In this method, a residue or group of target residues (e.g., charged residues, e.g., Arg, Asp, His, Lys, and Glu) are used to determine whether the interaction between an antibody and an antigen is affected. identified and replaced by a neutral or negatively charged amino acid (eg, alanine or polyalanine). Additional substitutions may be introduced at amino acid positions that exhibit functional sensitivity to the initial substitution. Alternatively, or in addition, a crystal structure of an antigen-antibody complex to identify points of contact between an antibody and an antigen. Such contact residues and adjacent residues may be targeted or excluded as candidates for substitution. Variants may be screened to determine whether they have desired properties.
[0238] Amino acid sequence insertions include amino-terminal and / or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing 100 or more residues, as well as intrasequences of one or more amino acid residues. Contains inserts. Examples of terminal insertions include antibodies with an N-terminal methionyl residue. Other insertional variants of antibody molecules include fusions of the N-terminus or C-terminus of the antibody to enzymes (eg, for ADEPT) or polypeptides that increase the serum half-life of the antibody.
[0239] b. Glycosylation variant In certain instances, anti-CD20 / anti-CD3 bispecific antibodies of the invention can be modified to increase or decrease the extent to which the antibody is glycosylated. Addition or deletion of glycosylation sites to the anti-CD20 / anti-CD3 bispecific antibodies of the invention can be conveniently performed by changing the amino acid sequence to create or remove one or more glycosylation sites. can be achieved.
[0240] If the antibody includes an Fc region, the carbohydrates attached to it may be modified. Natural antibodies produced by mammalian cells typically contain branched biantennary oligosaccharides commonly attached to Asn297 of the CH2 domain of the Fc region by an N-linkage. See, eg, Wright et al., TIBTECH 15:26-32 (1997). Oligosaccharides can include a variety of carbohydrates, such as mannose, N-acetylglucosamine (GlcNAc), galactose, and sialic acid, as well as fucose attached to GlcNAc in the "stem" of the biantennary oligosaccharide structure. In some instances, modifications of oligosaccharides in antibodies of the invention are made to create antibody variants with improved particular properties.
[0241] In one example, an anti-CD20 / anti-CD3 bispecific antibody variant is provided that has a carbohydrate structure lacking fucose attached (directly or indirectly) to the Fc region. For example, the amount of fucose within such an antibody can be 1% to 80%, 1% to 65%, 5% to 65% or 20% to 40%. The amount of fucose is measured for example by MALDI-TOF mass spectrometry as described in WO 2008 / 077546 for all sugar structures (e.g. complexes, hybrids, and high mannose structures) bound to Asn297. It is determined by calculating the average amount of fucose in the sugar chain at Asn297 relative to the sum of . Asn297 refers to the asparagine residue located at approximately position 297 (EU numbering of Fc region residues) within the Fc region; however, due to slight sequence variations in antibodies, Asn297 may be It may also be located downstream by ±3 amino acids, ie between positions 294 and 300. Such fucosylation variants may have improved ADCC function. See, for example, US Patent Application Publication No. 2003 / 0157108 (Presta, L.); US Patent Application Publication No. 2004 / 0093621 (Kyowa Hakko Kogyo Co., Ltd.). Examples of publications regarding "defucosylated" or "fucose-deficient" antibody variants include: US Patent Application Publication No. 2003 / 0157108; WO 2000 / 61739; International Publication No. 2001 / 29246; 2003 / 0115614; 2002 / 0164328; 2004 / 0093621; 2004 / 0132140; 2004 / 0110704; 2004 / 0110282; 2004 / 0109865; International Publication No. 2003 / 085119; 2003 / 084570; 2005 / 035586; 2005 / 035778; 2005 / 053742; 2002 / 031140; Okazaki et al.J.Mol.Biol. 336:1239-1249(2004); Yamane-Ohnuki et al.Biotech.Bioeng.87:614(2004). Examples of cell lines capable of producing defcosylated antibodies include Lec13 CHO cells, which are deficient in protein fucosylation (Ripka et al., Arch.Biochem.Biophys.249:533-545 (1986); U.S. Patent Application Publication No. No. 2003 / 0157108 A1, Presta, L; and WO 2004 / 056312 A1, Adams et al., especially Example 11), and knockout cell lines such as α-1,6-fucosyltransferase gene, FUT8, Knockout CHO cells (e.g., Yamane-Ohnuki et al.,Biotech.Bioeng.87:614(2004);Kanda,Y.et al.,Biotechnol.Bioeng.,94(4):680-688(2006); and (see International Publication No. 2003 / 085107).
[0242] In view of the above, in some examples, the methods of the invention include administering to a subject a variant of an anti-CD20 / anti-CD3 bispecific antibody having a mutation in an aglycosylation site in a fractionated dose escalation dosing regimen. be prepared to do something. In some instances, aglycosylation site mutations reduce the effector function of the antibody. In some instances, the aglycosylation site mutation is a substitution mutation. In some instances, the antibody contains a substitution mutation in the Fc region that reduces effector function. In some examples, the substitution mutations are at amino acid residues N297, L234, L235, and / or D265 (EU numbering). In some examples, the substitution mutation is selected from the group consisting of N297G, N297A, L234A, L235A, D265A, and P329G. In some examples, the substitution mutation is at amino acid residue N297. In a preferred example, the substitution mutation is N297A.
[0243] In some embodiments, the anti-CD20 arm of the anti-CD20 / anti-CD3 bispecific antibody further comprises the T366W and N297G substitution mutations (EU numbering). In some embodiments, the anti-CD3 arm of the anti-CD20 / anti-CD3 bispecific antibody further comprises the following substitution mutations (EU numbering): T366S, L368A, Y407V, and N297G. In some embodiments, (a) the anti-CD20 arm further comprises the T366W and N297G substitution mutations, and (b) the anti-CD3 arm further comprises the T366S, L368A, Y407V and N297G substitution mutations (EU numbering). .
[0244] Further provided are anti-CD20 / anti-CD3 bispecific antibody variants having a bisected oligosaccharide, eg, a biantennary oligosaccharide attached to the Fc region of the antibody is bisected by GlcNAc. Such antibody variants may have reduced fucosylation and / or improved ADCC function. Examples of such antibody variants are, for example, WO 2003 / 011878 (Jean-Mairet et al.); US Patent No. 6,602,684 (Umana et al.); and US Patent Application No. 2005 / 0123546 (Umana et al). Antibody variants having at least one galactose residue in the oligosaccharide attached to the Fc region are also provided. Such antibody variants may have improved CDC function. Such antibody variants are described, for example, in WO 1997 / 30087 (Patel et al.); WO 1998 / 58964 (Raju, S.); and WO 1999 / 22764 (Raju, S.). )It is described in.
[0245] c.Fc region variant In certain instances, one or more amino acid modifications are introduced into the Fc region of the anti-CD20 / anti-CD3 bispecific antibodies of the invention, thereby creating Fc region variants (e.g., U.S. Pat. (see issue No. 2012 / 0251531). Fc region variants can include human Fc region sequences (eg, human IgG1, IgG2, IgG3, or IgG4 Fc regions) that include amino acid modifications (eg, substitutions) at one or more amino acid positions.
[0246] In certain instances, the invention contemplates anti-CD20 / anti-CD3 bispecific antibody variants that have some, but not all, effector functions, such that the half-life of the antibody in vivo is important. make it a desirable candidate for applications where certain effector functions (such as complement and ADCC) are unnecessary or deleterious. In vitro and / or in vivo cytotoxicity assays can be performed to confirm reduction / deficiency of CDC and / or ADCC activity. For example, Fc receptor (FcR) binding assays can be performed to ensure that antibodies lack FcγR binding (and therefore may lack ADCC activity) but retain FcRn binding ability. . NK cells, the main cells mediating ADCC, express only FcγRIII, whereas monocytes express FcγRI, FcγRII, and FcγRIII. FcR expression in hematopoietic cells is summarized in Table 3 on page 464 of Ravetch and Kinet, Annu. Rev. Immunol. 9:457-492 (1991). A non-limiting example of an in vitro assay for assessing ADCC activity of a molecule of interest is described in U.S. Pat. 7063 (1986)) and Hellstrom, I et al., Proc. Natl Acad. Sci. USA 82:1499-1502 (1985); 5,821,337 (Bruggemann, M. et al., J. Exp. Med. 166: 1351-1361 (1987)). Alternatively, non-radioactive assay methods may be used (e.g., ACTI® Non-Radioactive Cytotoxicity Assay (CellTechnology, Inc. Mountain View, CA; and CYTOTOX 96® Non-Radioactive Assay for Flow Cytometry). (See Radiocytotoxicity Assay (Promega, Madison, WI)). Effector cells useful in such assays include peripheral blood mononuclear cells (PBMCs) and natural killer (NK) cells. Alternatively, the ADCC activity of the molecule of interest can be determined in vivo using animal models such as those disclosed in Clynes et al., Proc. Natl Acad. Sci. USA 95:652-656 (1998), etc. A C1q binding assay may also be performed to confirm that the antibody is unable to bind C1q and lacks CDC activity. For example, WO 2006 / See C1q and C3c binding ELISA in WO 029879 and WO 2005 / 100402. To assess complement activation, CDC assays may be performed (eg, Gazzano-Santoro et al., J. Immunol.Methods 202:163(1996); Cragg, M.S. et al., Blood.101:1045-1052(2003); and Cragg, M.S. and M.J.Glennie Blood.103:2738-2743(2004)).FcRn Determination of binding and in vivo clearance / half-life can also be performed using methods known in the art (e.g., Petkova, S.B. et al., Int'l. Immunol. 18(12): 1759-1769 (2006)).
[0247] Antibodies with reduced effector function include those in which one or more of Fc region residues 238, 265, 269, 270, 297, 327, and 329 are substituted (U.S. Pat. Nos. 6,737,056 and 8,219,149). . Such Fc mutants include Fc mutants having substitutions at two or more of amino acid positions 265, 269, 270, 297 and 327, where residues 265 and 297 are replaced with alanine; including so-called "DANA" Fc mutants (US Pat. Nos. 7,332,581 and 8,219,149).
[0248] In a particular example, the proline at position 329 of the wild-type human Fc region in the antibody is similar to proline 329 of the Fc and tryptophan residues Trp87 and Trp110 of FcgRIII (Sondermann et al.: Nature 406, 267-273 (20 Jul. 2000)). an amino acid residue of sufficient size to disrupt the proline sandwich within the Fc / Fc gamma receptor interface formed between the Fc / Fc gamma receptor interface, or a glycine or arginine. In certain examples, the antibody further comprises at least one amino acid substitution. In one example, the additional amino acid substitution is S228P, E233P, L234A, L235A, L235E, N297A, N297D, or P331S, and in yet another example, the at least one additional amino acid substitution is L234A and L235A, or S228P and L235E of the human IgG4 Fc region (see, e.g., U.S. Patent Application Publication No. 2012 / 0251531), and in yet another example, the at least one additional amino acid substitution is of the human IgG1 Fc region. They are L234A, L235A and P329G. Certain antibody variants with improved or decreased binding to FcR are described. (See, e.g., U.S. Patent No. 6,737,056; WO 2004 / 056312, and Shields et al., J. Biol. Chem. 9(2):6591-6604 (2001).)
[0249] In certain examples, the antibody variant comprises an Fc region that has one or more amino acid substitutions that improve ADCC, e.g., substitutions at positions 298, 333, and / or 334 (EU numbering of residues) of the Fc region. .
[0250] In some examples, C1q binding and / or Alternatively, changes are made within the Fc region that result in altered (ie, either enhanced or decreased) complement dependent cytotoxicity (CDC).
[0251] Antibodies with increased half-life and improved binding to neonatal Fc receptors (FcRn) responsible for transfer of maternal IgG to the fetus (Guyer et al., J. Immunol. 117:587 (1976) and Kim et al., J. Immunol. 24:249 (1994)) are described in US Patent Application Publication No. 2005 / 0014934 A1 (Hinton et al.). These antibodies contain an Fc region that has one or more substitutions therein that improve binding of the Fc region to FcRn. Such Fc variants include Fc region residues: 238, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382 , 413, 424, or 434, such as a substitution of Fc region residue 434 (US Pat. No. 7,371,826).
[0252] For other examples of Fc region variants, see also Duncan & Winter, Nature 322:738-40 (1988); US Pat. No. 5,648,260; US Pat. No. 5,624,821; and WO 94 / 29351.
[0253] In some embodiments, the anti-CD20 / anti-CD3 bispecific antibody comprises an Fc region that includes the N297G mutation (EU numbering).
[0254] In some examples, the anti-CD20 / anti-CD3 bispecific antibody comprises one or more heavy chain constant domains, and the one or more heavy chain constant domains are isolated from the first CH1 (CH1 1 ) domain, the first CH2 (CH2 1 ) domain, the first CH3 (CH3 1 ) domain, second CH1 (CH1 2 ) domain, second CH2 (CH2 2 ) domain, and a second CH3 (CH3 2 ) domain. In some examples, at least one of the one or more heavy chain constant domains is paired with another heavy chain constant domain. In some cases CH3 1 domain and CH3 2 Each domain contains protrusions or voids, CH3 1 The protrusions or voids within the domain are CH3 2 It can be placed in a void or protrusion within the domain. In some cases CH3 1 domain and CH3 2 The domains meet at the interface between the protrusion and the void. In some cases CH2 1 domain and CH2 2 Each domain constitutes a protrusion or a void, and CH2 1 The protrusions or voids in the domain are CH2 2 Each can be positioned in a void or a protrusion in the domain. In other examples, CH2 1 domain and CH2 2 The domains contact at the interface between the protrusion and the void. In some examples, the anti-CD20 / anti-CD3 bispecific antibody is an IgG1 antibody.
[0255] d. Cysteine-engineered antibody variants In certain instances, it is desirable to generate cysteine-engineered anti-CD20 / anti-CD3 bispecific antibodies, eg, "thioMAbs," in which one or more residues of the antibody are replaced with a cysteine residue. In certain instances, substituted residues occur at accessible sites on the antibody. By replacing these residues with cysteine, a reactive thiol group is thereby placed in an accessible site of the antibody, converting the antibody into a drug site or a linker drug site, etc., as further described herein. It may also be used to create immunoconjugates by conjugation to other sites such as. In certain examples, any one or more of the following residues are replaced with cysteine: V205 of the light chain (Kabat numbering), A118 of the heavy chain (EU numbering), and S400 of the heavy chain Fc region. (EU numbering). Cysteine artificial antibodies can be produced, for example, as described in US Pat. No. 7,521,541.
[0256] e. Antibody derivative In certain examples, the anti-CD20 / anti-CD3 bispecific antibodies provided herein are further modified to contain additional non-proteinaceous moieties that are known and readily available in the art. be done. Suitable sites for derivatization of antibodies include, but are not limited to, water-soluble polymers. Non-limiting examples of water-soluble polymers include polyethylene glycol (PEG), ethylene glycol / propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinylpyrrolidone, poly-1,3-dioxolane, poly- 1,3,6-trioxane, ethylene / maleic anhydride copolymers, polyamino acids (either homopolymers or random copolymers), and dextran or poly(n-vinylpyrrolidone) polyethylene glycol, propylene glycol homopolymers, Examples include, but are not limited to, polypropylene oxide / ethylene oxide copolymers, polyoxyethylated polyols (eg, glycerol), polyvinyl alcohol, and mixtures thereof. Polyethylene glycol propionaldehyde may be advantageous during manufacturing due to its stability in water. The polymer may be of any molecular weight and may be branched or unbranched. The number of polymers attached to the antibody can vary, and if multiple polymers are attached, they can be the same molecule or different molecules. In general, the number and / or type of polymers used for derivatization depends on, but is not limited to, the particular property or function of the antibody to be improved, the antibody derivative to be used therapeutically under the defined conditions. The determination can be made based on considerations including whether the
[0257] In another example, a conjugate of an antibody and a non-proteinaceous moiety is provided that can be selectively heated by exposure to radiation. In one example, the non-proteinaceous moiety is a carbon nanotube (Kam et al., Proc. Natl. Acad. Sci. USA 102:11600-11605 (2005)). The radiation can be of any wavelength, including wavelengths that do not harm normal cells but heat the non-protective sites to a temperature that kills cells proximal to the antibody-unprotected sites. but not limited to.
[0258] 7.Recombinant production method The anti-CD20 / anti-CD3 bispecific antibodies of the invention are produced using recombinant methods and compositions, e.g., as described in U.S. Pat. No. 4,816,567, which is incorporated herein by reference in its entirety. can be done.
[0259] For recombinant production of anti-CD20 / anti-CD3 bispecific antibodies, the nucleic acid encoding the anti-antibody is isolated and used in one or more vectors for further cloning and / or expression in host cells. inserted within. Such nucleic acids are easily isolated using conventional procedures (e.g., by using oligonucleotide probes that can specifically bind to genes encoding the heavy and light chains of antibodies). , can be sequenced.
[0260] Suitable host cells for cloning or expression of antibody-encoding vectors include prokaryotic or eukaryotic cells as described herein. For example, antibodies may be produced in bacteria, especially if glycosylation and Fc effector function are not required. For expression of antibody fragments and polypeptides in bacteria, see, eg, US Patent Nos. 5,648,237, 5,789,199, and 5,840,523. (See also Charlton, Methods in Molecular Biology, Vol. 248 (B.K.C. Lo, ed., Humana Press, Totowa, NJ, 2003), pp. 245-254, which describes the expression of antibody fragments in E. coli) After expression, Antibodies of the invention may be isolated in the soluble fraction from bacterial cell pastes and may be further purified.
[0261] In addition to prokaryotes, eukaryotes such as filamentous fungi and yeast are suitable cloning or expression hosts for antibody-encoding vectors, including strains with "humanized" glycosylation pathways and yeast. strains that result in the production of antibodies with partially or fully human glycosylation patterns. See Gerngross, Nat. Biotech. 22:1409-1414 (2004) and Li et al., Nat. Biotech. 24:210-215 (2006).
[0262] Suitable host cells for expressing glycosylated antibodies are also derived from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plant cells and insect cells. A number of baculovirus strains have been identified that can be used in combination with insect cells, particularly for the transfection of Spodoptera frugiperda cells.
[0263] Plant cell cultures can also be utilized as hosts. See, eg, US Pat.
[0264] Vertebrate cells are also used as hosts. For example, mammalian cell lines that are adapted to grow in suspension may be useful. Other examples of useful mammalian host cell lines include the monkey kidney CV1 strain transformed with SV40 (COS-7), the human embryonic kidney strain (e.g., Graham et al., J. Gen Virol. 36:59 ( 1977), baby hamster kidney cells (BHK), mouse Sertoli cells (e.g. TM4 as described in Mather, Biol. Reprod. 23:243-251 (1980)). cells), monkey kidney cells (CV1), African green monkey kidney cells (VERO-76), human neck carcinoma cells (HELA), dog kidney cells (MDCK), buffalo rat liver cells (BRL 3A), human lung cells ( W138), human liver cells (Hep G2), mouse mammary tumor cells (MMT 060562), TRI cells (e.g. cells described in Mather et al., Annals N.Y.Acad.Sci.383:44-68 (1982); MRC5 cells; and FS4 cells. Other useful mammalian host cell lines include DHFR - Chinese hamster ovary (CHO) cells, including CHO cells (Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216 (1980)), and myeloma cell lines such as Y0, NS0, and Sp2 / 0, Can be mentioned. For a review of specific mammalian host cell lines suitable for antibody production, see, e.g., Yazaki and Wu, Methods in Molecular Biology, Vol. 248 (B.K.C. Lo, ed., Humana Press, Totowa, NJ), pp. 255- 268(2003),
[0265] 8.Immune conjugates The present invention also includes one or more cytotoxic agents, such as chemotherapeutic agents or drugs, growth inhibitors, toxins (e.g., protein toxins, enzymatically active toxins of bacterial, fungal, plant or animal origin, or immunoconjugates comprising an anti-CD20 / anti-CD3 bispecific antibody of the invention conjugated to a radioisotope) or a radioactive isotope.
[0266] In some examples, the immunoconjugate is an antibody-drug conjugate (ADC), in which the antibody is a maytansinoid (U.S. Pat. No. 5,208,020, US Pat. No. 5,416,064, and Auristatin, such as monomethyl auristatin drug moieties DE and DF (MMAE and MMAF) (see U.S. Pat. No. 5,635,483, U.S. Pat. No. 5,780,588, and U.S. Pat. No. 7,498,298); Dolastatin; Calicaa Mycin or its derivatives (U.S. Patent Nos. 5,712,374, 5,714,586, 5,739,116, 5,767,285, 5,770,701, 5,770,710, 5,773,001, and 5,877,296; Hinman et al. ., Cancer Res. 53:3336-3342 (1993); and Lode et al., Cancer Res. 58:2925-2928 (1998)); anthracyclines such as daunomycin and doxorubicin (e.g. Kratz et al., Current Med.Chem.13:477-523(2006);Jeffrey et al.,Bioorganic&Med.Chem.Letters 16:358-362(2006);Torgov et al.,Bioconj.Chem.16:717-721(2005); Nagy et al.,Proc.Natl.Acad.Sci.USA 97:829-834(2000);Dubowchik et al.,Bioorg.&Med.Chem.Letters 12:1529-1532(2002);King et al.,J .Med.Chem.45:4336-4343 (2002); and US Pat. No. 6,630,579); methotrexate; vindesine; taxanes such as docetaxel, paclitaxel, larotaxel, tesetaxel, and ortataxel; trichothecenes; It binds to the above drugs.
[0267] In another example, the immunoconjugate includes diphtheria A chain, non-binding active fragment of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modecin A chain, alpha-sarcin, cina Aburagiri protein, diansin protein, pokeweed protein (PAPI, PAPII, and PAP-S), turmeric inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitgelin, restrictocin, phenomycin, enomycin , and anti-CD20 / anti-CD3 bispecific antibodies conjugated to enzymatically active toxins or fragments thereof, including, but not limited to, trichothecenes.
[0268] In another example, the immunoconjugate comprises an anti-CD20 / anti-CD3 bispecific antibody that is conjugated to a radioactive atom to form a radioactive conjugate. A variety of radioisotopes are available for the production of radioactive conjugates. For example, 211 At, 131 I, 125 I, 90 Y, 186 Re, 188 Re, 153 Sm, 212 Bi, 32 P, 212 Mention may be made of radioactive isotopes of Pb and Lu. When a radioactive substance is used for detection, it is a radioactive atom for scintigraphic studies, e.g. 99m Tc or 123 I, or spin labels for nuclear magnetic resonance (NMR) imaging (also known as magnetic resonance imaging, MRI), such as again iodine-123, iodine-131, indium-111, fluorine-19, carbon-13, nitrogen-15, oxygen 17, may contain gadolinium, manganese or iron.
[0269] Conjugates of antibodies and cytotoxic agents can be made using, for example, various bifunctional protein coupling agents, N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP), succinimidyl-4-(N-maleimidomethyl) Cyclohexane-1-carboxylate (SMCC), iminothiolane (IT), bifunctional derivatives of imidoesters (dimethyladipimidate HCl, etc.), active esters (disuccinimidyl suberate, etc.), aldehydes (glutaraldehyde, etc.) , bisazide compounds (bis(p-azidobenzoyl)hexanediamine, etc.), bis-diazonium derivatives (bis-(p-diazoniumbenzoyl)-ethylenediamine, etc.), diisocyanates (toluene 2,6-diisocyanate, etc.), and diactive fluorine compounds. (1,5-difluoro-2,4-dinitrobenzene, etc.). For example, ricin immunotoxins can be prepared as described in Vitetta et al., Science 238:1098 (1987). Carbon-14 labeled 1-isothiocyanatobenzyl-3-methyldiethylenetriaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugating radionucleotides to antibodies. See WO 94 / 11026. The linker may be a "cleavable linker" that facilitates release of the cytotoxic drug within the cell. For example, using acid-labile linkers, peptidase-sensitive linkers, photolabile linkers, dimethyl linkers or disulfide-containing linkers (Chari et al., Cancer Res. 52:127-131 (1992); U.S. Pat. No. 5,208,020). be able to.
[0270] Immunoconjugates or ADCs herein include, but are not limited to, BMPS, EMCS, GMBS, HBVS, LC-SMCC, MBS, MPBH, which are commercially available (e.g., from Pierce Biotechnology Inc., Rockford, IL, USA). , SBAP, SIA, SIAB, SMCC, SMPB, SMPH, sulfo-EMCS, sulfo-GMBS, sulfo-KMUS, sulfo-MBS, sulfo-SIAB, sulfo-SMCC and sulfo-SMPB, and SVSB (succinimidyl-(4-vinyl Conjugates prepared using crosslinking reagents including, but not limited to, sulfone)benzoate) are specifically contemplated.
[0271] D. Additional therapeutic agents In some examples, the methods described herein combine bispecific anti-CD20 / anti-CD3 antibodies with additional therapeutic agents (e.g., antibody-drug conjugates (ADCs) and / or additional chemotherapeutic agents). and / or). In some examples, the bispecific anti-CD20 / anti-CD3 antibody is co-administered with one or more additional chemotherapeutic agents selected from cyclophosphamide, doxorubicin, rituximab and prednisolone. In some instances, a bispecific anti-CD20 / anti-CD3 antibody is co-administered with CHOP, in which case vincristine is replaced with the ADC. In some instances, the bispecific anti-CD20 / anti-CD3 antibody is co-administered with an anti-CD19 antibody drug conjugate, an anti-CD22 antibody drug conjugate, an anti-CD45 antibody drug conjugate or an anti-CD32 antibody drug conjugate. .
[0272] In some examples, the additional therapeutic agent is an anti-CD79b ADC, such as any of the anti-CD79b antibody drug conjugates described in U.S. Patent No. 8,088,378, which is incorporated herein by reference in its entirety. . In some examples, the anti-CD79b antibody drug conjugate comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 33; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 34; (c) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 35. HVR-H3 containing the amino acid sequence of SEQ ID NO: 36; (d) HVR-L1 containing the amino acid sequence of SEQ ID NO: 36; (e) HVR-L2 containing the amino acid sequence of SEQ ID NO: 37; (f) containing the amino acid sequence of SEQ ID NO: 38. The anti-CD79b binding domain comprises at least one, two, three, four, five or six hypervariable regions (HVR) selected from HVR-L3. In some examples, the anti-CD79b antibody drug conjugate comprises an anti-79b binding domain comprising all six of the following HVRs: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 33; (b) SEQ ID NO: HVR-H2 containing the amino acid sequence of SEQ ID NO: 34, (c) HVR-H3 containing the amino acid sequence of SEQ ID NO: 35, (d) HVR-L1 containing the amino acid sequence of SEQ ID NO: 36, (e) the amino acid sequence of SEQ ID NO: 37. (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 38. In some examples, the anti-CD79b antibody drug conjugate comprises at least one of the heavy chain framework regions FR-H1, FR-H2, FR-H3, and FR-H4, each comprising a sequence of SEQ ID NOs: 39-42. (e.g., one, two, three, or four) and / or light chain framework regions FR-L1, FR-L2, FR-L3, and FR, each comprising a sequence of SEQ ID NOs: 43 to 46. - at least one (eg, one, two, three, or four) of L4. In some examples, the anti-CD79b antibody drug conjugate has (a) at least 90% sequence identity to SEQ ID NO: 47 (e.g., at least 91%, 92%, 93%, 94%, 95%, 96 (b) a sequence of at least 90% to SEQ ID NO: 48; an amino acid sequence with identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) or the sequence of SEQ ID NO: 48. or (c) a VH domain as in (a) and a VL domain as in (b). Thus, in some examples, the first binding domain comprises a VH domain comprising the amino acid sequence of SEQ ID NO: 47 and a VL domain comprising the amino acid sequence of SEQ ID NO: 48.
[0273] In some examples, the anti-CD79b antibody is linked to a toxin, such as monomethyl auristatin E (MMAE, ie, vedotin). In some instances, the anti-CD79b antibody drug conjugate is defined by the International Nonproprietary Names (INN) List 110 (WHO Drug Information, Vol. 27, No. 4, 2016, p. 443). Polatuzumab vedotin (immunoglobulin G1-kappa auristatin E conjugate, anti-[Homo sapiens CD79B (immunoglobulin-related CD79 beta)], a humanized monoclonal antibody conjugated to auristatin E; gamma Single heavy chain (1-447) [Humanized VH (Homo sapiens) IGHV3-23*04(76.50%)-(IGHD)-IGHJ4*01)[8.8.10](1-117)-Homo ·Sapiens (Homo sapiens) IGHG1*03 (CH1 R120>K(214)(118-215), Hinge (216-230), CH2(231-340), CH3(341-445), CHS(446-447) )(118-447)], (220-218')-disulfide with kappa light chain (1'-218') [humanized V-KAPPA (Homo sapiens) IGKV1-39*01 (85.90% )-IGKJ1*01)[10.3.9](1'-111')-Homo sapiensIGKC*01(112'-218')];Dimer(226-226'':229-229' ')--bisdisulfide; an average of 3 to 4 cysteinyls to monomethyl auristatin via a cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. RG-7596, also known as RO5541077-000)). Polatuzumab vedotin is also referred to as IUPHAR / BPS number 8404, KEGG number D10761, or CAS registration number 1313206-42-6. Polatuzumab vedotin is also interchangeably referred to as "polatuzumab vedotin-piiq", "huMA79bv28-MC-vc-PAB-MMAE", or "DCDS4501A". In some examples, the anti-CD79b antibody or anti-CD79b ADC comprises the heavy chain sequence of SEQ ID NO: 49 and the light chain sequence of SEQ ID NO: 50.
[0274] In some instances, the additional therapeutic agent is a biological modifier. In one example, bispecific anti-CD20 / anti-CD3 antibodies include BCL-2 inhibitors (e.g., GDC-0199 / ABT-199), lenalidomide (REVLIMID()), PI3K delta inhibitors (e.g., idelalisib (ZYDELIG()), )), PI3K inhibitors (e.g. alpelisib, copanlisib or duvelisib), PD-1 axis binding antagonists, tremelimumab (also known as ticilimumab or CP-675,206), urelumumab (also known as BMS-663513), MGA271, an antagonist to TGF beta, such as metelimumab (also known as CAT-192), fresolimumab (also known as GC1008), LY2157299k, and T cells expressing chimeric antigen receptors (CARs) (e.g., cytotoxic (e.g., adoptive transfer of T cells containing a dominant negative TGF beta receptor, e.g., a dominant negative TGF beta type II receptor). administered.
[0275] In some of the methods described herein, the dosage regimen may include administration of one or more additional therapeutic agents. For example, in certain instances, bispecific anti-CD20 / anti-CD3 antibodies may be administered concurrently with obinutuzumab (GAZYVA®) or tocilizumab (ACTEMRA® / RoACTEMRA®). Yes, subjects receive bispecific anti-CD20 / anti-CD3 antibodies separately after first receiving obinutuzumab (GAZYVA®) or tocilizumab (ACTEMRA® / RoACTEMRA®). (eg, the subject has been previously treated with obinutuzumab (GAZYVA®) or tocilizumab (ACTEMRA® / RoACTEMRA®)). In some instances, administration of tocilizumab as an additional therapeutic agent is to reduce the impact of certain adverse effects associated with CRS. In some instances, the subject is pretreated with tocilizumab as a prophylactic approach against CRS. In some examples, prophylactic treatment for CRS includes administration of tocilizumab and / or adalimumab.
[0276] In some examples, the PD-1 binding antagonist is an anti-PD-1 antibody. A variety of anti-PD-1 antibodies can be utilized in the methods and uses disclosed herein. In any of the examples herein, the PD-1 antibody is capable of binding human PD-1 or a variant thereof. In some instances, the anti-PD-1 antibody is a monoclonal antibody. In some examples, the anti-PD-1 antibody is an antibody fragment selected from the group consisting of Fab fragments, Fab' fragments, Fab'-SH fragments, Fv fragments, scFv fragments, and (Fab')2 fragments. . In some instances, the anti-PD-1 antibody is a humanized antibody. In other examples, the anti-PD-1 antibody is a human antibody. Exemplary anti-PD-1 antagonist antibodies include nivolumab, pembrolizumab, MEDI-0680, PDR001 (spartalizumab), REGN2810 (cemiplimab), BGB-108, prolgolimab, canrelizumab, sintilimab, tislelizumab, toripalimab, dostarimab, retifanlimab, sasanlimab, pemplimab, CS1003, HLX10, SCT-I10A, zimbelelimab, balstilimab, genolimuzumab, BI754091, setrelimab, YBL-006, BAT1306, HX008, budicalimab, CX-188, JTX-4014, 609A, Sym021, LZM009, F520, SG 001, AM0001, ENUM 244C8, ENUM 388D4, STI-1110, AK-103 and hAb21. In some examples, the anti-PD-1 antibody is nivolumab (CAS Registration Number: 946414-94-4). Nivolumab (Bristol-Myers Squibb / Ono), also known as MDX-1106-04, MDX-1106, ONO-4538, BMS-936558, and OPDIVO®, is an anti-PD drug described in WO 2006 / 121168. -1 antibody. In some examples, the anti-PD-1 antibody is pembrolizumab (CAS Registration Number: 1374853-91-4). Pembrolizumab (Merck), also known as MK-3475, Merck 3475, lambrolizumab, KEYTRUDA®, and SCH-900475, is an anti-PD-1 antibody described in WO 2009 / 114335. In some examples, the anti-PD-1 antibody is MEDI-0680 (AMP-514; AstraZeneca). MEDI-0680 is a humanized IgG4 anti-PD-1 antibody. In some examples, the anti-PD-1 antibody is PDR 001 (CAS Registration Number 1859072-53-9; Novartis). PDR001 is a humanized IgG4 anti-PD-1 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1. In some examples, the anti-PD-1 antibody is REGN2810 (Regeneron). REGN 2810 is a human anti-PD-1 antibody. In some examples, the anti-PD-1 antibody is BGB-108 (BeiGene). In some examples, the anti-PD-1 antibody is BGB-A317 (BeiGene). In some examples, the anti-PD-1 antibody is JS-001 (Shanghai Junshi). JS-001 is a humanized anti-PD-1 antibody. In some examples, the anti-PD-1 antibody is STI-A1110 (Sorrento). STI-A 1110 is a human anti-PD-1 antibody. In some examples, the anti-PD-1 antibody is INCSHR-1210 (Incyte). INCSHR-1210 is a human IgG4 anti-PD-1 antibody. In some examples, the anti-PD-1 antibody is PF-06801591 (Pfizer). In some instances, the anti-PD-1 antibody is TSR-042 (also known as ANB 011; Tesaro / AnaptysBio) In some instances, the anti-PD-1 antibody is AM 0001 (ARMO Biosciences) . In some examples, the anti-PD-1 antibody is ENUM 244C8 (Enumeral Biomedical Holdings). ENUM 244C8 is an anti-PD-1 antibody that inhibits PD-1 function without blocking PD-L1 binding to PD-1. In some examples, the anti-PD-1 antibody is ENUM 388D4 (Enumeral Biomedical Holdings). ENUM388D4 is an anti-PD-1 antibody that competitively inhibits the binding of PD-L1 to PD-1. In some examples, the anti-PD-1 antibody is WO 2015 / 112800, WO 2015 / 112805, WO 2015 / 112900, US Patent Application Publication No. 20150210769, WO 2016 / 089873, WO 2015 / 035606, WO 2015 / 085847, WO 2014 / 206107, WO 2012 / 145493, US Patent No. 9,205,148, WO 2015 / 119930, International 6 derived from anti-PD-1 antibodies described in Publication No. 2015 / 119923, International Publication No. 2016 / 032927, International Publication No. 2014 / 179664, International Publication No. 2016 / 106160, and International Publication No. 2014 / 194302 HVR sequences (eg, three heavy chain HVRs and three light chain HVRs) and / or a heavy chain variable domain and a light chain variable domain.
[0277] In other examples, the PD-1 binding antagonist is an immunoadhesin, such as an extracellular or PD-1 binding portion of PD-L1 or PD-L2 fused to a constant region (e.g., the Fc region of an immunoglobulin sequence). immunoadhesin). In other examples, the PD-1 binding antagonist is AMP-224. AMP-224, also known as B7-DCIg, is a PD-L2-Fc fusion soluble receptor described in PCT Publication No. WO 2010 / 027827 and WO 2011 / 066342. .
[0278] In some examples, the PD-L1 binding antagonist is an anti-PD-L1 antibody. A variety of anti-PD-L1 antibodies are contemplated and described herein. In any of the examples herein, the isolated anti-PD-L1 antibody is human PD-L1, e.g., human PD-L1 as set forth in UniProtKB / Swiss-Prot accession number Q9NZQ7-1, or its Can be combined into variants. In some examples, anti-PD-L1 antibodies can inhibit binding between PD-L1 and PD-1 and / or between PD-L1 and B7-1. In some examples, the anti-PD-L1 antibody is a monoclonal antibody. In some examples, the anti-PD-L1 antibody is an antibody fragment selected from the group consisting of Fab fragments, Fab'-SH fragments, Fv fragments, scFv fragments, and (Fab')2 fragments. In some instances, the anti-PD-L1 antibody is a humanized antibody. In some examples, the anti-PD-L1 antibody is a human antibody. Exemplary anti-PD-L1 antibodies include atezolizumab, MDX-1105, MEDI4736 (durvalumab), MSB0010718C (avelumab), SHR-1316, CS1001, embafolimab, TQB2450, ZKAB001, LP-002, CX-072, IMC-001 , KL-A167, APL-502, cosibelimab, rhodapolimab, FAZ053, TG-1501, BGB-A333, BCD-135, AK-106, LDP, GR1405, HLX20, MSB2311, RC98, PDL-GEX, KD036, KY1003, YBL -007, HS-636, LY3300054 (Eli Lilly), STI-A1014 (Sorrento), and KN035 (Suzhou Alphamab). In some examples, an anti-PDL1 antibody, upon cleavage (e.g., by a protease in the tumor microenvironment), activates the antibody antigen-binding domain to increase its It consists of a cleavable site or linker that allows antigen to be attached. In some examples, the anti-PDL-1 antibody is CX-072 (CytomX Therapeutics). In some examples, the anti-PD-L1 antibody comprises six HVR sequences (e.g., three heavy chain HVRs and three light chain HVRs), and / or U.S. Patent Application No. 20160108123, WO 2016 / 000619 No., WO 2012 / 145493, US Patent No. Includes heavy chain variable domains and light chain variable domains from anti-PD-L1 antibodies described in WO 9,205,148, WO 2013 / 181634, or WO 2016 / 061142. Examples of anti-PD-L1 antibodies useful in the methods of the invention and methods of making them are described in WO 2010 / 077634 and US Pat. No. 8,217,149, each of which is incorporated by reference. Incorporated herein in its entirety.
[0279] In other examples, the PD-L2 binding antagonist is an anti-PD-L2 antibody (eg, a human, humanized, or chimeric anti-PD-L2 antibody). In some examples, the PD-L2 binding antagonist is an immunoadhesin.
[0280] An effective amount of a PD-1 axis binding antagonist (e.g., an anti-PD-L1 antagonist antibody (e.g., atezolizumab)) is about 80 mg to about 2000 mg (e.g., about 100 mg to about 1600 mg, e.g., about 200mg to about 1600mg, for example, about 300mg to about 1600mg, for example, about 400mg to about 1600mg, for example, about 500mg to about 1600mg, for example, about 600mg to about 1600mg, for example, about 700mg to about 1600mg, for example, about 800mg to About 1600 mg, for example, about 900 mg to about 1500 mg, for example, about 1000 mg to about 1400 mg, for example, about 1050 mg to about 1350 mg, for example, about 1100 mg to about 1300 mg, for example, about 1150 mg to about 1250 mg, for example, about 1175 mg to about 1225 mg. , such as from about 1190 mg to about 1210 mg, such as 1200 mg±5 mg, such as 1200±2.5 mg, such as 1200±1.0 mg, such as 1200±0.5 mg, such as 1200 mg). In some examples, an effective amount of a PD-1 axis binding antagonist (e.g., an anti-PD-L1 antagonist antibody (e.g., atezolizumab)) is about 1200 mg (e.g., 1200 mg ± 10 mg, e.g., 1200 ± 6 mg) every 3 weeks. , eg 1200±5 mg, eg 1200±3 mg, eg 1200±1 mg, eg 1200±0.5 mg, eg 1200 mg every 3 weeks). In some examples, a PD-1 axis binding antagonist (e.g., an anti-PD-L1 antagonist antibody (e.g., atezolizumab)) is administered at a dose of about 200 mg to about 1400 mg every 3 weeks (e.g., about 200 mg every 3 weeks). ~about 1200mg, for example, about 200mg to about 1000mg every three weeks, for example, about 200mg to about 800mg every three weeks, for example, about 200mg to about 600mg every three weeks, for example, about 200mg to about every three weeks 500 mg, eg, about 200 mg to about 450 mg every 3 weeks, eg, about 250 mg to about 450 mg every 3 weeks).
[0281] In some instances, the bispecific anti-CD20 / anti-CD3 antibody is administered simultaneously with rituximab and one or more chemotherapeutic agents. In one example, a bispecific anti-CD20 / anti-CD3 antibody is administered simultaneously with rituximab and CHOP. In one example, a bispecific anti-CD20 / anti-CD3 antibody is administered simultaneously with rituximab and an ADC. In one example, a bispecific anti-CD20 / anti-CD3 antibody is co-administered with rituximab and CHOP, where vincristine is replaced with ADC. In one example, the bispecific anti-CD20 / anti-CD3 antibody is co-administered with an ADC selected from an anti-CD19 antibody drug conjugate, an anti-CD22 antibody drug conjugate, an anti-CD45 antibody drug conjugate, and an anti-CD32 antibody drug conjugate. Ru.
[0282] In some examples, the bispecific anti-CD20 / anti-CD3 antibody is associated with rituximab as well as BCL-2 inhibitors (e.g., GDC-0199 / ABT-199), lenalidomide (REVLIMID()), PI3K delta inhibitors ( For example, idelalisib (ZYDELIG®)), PI3K inhibitors (e.g. alpelisib, copanlisib or duvelisib), PD-1 axis binding antagonists, tremelimumab (also known as ticilimumab or CP-675,206), urelumumab (BMS-663513) ), MGA271, an antagonist to TGF beta, such as metelimumab (also known as CAT-192), fresolimumab (also known as GC1008), LY2157299k, and TGF expressing chimeric antigen receptor (CAR). one or more organisms selected from adoptive transfer of cells (e.g., cytotoxic T cells or CTLs) (e.g., adoptive transfer of T cells containing a dominant negative TGF beta receptor, e.g., a dominant negative TGF beta type II receptor); Co-administered with a chemical modifier.
[0283] In some examples, the bispecific anti-CD20 / anti-CD3 antibody is used to treat rituximab, one or more chemotherapeutic agents, as well as a BCL-2 inhibitor (e.g., GDC-0199 / ABT-199), lenalidomide (REVLIMID) )), PI3K delta inhibitors (e.g. idelalisib (ZYDELIG®)), PD-1 axis binding antagonists, tremelimumab (also known as ticilimumab or CP-675,206), urelumumab (also known as BMS-663513) , MGA271, an antagonist to TGF beta, e.g., metelimumab (also known as CAT-192), fresolimumab (also known as GC1008), LY2157299k, and T cells (e.g., cells) expressing chimeric antigen receptors (CARs). (e.g., adoptive transfer of T cells containing a dominant negative TGF beta receptor, e.g. a dominant negative TGF beta type II receptor); Administered simultaneously.
[0284] In some instances, the bispecific anti-CD20 / anti-CD3 antibody is administered simultaneously with obinutuzumab and one or more chemotherapeutic agents. In one example, a bispecific anti-CD20 / anti-CD3 antibody is administered simultaneously with obinutuzumab and CHOP. In one example, a bispecific anti-CD20 / anti-CD3 antibody is administered simultaneously with obinutuzumab and an ADC. In one example, a bispecific anti-CD20 / anti-CD3 antibody is co-administered with obinutuzumab and CHOP, where vincristine is replaced with ADC. In one example, the bispecific anti-CD20 / anti-CD3 antibody is an anti-CD79b antibody drug conjugate (e.g., anti-CD79b-MC-vc-PAB-MMAE, or U.S. Patent No. 8,088,378 and / or U.S. Patent No. 2014 / 0030280). anti-CD79b antibody-drug conjugates, or polatuzumab vedotin), anti-CD19 antibody-drug conjugates, anti-CD22 antibody-drug conjugates, anti-CD45 antibody-drug conjugates, and anti-CD32 drug conjugates as described in any one of the above issues. Co-administered with an ADC selected from the gate. In one example, the bispecific anti-CD20 / anti-CD3 antibody is directed against obinutuzumab as well as BCL-2 inhibitors (e.g., GDC-0199 / ABT-199), lenalidomide (REVLIMID()), PI3K delta inhibitors (e.g., idelalisib). (ZYDELIG®)), PI3K inhibitors (e.g. alpelisib, copanlisib or duvelisib), PD-1 axis binding antagonists, tremelimumab (also known as ticilimumab or CP-675,206), urelumumab (also known as BMS-663513), ), antagonists to TGF beta, such as MGA271, e.g. metelimumab (also known as CAT-192), fresolimumab (also known as GC1008), LY2157299k, and T cells expressing chimeric antigen receptors (CARs) (e.g. , cytotoxic T cells or CTLs) (e.g., adoptive transfer of T cells containing a dominant negative TGF beta receptor, e.g. a dominant negative TGF beta type II receptor). Co-administered with the substance.
[0285] In some examples, the bispecific anti-CD20 / anti-CD3 antibody is associated with obinutuzumab as well as BCL-2 inhibitors (e.g., GDC-0199 / ABT-199), lenalidomide (REVLIMID()), PI3K delta inhibitors ( For example, idelalisib (ZYDELIG®)), PI3K inhibitors (e.g. alpelisib, copanlisib or duvelisib), PD-1 axis binding antagonists, tremelimumab (also known as ticilimumab or CP-675,206), urelumumab (BMS-663513) ), MGA271, an antagonist to TGF beta, such as metelimumab (also known as CAT-192), fresolimumab (also known as GC1008), LY2157299k, and TGF expressing chimeric antigen receptor (CAR). one or more organisms selected from adoptive transfer of cells (e.g., cytotoxic T cells or CTLs) (e.g., adoptive transfer of T cells containing a dominant negative TGF beta receptor, e.g., a dominant negative TGF beta type II receptor); Co-administered with a chemical modifier.
[0286] In some examples, the additional therapy includes an alkylating agent. In one example, the alkylating agent is 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid and salts thereof. In one example, the alkylating agent is bendamustine.
[0287] In some examples, the additional therapy includes a BCL-2 inhibitor. In one embodiment, the BCL-2 inhibitor is 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl )-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy) Benzamide and its salts. In one example, the BCL-2 inhibitor is venetoclax (CAS number: 1257044-40-8).
[0288] In some examples, the additional therapy includes a phosphoinositide 3-kinase (PI3K) inhibitor. In one example, a PI3K inhibitor inhibits the delta isoform PI3K (ie, P110δ). In some examples, the PI3K inhibitor is 5-fluoro-3-phenyl-2-[(1S)-1-(7H-purin-6-ylamino)propyl]-4(3H)-quinazolinone and its salts. be. In some examples, the PI3K inhibitor is idelalisib (CAS number: 870281-82-6). In one example, a PI3K inhibitor inhibits alpha and delta isoforms of PI3K. In some examples, the PI3K inhibitor is 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[ f] imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide and its salts. In some examples, the PI3K inhibitor is taselisib (CAS number: 1282512-48-4). In some examples, the PI3K inhibitor is 2-amino-N-[2,3-dihydro-7-methoxy-8-[3-(4-morpholinyl)propoxy]imidazo[1,2-c]quinazoline-5 -yl]-5-pyrimidinecarboxamide and its salts. In some examples, the PI3K inhibitor is copanlisib (CAS Number: 1032568-63-0). In some examples, the PI3K inhibitor is 8-chloro-2-phenyl-3-[(1S)-1-(9H-purin-6-ylamino)ethyl]-1(2H)-isoquinolinone and salts thereof . In some examples, the PI3K inhibitor is duvelisib (CAS number: 1201438-56-3). In some examples, the PI3K inhibitor is (2S)-N1-[4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]- 2-thiazolyl]-1,2-pyrrolidinedicarboxamide and its salts. In some examples, the PI3K inhibitor is alpelisib (CAS Number: 1217486-61-7). In some examples, the PI3K inhibitor is 2-[(1S)-1-[4-amino-3-[3-fluoro-4-(1-methylethoxy)phenyl]-1H-pyrazolo[3,4- d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)-4H-1-benzopyran-4-one and its salts. In some examples, the PI3K inhibitor is umblalisib (CAS number: 1532533-67-7).
[0289] In a further aspect of the invention, the additional therapy comprises a Bruton's tyrosine kinase (BTK) inhibitor. In one example, the BTK inhibitor is 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1 -yl]prop-2-en-1-one and its salts. In one example, the BTK inhibitor is ibrutinib (CAS number: 936563-96-1). In some examples, the BTK inhibitor is (7S)-4,5,6,7-tetrahydro-7-[1-(1-oxo-2-propen-1-yl)-4-piperidinyl]-2 -(4-phenoxyphenyl)-pyrazolo[1,5-a]pyrimidine-3-carboxamide and its salts. In some examples, the BTK inhibitor is zanubrutinib (CAS number: 1691249-45-2). In some examples, the BTK inhibitor is 4-[8-amino-3-[(2S)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl]imidazo[1,5 -a]pyrazin-1-yl]-N-2-pyridinyl-benzamide and its salts. In some examples, the BTK inhibitor is acalabrutinib (CAS number: 1420477-60-6).
[0290] In some examples, the additional treatment includes thalidomide or a derivative thereof. In one example, thalidomide or its derivative is (RS)-3-(4-amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione and salts thereof. . In one example, thalidomide or its derivative is lendridomide (CAS number: 191732-72-6).
[0291] When the methods described herein involve combination therapy, such as certain combination therapies described above, the combination therapy includes combination of bispecific anti-CD20 / anti-CD3 antibodies with one or more additional therapeutic agents. Such co-administration can be co-administration (the two or more therapeutic agents are in the same formulation, or in separate formulations), or separate administration; in this example, anti-CD20 / Administration of the anti-CD3 bispecific antibody can occur before, simultaneously with, and / or after the administration of the additional therapeutic agent or therapeutic agents. . In one embodiment, the administration of the anti-CD20 / anti-CD3 bispecific antibody, administration of the additional therapeutic agent, or exposure to radiation therapy is within about 1 month of each other, or about 1 week, 2 weeks, or 3 weeks. or within about 1, 2, 3, 4, 5, or 6 days. In certain instances, the bispecific anti-CD20 / anti-CD3 antibody can be administered concurrently with obinutuzumab (GAZYVA®), and the subject receives obinutuzumab (GAZYVA®) first. The bispecific anti-CD20 / anti-CD3 antibody is then administered separately (eg, the subject has been previously treated with obinutuzumab (GAZYVA®)). In another specific example, a bispecific anti-CD20 / anti-CD3 antibody and an anti-CD79b ADC can be co-administered with tocilizumab (ACTEMRA® / RoACTEMRA®) and the subject initially tocilizumab (ACTEMRA® / RoACTEMRA®) and then separately administer a bispecific anti-CD20 / anti-CD3 antibody (e.g., the subject receives tocilizumab (ACTEMRA® / RoACTEMRA®) (registered trademark))). In some instances, administration of tocilizumab as an additional therapeutic agent is to reduce the impact of certain adverse effects associated with CRS. In some instances, the subject is pretreated with tocilizumab as a prophylactic approach against CRS. In some examples, prophylactic treatment for CRS includes administration of tocilizumab and / or adalimumab.
[0292] The methods described herein can be applied to CD20-positive cell proliferative disorders, e.g. ), e.g. non-Hodgkin's lymphoma (NHL; e.g., diffuse large B-cell lymphoma (DLBCL; e.g., Richter's transformation), follicular lymphoma (FL; e.g., grade 1FL, grade 2FL, grade 3FL (e.g., grade 3aFL) or grade 3bFL) or transformed FL), mantle cell lymphoma (MCL), or marginal zone lymphoma (MZL)), or chronic lymphocytic leukemia (CLL), such as relapsed or refractory NHL (e.g. relapsed or refractory relapsed or refractory DLBCL, relapsed or refractory FL, relapsed or refractory MCL, or relapsed or refractory MZL) or relapsed or refractory CLL. In some instances, treatment using the methods described herein will result in the anti-CD20 / anti-CD3 bispecific antibody being administered in the context of a split-dose titration regimen, using a non-divided dosing regimen. Cytokine-driven toxicity (e.g., cytokine release syndrome (CRS)), infusion-related reactions (IRR), macrophage activation syndrome (MAS), neurotoxicity, severe tumor lysis syndrome (TLS), neutropenia, thrombocytopenia, elevated liver enzymes and / or reduction of undesirable events such as hepatotoxicity (e.g. by 20% or more, 25% or more, 30% or more, 35% or more, 40% or more, 45% or more, 50% or more, 55% or more, 60% or more, 65% or more, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more; For example, 20%~ Between 100%, between 20%~90%, between 20%~80%, between 20%~70%, between 20%~60%, between 20%~50%, 20%~40% Between, Between 20%~30%, Between 40%~100%, Between 60%~100%, Between 80%~100%, Between 30%~70%, Between 40%~60% , between 30% and 50%, between 50% and 80%, or between 90% and 100%; for example, about 20%, about 25%, about 30%, about 35%, about 40%, about 45 %, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 97%, about 99%, or approximately 100%)) or complete inhibition (100% reduction).
[0293] For all of these methods described herein, the anti-CD20 / anti-CD3 bispecific antibodies are formulated, dosed, and administered in a manner consistent with good medical practice. Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical pathology of the individual subject, the cause of the disorder, the site of delivery of the drug, the method of administration, and the scheduling of administration. , and other factors known to health care professionals. The anti-CD20 / anti-CD3 bispecific antibody is optionally, but not necessarily, formulated with one or more drugs currently used to prevent or treat the disease in question. Effective amounts of other agents such as these will depend on the amount of anti-CD20 / anti-CD3 bispecific antibody present in the formulation, the type of disorder or treatment, and other factors discussed above. The anti-CD20 / anti-CD3 bispecific antibody can be suitably administered to a subject over a series of treatments.
[0294] In some examples, additional therapeutic agents useful in the invention include alemtuzumab (CAMPATH®), bevacizumab (AVASTIN®, Genentech), cetuximab (ERBITUX®, Imclone), panitumumab (VECTIBIX®, Amgen), rituximab (RITUXAN®, Genentech / Biogen Idec), pertuzumab (OMNITARG®, 2C4, Genentech), trastuzumab (HERCEPTIN®, Genentech), tositumomab ( Examples include therapeutic antibodies such as BEXXAR (registered trademark), Corixia) and the like. Additional humanized monoclonal antibodies that have therapeutic potential as drugs in combination with compounds of the invention include apolizumab, acerizumab, atolizumab, bapineuzumab, bivatuzumab mertansine, briakinumab, cantuzumab mertansine, cedelizumab, celery Zumab pegol, sidofusituzumab, siduzumab, daclizumab, eculizumab, efalizumab, epratuzumab, erlizumab, felbizumab, fontolizumab, gemtuzumab ozogamicin, inotuzumab ozogamicin, ipilimumab, labetuzumab, lintuzumab, matuzumab, mepolizumab , motavizumab, motovizumab, natalizumab, nimotuzumab, norovizumab, numavizumab, ocrelizumab, omalizumab, palivizumab, pascolizumab, pecfucituzumab, pexelizumab, pexelizumab, laribizumab, ranibizumab, reslibizumab, reslizumab, reslibizumab, lobelizumab, lupizumab, sibrotuzumab, prizumab, sontuzumab, takatuzu These include mabtetraxetane, tadoxizumab, tafasitamab, talizumab, tefibazumab, tocilizumab, tralizumab, tukotzumab selmoleukin, tuxituzumab, umavizumab, ultoxazumab, ustekinumab, and vigilizumab.
[0295] IV. Pharmaceutical compositions and formulations Any of the antibodies described herein (eg, anti-CD20 / anti-CD3 bispecific antibodies) can be used in pharmaceutical compositions and formulations. Pharmaceutical compositions and formulations of antibodies and / or other agents described herein include one, two, or all three agents in one, in the form of a lyophilized formulation or an aqueous solution, with the desired purity. It can be prepared by mixing with any of the above pharmaceutically acceptable carriers (Remington's Pharmaceutical Sciences 16th edition, Osol, A.Ed. (1980)). Pharmaceutically acceptable carriers are generally non-toxic to recipients at the dosages and concentrations employed and include buffers such as phosphoric acid, citric acid, and other organic acids; ascorbic acid and methionine. antioxidants, including; preservatives (e.g., octadecyldimethylbenzylammonium chloride, hexamethonium chloride, benzalkonium chloride, benzethonium chloride; phenol, butyl, or benzyl alcohol; alkylparabens such as methyl or propylparaben; catechol; resorcinol) ;cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins such as serum albumin, gelatin, or immunoglobulin; hydrophilic polymers such as polyvinylpyrrolidone; glycine, glutamine , asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrin; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose, or sorbitol; Examples include, but are not limited to, salt-forming counterions such as sodium; metal complexes (eg, Zn-protein complexes); and / or nonionic surfactants such as polyethylene glycol (PEG).
[0296] Exemplary lyophilized antibody formulations are described in US Pat. No. 6,267,958. Aqueous antibody formulations include those described in US Pat. No. 6,171,586 and WO 2006 / 044908, the latter formulation comprising a histidine acetate buffer.
[0297] The formulations herein may also contain more than one active ingredient as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. . For example, it may be desirable to further provide additional therapeutic agents (e.g., chemotherapeutic agents, cytotoxic agents, growth inhibitory agents, and / or antihormonal agents, e.g., those mentioned herein above). be. Such active ingredients are suitably present in combination in an effective amount for the intended purpose.
[0298] The active ingredient can also be used in colloidal drug delivery systems (e.g. by microcapsules prepared by coacervation techniques or by interfacial polymerization, e.g. hydroxymethyl cellulose or gelatin microcapsules and poly-(methyl methacrylate) microcapsules, respectively). , liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules) or even into macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980).
[0299] Sustained release preparations may also be prepared. Suitable examples of sustained release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, such as films or microcapsules.
[0300] Formulations used for in vivo administration are generally sterile. Sterilization can be easily achieved, for example, by filtration through a sterile filter membrane.
[0301] V. Kits and Manufactured Products In another aspect of the invention, kits or articles of manufacture containing materials useful for the treatment, prevention and / or diagnosis of the disorders described above are provided. The kit or article of manufacture includes a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, intravenous solution bags, and the like. The container may be formed from a variety of materials such as glass or plastic. The container holds the composition alone or in combination with another composition effective to treat, prevent and / or diagnose the condition, and can have a sterile access port (e.g., the container can (can be a vial with a stopper pierceable by a hypodermic needle). At least one active agent in the composition is an anti-CD20 / anti-CD3 bispecific antibody described herein. The label or package insert indicates that the composition may be used to treat the selected condition (e.g., B-cell proliferative disorders, e.g., non-Hodgkin's lymphoma (NHL), e.g., diffuse large B-cell lymphoma (DLBCL), e.g., relapsed treatment for patients with severe or refractory DLBCL) and further includes information regarding at least one of the dosing regimens described herein. Additionally, the kit or article of manufacture comprises: (a) a first container containing therein a composition comprising an anti-CD20 / anti-CD3 bispecific antibody described herein; and (b) an additional cytotoxic agent. It may include a second container having a composition therein containing a sexual drug or other therapeutic agent. Alternatively, or in addition, the kit or article of manufacture contains pharmaceutically acceptable buffers, such as bacteriostatic water for injection (BWFI), phosphate buffered saline, Ringer's solution, and dextrose solution. It may further include a second (or third) container containing. The article of manufacture may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles and syringes.
[0302] VI. Embodiment Some embodiments of the techniques described herein may be defined according to any of the numbered embodiments below.
[0303] 1. A method of treating a subject with a CD20-positive cell proliferative disorder, the method comprising: administering a bispecific antibody that binds to CD20 and CD3 in a dosing regimen comprising at least a first dosing cycle and a second dosing cycle. comprising administering to a subject; (a) said first administration cycle comprises a first dose (C1D1), a second dose (C1D2) and a third dose (C1D3) of said bispecific antibody, wherein said C1D1 is about 0.02 mg; ~ about 2.0 mg, the C1D2 is about 0.05 mg to about 4.0 mg, and the C1D3 is more than about 50 mg, (b) The method, wherein said second administration cycle comprises a single dose (C2D1) of said bispecific antibody.
[0304] 2. A bispecific antibody that binds CD20 and CD3 for use in treating a subject with a CD20-positive cell proliferative disorder, wherein said bispecific antibody formulated for administration to said subject in a dosing regimen comprising two dosing cycles; (a) said first administration cycle comprises a first dose (C1D1), a second dose (C1D2) and a third dose (C1D3) of said bispecific antibody, wherein said C1D1 is about 0.02 mg; ~ about 2.0 mg, the C1D2 is about 0.05 mg to about 4.0 mg, and the C1D3 is more than about 50 mg, (b) A bispecific antibody, wherein said second administration cycle comprises a single dose (C2D1) of said bispecific antibody.
[0305] 3. Use of a bispecific antibody that binds CD20 and CD3 in the treatment of a subject with a CD20-positive cell proliferative disorder, wherein said bispecific antibody formulated for administration to said subject in a dosing regimen comprising dosing cycles; (a) said first administration cycle comprises a first dose (C1D1), a second dose (C1D2) and a third dose (C1D3) of said bispecific antibody, wherein said C1D1 is about 0.02 mg; ~ about 2.0 mg, the C1D2 is about 0.05 mg to about 4.0 mg, and the C1D3 is more than about 50 mg, (b) The use, wherein said second administration cycle comprises a single dose (C2D1) of said bispecific antibody.
[0306] 4. Use of a bispecific antibody that binds CD20 and CD3 in the manufacture of a medicament for treating a subject with a CD20-positive cell proliferative disorder, wherein said bispecific antibody binds to CD20 and CD3 for at least the first administration cycle. and a second administration cycle; (a) said first administration cycle comprises a first dose (C1D1), a second dose (C1D2) and a third dose (C1D3) of said bispecific antibody, wherein said C1D1 is about 0.02 mg; ~ about 2.0 mg, the C1D2 is about 0.05 mg to about 4.0 mg, and the C1D3 is more than about 50 mg, (b) The use, wherein said second administration cycle comprises a single dose (C2D1) of said bispecific antibody.
[0307] 5. The method, bispecific antibody for use, or use according to any one of embodiments 1 to 4, wherein the C1D3 is 50 mg to 200 mg.
[0308] 6. The method, bispecific antibody for use, or use of embodiment 5, wherein said C1D3 is about 60 mg.
[0309] 7. A method, bispecific antibody for use, or use according to any one of embodiments 1 to 6, wherein said C1D1 is about 1 mg.
[0310] 8. The method, bispecific antibody for use, or use according to any one of embodiments 1 to 7, wherein said C1D2 is about 2 mg.
[0311] 9. The method, bispecific antibody for use, or use of any one of embodiments 1 to 8, wherein said C2D1 is in an approximately equivalent amount to said C1D3.
[0312] 10. said C1D1, C1D2 and C1D3 are administered to said subject on days 1, 8 and 15, or about days 1, 8 and 15, respectively, of said first administration cycle; A method, a bispecific antibody for use, or a use according to any one of embodiments 1 to 9, wherein the bispecific antibody is administered or administered.
[0313] 11. The method, use of any one of embodiments 1-10, wherein said C2D1 is or will be administered to said subject on day 1 of said second administration cycle. Bispecific antibodies, or use for.
[0314] 12. The bispecific antibody for use in the method of any one of embodiments 1-11, wherein the first administration cycle and the second administration cycle are 21 day administration cycles, or use.
[0315] 13. The method, use according to any one of embodiments 1-12, wherein said first administration cycle is a 21 day administration cycle and said second administration cycle is a 28 day administration cycle. Bispecific antibodies, or use of.
[0316] 14. The method of any one of embodiments 1-13, bispecific for use, wherein said dosing regimen further comprises one or more additional dosing cycles after said second dosing cycle. Antibodies or use.
[0317] 15. The method, bispecific antibody for use, or use of embodiment 14, wherein said dosing regimen comprises 6 to 15 additional dosing cycles after said second dosing cycle.
[0318] 16. The method, bispecific antibody for use, or use of embodiment 14 or 15, wherein said additional administration cycle is a 21 day administration cycle.
[0319] 17. The method, bispecific antibody for use, or use of embodiment 15 or 16, wherein said additional administration cycle is a 28 day administration cycle.
[0320] 18. A bispecific antibody for use in the method of any one of embodiments 14-17, wherein said one or more additional administration cycles comprises an additional single dose of said bispecific antibody. , or use.
[0321] 19. The method of embodiment 18, wherein said additional single dose of said bispecific antibody is or will be administered to said subject on day 1 of each additional administration cycle. , bispecific antibodies for use, or uses.
[0322] 20. The method of embodiment 18 or 19, bispecific for use, wherein said additional single dose of said bispecific antibody is more than said C1D1 and less than said C1D3 and / or said C2D1. Antibodies or use.
[0323] 21. The method, use according to any one of embodiments 18 to 20, wherein said additional single dose of said bispecific antibody is 20% to 80% of said C1D3 and / or said C2D1. Bispecific antibodies, or use for.
[0324] 22. The method, use or bispecific antibody of embodiment 21, wherein said additional single dose of said bispecific antibody is about 50% of said C1D3 and / or said C2D1, or use.
[0325] 23. The method, bispecific antibody for use, or use of any one of embodiments 18-22, wherein said additional single dose of said bispecific antibody is about 30 mg.
[0326] 24. A method of treating a subject with a CD20-positive cell proliferative disorder, the regimen comprising at least a first administration cycle, a second administration cycle, and a third administration cycle, comprising: administering a heavy specific antibody to said subject; (a) said first administration cycle comprises a first dose (C1D1), a second dose (C1D2) and a third dose (C1D3) of said bispecific antibody, wherein said C1D1 is about 0.02 mg; ~ about 2.0 mg, the C1D2 is about 0.05 mg to about 4.0 mg, and the C1D3 is more than about 20 mg, (b) said second administration cycle comprises a single dose (C2D1) of said bispecific antibody, said C2D1 in an amount approximately equivalent to said C1D3; (c) The method wherein said third administration cycle comprises a single dose (C3D1) of said bispecific antibody, said C3D1 being more than said C1D1 and less than said C2D1.
[0327] 25. A bispecific antibody that binds CD20 and CD3 for use in treating a subject with a CD20-positive cell proliferative disorder, wherein said bispecific antibody 2 administration cycles, and a third administration cycle; (a) said first administration cycle comprises a first dose (C1D1), a second dose (C1D2) and a third dose (C1D3) of said bispecific antibody, wherein said C1D1 is about 0.02 mg; ~ about 2.0 mg, the C1D2 is about 0.05 mg to about 4.0 mg, and the C1D3 is more than about 20 mg, (b) said second administration cycle comprises a single dose (C2D1) of said bispecific antibody, said C2D1 in an amount approximately equivalent to said C1D3; (c) said third administration cycle comprises a single dose (C3D1) of said bispecific antibody, wherein said C3D1 is more than said C1D1 and less than said C2D1.
[0328] 26. Use of a bispecific antibody that binds CD20 and CD3 in the treatment of a subject with a CD20-positive cell proliferative disorder, wherein said bispecific antibody an administration cycle, and a third administration cycle; (a) said first administration cycle comprises a first dose (C1D1), a second dose (C1D2) and a third dose (C1D3) of said bispecific antibody, wherein said C1D1 is about 0.02 mg; ~ about 2.0 mg, the C1D2 is about 0.05 mg to about 4.0 mg, and the C1D3 is more than about 20 mg, (b) said second administration cycle comprises a single dose (C2D1) of said bispecific antibody, said C2D1 in an amount approximately equivalent to said C1D3; (c) Use wherein said third administration cycle comprises a single dose (C3D1) of said bispecific antibody, said C3D1 being more than said C1D1 and less than said C2D1.
[0329] 27. Use of a bispecific antibody that binds CD20 and CD3 in the manufacture of a medicament for treating a subject with a CD20-positive cell proliferative disorder, wherein said bispecific antibody binds to CD20 and CD3 for at least the first cycle of administration. , a second cycle of administration, and a third cycle of administration to the subject; (a) said first administration cycle comprises a first dose (C1D1), a second dose (C1D2) and a third dose (C1D3) of said bispecific antibody, wherein said C1D1 is about 0.02 mg; ~ about 2.0 mg, the C1D2 is about 0.05 mg to about 4.0 mg, and the C1D3 is more than about 20 mg, (b) said second administration cycle comprises a single dose (C2D1) of said bispecific antibody, said C2D1 in an amount approximately equivalent to said C1D3; (c) Use wherein said third administration cycle comprises a single dose (C3D1) of said bispecific antibody, said C3D1 being more than said C1D1 and less than said C2D1.
[0330] 28. The method, bispecific antibody for use, or use of any one of embodiments 24-27, wherein said C1D3 and said C2D1 are each from 20 mg to 200 mg.
[0331] 29. The method, bispecific antibody for use, or use of embodiment 28, wherein said C1D3 and said C2D1 are each about 60 mg.
[0332] 30. The method, bispecific antibody for use, or use of any one of embodiments 24-29, wherein said C3D1 is 20% to 80% of said C2D1.
[0333] 31. The method, bispecific antibody for use, or use of embodiment 30, wherein said C3D1 is about 50% of said C2D1.
[0334] 32. The method, bispecific antibody for use, or use of any one of embodiments 24-31, wherein said C3D1 is about 30 mg.
[0335] 33. The method, bispecific antibody for use, or use of any one of embodiments 24-32, wherein said C1D1 is about 1 mg.
[0336] 34. The method, bispecific antibody for use, or use of any one of embodiments 24-33, wherein said C1D2 is about 2 mg.
[0337] 35. said C1D1, C1D2 and C1D3 are administered to said subject on days 1, 8 and 15, or about days 1, 8 and 15, respectively, of said first administration cycle; 35. A method, bispecific antibody for use, or use according to any one of embodiments 24-34, wherein the bispecific antibody is administered or administered.
[0338] 36. said C2D1 is or will be administered to said subject on day 1 of said second administration cycle, and said C3D1 is administered to said subject on day 1 of said third administration cycle. 36. A method, bispecific antibody for use, or use according to any one of embodiments 24-35, wherein the bispecific antibody is administered or administered.
[0339] 37. The method of any one of embodiments 24-36, for use, wherein the first administration cycle, the second administration cycle, and the third administration cycle are 21-day administration cycles. Bispecific antibodies, or use.
[0340] 38. According to any one of embodiments 24-36, wherein the first administration cycle is a 21 day administration cycle, and the second administration cycle and the third administration cycle are 28 day administration cycles. Bispecific antibodies for, or uses of, the methods described.
[0341] 39. The method of any one of embodiments 24-38, bispecific for use, wherein said dosing regimen further comprises one or more additional dosing cycles after said third dosing cycle. Antibodies or use.
[0342] 40. The method, bispecific antibody for use, or use of embodiment 39, wherein said dosing regimen comprises 5 to 14 additional dosing cycles after said third dosing cycle.
[0343] 41. The method, bispecific antibody for use, or use of embodiment 39 or 40, wherein said additional administration cycle is a 21 day administration cycle.
[0344] 42. The method, bispecific antibody for use, or use of embodiment 39 or 40, wherein said additional administration cycle is a 28 day administration cycle.
[0345] 43. A bispecific antibody for use in the method of any one of embodiments 39-42, wherein said one or more additional administration cycles comprises an additional single dose of said bispecific antibody. , or use.
[0346] 44. The method of embodiment 43, wherein the additional single dose of the bispecific antibody is or will be administered to the subject on day 1 of each additional administration cycle. , bispecific antibodies for use, or uses.
[0347] 45. The method, bispecific antibody for use, or use of embodiment 43 or 44, wherein said additional single dose of said bispecific antibody is in an amount approximately equivalent to C3D1.
[0348] 46. A method of treating a subject with a CD20-positive cell proliferative disorder, the method comprising administering to said subject a bispecific antibody that binds CD20 and CD3 in a regimen comprising eight or more administration cycles. including, (a) said first administration cycle comprises a first dose (C1D1), a second dose (C1D2) and a third dose (C1D3) of said bispecific antibody, wherein said C1D1 is about 0.02 mg; ~ about 2.0 mg, the C1D2 is about 0.05 mg to about 4.0 mg, and the C1D3 is more than about 20 mg, (b) said second administration cycle comprises a single dose (C2D1) of said bispecific antibody, said C2D1 in an amount approximately equivalent to said C1D3; (c) said third administration cycle comprises a single dose (C3D1) of said bispecific antibody, said C3D1 being more than said C1D1 and less than said C2D1; (d) said fourth administration cycle comprises a single dose (C4D1) of said bispecific antibody; (e) said fifth administration cycle comprises a single dose (C5D1) of said bispecific antibody; (f) said sixth administration cycle comprises a single dose (C6D1) of said bispecific antibody; (g) said seventh administration cycle comprises a single dose (C7D1) of said bispecific antibody; (h) said eighth administration cycle comprises a single dose (C8D1) of said bispecific antibody; The method, wherein the amounts of C3D1 to C8D1 are approximately equal.
[0349] 47. A bispecific antibody that binds CD20 and CD3 for use in the treatment of a subject with a CD20-positive cell proliferative disorder, wherein said bispecific antibody comprises eight or more cycles of administration. formulated for administration to said subject in a dosage regimen; (a) said first administration cycle comprises a first dose (C1D1), a second dose (C1D2) and a third dose (C1D3) of said bispecific antibody, wherein said C1D1 is about 0.02 mg; ~ about 2.0 mg, the C1D2 is about 0.05 mg to about 4.0 mg, and the C1D3 is more than about 20 mg, (b) said second administration cycle comprises a single dose (C2D1) of said bispecific antibody, said C2D1 in an amount approximately equivalent to said C1D3; (c) said third administration cycle comprises a single dose (C3D1) of said bispecific antibody, said C3D1 being more than said C1D1 and less than said C2D1; (d) said fourth administration cycle comprises a single dose (C4D1) of said bispecific antibody; (e) said fifth administration cycle comprises a single dose (C5D1) of said bispecific antibody; (f) said sixth administration cycle comprises a single dose (C6D1) of said bispecific antibody; (g) said seventh administration cycle comprises a single dose (C7D1) of said bispecific antibody; (h) said eighth administration cycle comprises a single dose (C8D1) of said bispecific antibody; A bispecific antibody in which the amounts of C3D1 to C8D1 are approximately equal.
[0350] 48. Use of a bispecific antibody that binds CD20 and CD3 in the treatment of a subject with a CD20-positive cell proliferative disorder, wherein the bispecific antibody is administered in a regimen comprising eight or more cycles of administration. is formulated for administration to said subject in (a) said first administration cycle comprises a first dose (C1D1), a second dose (C1D2) and a third dose (C1D3) of said bispecific antibody, wherein said C1D1 is about 0.02 mg; ~ about 2.0 mg, the C1D2 is about 0.05 mg to about 4.0 mg, and the C1D3 is more than about 20 mg, (b) said second administration cycle comprises a single dose (C2D1) of said bispecific antibody, said C2D1 in an amount approximately equivalent to said C1D3; (c) said third administration cycle comprises a single dose (C3D1) of said bispecific antibody, said C3D1 being more than said C1D1 and less than said C2D1; (d) said fourth administration cycle comprises a single dose (C4D1) of said bispecific antibody; (e) said fifth administration cycle comprises a single dose (C5D1) of said bispecific antibody; (f) said sixth administration cycle comprises a single dose (C6D1) of said bispecific antibody; (g) said seventh administration cycle comprises a single dose (C7D1) of said bispecific antibody; (h) said eighth administration cycle comprises a single dose (C8D1) of said bispecific antibody; The C3D1 to C8D1 are used in substantially equal amounts.
[0351] 49. Use of a bispecific antibody that binds CD20 and CD3 in the manufacture of a medicament for treating a subject with a CD20-positive cell proliferative disorder, wherein said bispecific antibody is formulated for administration to said subject in a dosage regimen comprising; (a) said first administration cycle comprises a first dose (C1D1), a second dose (C1D2) and a third dose (C1D3) of said bispecific antibody, wherein said C1D1 is about 0.02 mg; ~ about 2.0 mg, the C1D2 is about 0.05 mg to about 4.0 mg, and the C1D3 is more than about 20 mg, (b) said second administration cycle comprises a single dose (C2D1) of said bispecific antibody, said C2D1 in an amount approximately equivalent to said C1D3; (c) said third administration cycle comprises a single dose (C3D1) of said bispecific antibody, said C3D1 being more than said C1D1 and less than said C2D1; (d) said fourth administration cycle comprises a single dose (C4D1) of said bispecific antibody; (e) said fifth administration cycle comprises a single dose (C5D1) of said bispecific antibody; (f) said sixth administration cycle comprises a single dose (C6D1) of said bispecific antibody; (g) said seventh administration cycle comprises a single dose (C7D1) of said bispecific antibody; (h) said eighth administration cycle comprises a single dose (C8D1) of said bispecific antibody; The C3D1 to C8D1 are used in substantially equal amounts.
[0352] 50. The method, bispecific antibody for use, or use of any one of embodiments 46-49, wherein said C1D3 and said C2D1 are each from 20 mg to 200 mg.
[0353] 51. The method, bispecific antibody for use, or use of embodiment 50, wherein said C1D3 and said C2D1 are each about 60 mg.
[0354] 52. The method, bispecific antibody for use, or use of any one of embodiments 46-51, wherein said C3D1 is 20% to 80% of said C2D1.
[0355] 53. The method, bispecific antibody for use, or use of embodiment 52, wherein said C3D1 is about 50% of said C2D1.
[0356] 54. The method, bispecific antibody for use, or use of any one of embodiments 46-53, wherein said C3D1 is about 30 mg.
[0357] 55. The method, bispecific antibody for use, or use of any one of embodiments 46-54, wherein said C1D1 is about 1 mg.
[0358] 56. The method, bispecific antibody for use, or use of any one of embodiments 46-55, wherein said C1D2 is about 2 mg.
[0359] 57. Said C1D1, C1D2 and C1D3 are administered to said subject on days 1, 8 and 15, or about days 1, 8 and 15, respectively, of said first administration cycle. 57. A method, bispecific antibody for use, or use according to any one of embodiments 46-56, wherein the bispecific antibody is administered or administered.
[0360] 58. The method of any one of embodiments 46 to 57, wherein each of said C2D1 to C8D1 is administered to said subject on day 1 of said second to eighth administration cycles, respectively. Heavy specific antibodies, or use.
[0361] 59. The method, bispecific antibody for use, or use of any one of embodiments 46-58, wherein said administration cycle is a 21 day administration cycle.
[0362] 60. The method of any one of embodiments 46-58, wherein the first administration cycle is a 21-day administration cycle and the second to eighth administration cycles are 28-day administration cycles. Bispecific antibodies for use, or uses.
[0363] 61. The bispecific antibody for use in the method of any one of embodiments 46-60, wherein said dosing regimen comprises one or more additional dosing cycles after said eighth dosing cycle. , or use.
[0364] 62. The method, bispecific antibody for use, or use of embodiment 61, wherein said additional administration cycle is a 21 day administration cycle.
[0365] 63. The method, bispecific antibody for use, or use of embodiment 61, wherein said additional administration cycle is a 28 day administration cycle.
[0366] 64. A bispecific antibody for use in the method of any one of embodiments 61-63, wherein said one or more additional administration cycles comprises an additional single dose of said bispecific antibody. , or use.
[0367] 65. The method of embodiment 64, wherein the additional single dose of the bispecific antibody is or will be administered to the subject on day 1 of each additional administration cycle. , bispecific antibodies for use, or uses.
[0368] 66. A bispecific antibody for use in the method of embodiment 64 or 65, wherein said additional single dose of said bispecific antibody is approximately equivalent in amount to any one of C3D1-C8D1. , or use.
[0369] 67. A method of treating a subject with a CD20-positive cell proliferative disorder, the method comprising administering to said subject a bispecific antibody that binds CD20 and CD3 in a regimen comprising eight or more 21-day dosing cycles. including doing; (a) said first 21 day administration cycle comprises a first dose (C1D1), a second dose (C1D2) and a third dose (C1D3) of said bispecific antibody, wherein said C1D1 is about 1 mg, the C1D2 is about 2 mg, the C1D3 is about 60 mg, (b) said second administration cycle comprises a single dose (C2D1) of said bispecific antibody, said C2D1 being about 60 mg; (c) said third administration cycle comprises a single dose (C3D1) of said bispecific antibody; (d) said fourth administration cycle comprises a single dose (C4D1) of said bispecific antibody; (e) said fifth administration cycle comprises a single dose (C5D1) of said bispecific antibody; (f) said sixth administration cycle comprises a single dose (C6D1) of said bispecific antibody; (g) said seventh administration cycle comprises a single dose (C7D1) of said bispecific antibody; (h) said eighth administration cycle comprises a single dose (C8D1) of said bispecific antibody; The method, wherein each of the C3D1 to C8D1 is about 30 mg.
[0370] 68. A bispecific antibody that binds CD20 and CD3 for use in the treatment of a subject with a CD20-positive cell proliferative disorder, wherein said bispecific antibody is administered for eight or more 21 days. is formulated for administration to said subject in a regimen comprising cycles; (a) said first 21 day administration cycle comprises a first dose (C1D1), a second dose (C1D2) and a third dose (C1D3) of said bispecific antibody, wherein said C1D1 is about 1 mg, the C1D2 is about 2 mg, the C1D3 is about 60 mg, (b) said second administration cycle comprises a single dose (C2D1) of said bispecific antibody, said C2D1 being about 60 mg; (c) said third administration cycle comprises a single dose (C3D1) of said bispecific antibody; (d) said fourth administration cycle comprises a single dose (C4D1) of said bispecific antibody; (e) said fifth administration cycle comprises a single dose (C5D1) of said bispecific antibody; (f) said sixth administration cycle comprises a single dose (C6D1) of said bispecific antibody; (g) said seventh administration cycle comprises a single dose (C7D1) of said bispecific antibody; (h) said eighth administration cycle comprises a single dose (C8D1) of said bispecific antibody; A bispecific antibody in which each of the C3D1 to C8D1 is about 30 mg.
[0371] 69. Use of a bispecific antibody that binds CD20 and CD3 in the treatment of a subject with a CD20-positive cell proliferative disorder, wherein said bispecific antibody is administered for eight or more 21-day administration cycles. is formulated for administration to said subject in a dosage regimen comprising; (a) said first 21 day administration cycle comprises a first dose (C1D1), a second dose (C1D2) and a third dose (C1D3) of said bispecific antibody, wherein said C1D1 is about 1 mg, the C1D2 is about 2 mg, the C1D3 is about 60 mg, (b) said second administration cycle comprises a single dose (C2D1) of said bispecific antibody, said C2D1 being about 60 mg; (c) said third administration cycle comprises a single dose (C3D1) of said bispecific antibody; (d) said fourth administration cycle comprises a single dose (C4D1) of said bispecific antibody; (e) said fifth administration cycle comprises a single dose (C5D1) of said bispecific antibody; (f) said sixth administration cycle comprises a single dose (C6D1) of said bispecific antibody; (g) said seventh administration cycle comprises a single dose (C7D1) of said bispecific antibody; (h) said eighth administration cycle comprises a single dose (C8D1) of said bispecific antibody; A bispecific antibody in which each of the C3D1 to C8D1 is about 30 mg.
[0372] 70. Use of a bispecific antibody that binds to CD20 and CD3 in the manufacture of a medicament for treating a subject with a CD20-positive cell proliferative disorder, wherein said bispecific antibody is formulated for administration to said subject in a dosing regimen comprising cycles of administration of (a) said first 21 day administration cycle comprises a first dose (C1D1), a second dose (C1D2) and a third dose (C1D3) of said bispecific antibody, wherein said C1D1 is about 1 mg, the C1D2 is about 2 mg, the C1D3 is about 60 mg, (b) said second administration cycle comprises a single dose (C2D1) of said bispecific antibody, said C2D1 being about 60 mg; (c) said third administration cycle comprises a single dose (C3D1) of said bispecific antibody; (d) said fourth administration cycle comprises a single dose (C4D1) of said bispecific antibody; (e) said fifth administration cycle comprises a single dose (C5D1) of said bispecific antibody; (f) said sixth administration cycle comprises a single dose (C6D1) of said bispecific antibody; (g) said seventh administration cycle comprises a single dose (C7D1) of said bispecific antibody; (h) said eighth administration cycle comprises a single dose (C8D1) of said bispecific antibody; Use in which each of the C3D1 to C8D1 is about 30 mg.
[0373] 71. A method of treating a subject with a CD20-positive cell proliferative disorder, the dosing regimen comprising a 21-day dosing cycle and seven or more 28-day dosing cycles, comprising a bispecific drug that binds to CD20 and CD3. administering an antibody to the subject; (a) said first 21 day administration cycle comprises a first dose (C1D1), a second dose (C1D2) and a third dose (C1D3) of said bispecific antibody, wherein said C1D1 is about 1 mg, the C1D2 is about 2 mg, the C1D3 is about 60 mg, (b) said second administration cycle comprises a single dose (C2D1) of said bispecific antibody, said C2D1 being about 60 mg; (c) said third administration cycle comprises a single dose (C3D1) of said bispecific antibody; (d) said fourth administration cycle comprises a single dose (C4D1) of said bispecific antibody; (e) said fifth administration cycle comprises a single dose (C5D1) of said bispecific antibody; (f) said sixth administration cycle comprises a single dose (C6D1) of said bispecific antibody; (g) said seventh administration cycle comprises a single dose (C7D1) of said bispecific antibody; (h) said eighth administration cycle comprises a single dose (C8D1) of said bispecific antibody; Use in which each of the C3D1 to C8D1 is about 30 mg.
[0374] 72. A bispecific antibody that binds CD20 and CD3 for use in the treatment of a subject with a CD20-positive cell proliferative disorder, wherein said bispecific antibody comprises a 21-day administration cycle and 7 administration cycles. formulated for administration to said subject on a dosing regimen comprising a 28-day dosing cycle as described above; (a) said first 21 day administration cycle comprises a first dose (C1D1), a second dose (C1D2) and a third dose (C1D3) of said bispecific antibody, wherein said C1D1 is about 1 mg, the C1D2 is about 2 mg, the C1D3 is about 60 mg, (b) said second administration cycle comprises a single dose (C2D1) of said bispecific antibody, said C2D1 being about 60 mg; (c) said third administration cycle comprises a single dose (C3D1) of said bispecific antibody; (d) said fourth administration cycle comprises a single dose (C4D1) of said bispecific antibody; (e) said fifth administration cycle comprises a single dose (C5D1) of said bispecific antibody; (f) said sixth administration cycle comprises a single dose (C6D1) of said bispecific antibody; (g) said seventh administration cycle comprises a single dose (C7D1) of said bispecific antibody; (h) said eighth administration cycle comprises a single dose (C8D1) of said bispecific antibody; Use in which each of the C3D1 to C8D1 is about 30 mg.
[0375] 73. Use of a bispecific antibody that binds CD20 and CD3 in the treatment of a subject with a CD20-positive cell proliferative disorder, the bispecific antibody comprising a 21 day administration cycle and 7 or more 28 is formulated for administration to said subject in a dosing regimen comprising a daily dosing cycle; (a) said first 21 day administration cycle comprises a first dose (C1D1), a second dose (C1D2) and a third dose (C1D3) of said bispecific antibody, wherein said C1D1 is about 1 mg, the C1D2 is about 2 mg, the C1D3 is about 60 mg, (b) said second administration cycle comprises a single dose (C2D1) of said bispecific antibody, said C2D1 being about 60 mg; (c) said third administration cycle comprises a single dose (C3D1) of said bispecific antibody; (d) said fourth administration cycle comprises a single dose (C4D1) of said bispecific antibody; (e) said fifth administration cycle comprises a single dose (C5D1) of said bispecific antibody; (f) said sixth administration cycle comprises a single dose (C6D1) of said bispecific antibody; (g) said seventh administration cycle comprises a single dose (C7D1) of said bispecific antibody; (h) said eighth administration cycle comprises a single dose (C8D1) of said bispecific antibody; Use in which each of the C3D1 to C8D1 is about 30 mg.
[0376] 74. Use of a bispecific antibody that binds CD20 and CD3 in the manufacture of a medicament for treating a subject with a CD20-positive cell proliferative disorder, wherein said bispecific antibody binds to a 21-day administration cycle and formulated for administration to said subject in a dosing regimen comprising seven or more 28-day dosing cycles; (a) said first 21 day administration cycle comprises a first dose (C1D1), a second dose (C1D2) and a third dose (C1D3) of said bispecific antibody, wherein said C1D1 is about 1 mg, the C1D2 is about 2 mg, the C1D3 is about 60 mg, (b) said second administration cycle comprises a single dose (C2D1) of said bispecific antibody, said C2D1 being about 60 mg; (c) said third administration cycle comprises a single dose (C3D1) of said bispecific antibody; (d) said fourth administration cycle comprises a single dose (C4D1) of said bispecific antibody; (e) said fifth administration cycle comprises a single dose (C5D1) of ...
Claims
[Claim 1] An invention as described in the specification.
